¥xÆW¥¼¤W¥«ªÑ²¼ °]¸gºô 

¥¼¤W¥«  

¥¼¤W¥«ªÑ²¼¦æ±¡,¿³ÂdªÑ²¼¶R½æ,¥¼¤W¥«ÂdªÑ²¼¬d¸ß,§Ö³t´x´¤¥¼¤W¥«ªÑ²¼¶R½æ¯ß°Ê

Åwªï¨Ó¨ì¥²´Iºô ¤â¾÷ª© ¥[¤J·|­û µn¤J ­º­¶
¥¼¤W¥«ÂdªÑ²¼¦æ±¡¬d¸ß,¥¼¤W¥«ªÑ²¼¶R½æ¹L¤á,¿³ÂdªÑ²¼¦æ±¡¬d¸ß¡ã§K¥I¶O±M½u¡G0800-035-178
°Q½×°Ï>ÃĵØÂåÃÄ
ªø´Á«ù¦³¥Ø¼Ð»ù500¤¸¥H¤W     µoªí·s¸ÜÃD ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2014/7/22 ¤W¤È 09:05:58
ÃÒ¥æ©Ò­«¤j°T®§¤½§i

(6446)ÃĵØÃĤ½§i¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡A¤wÀòFDA®Ö­ã¡C

1.¨Æ¹êµo¥Í¤é:103/07/21

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò(­Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î

5.µo¥Í½t¥Ñ:¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç(IND½s¸¹119047)¡A¤wÀòFDA¥¿¦¡³qª¾¥i«ö­pµe¶i¦æ(¥ç§Y¬ü°êFDA®Ö­ã±µ¨ü¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç­pµe)¡C

6. ¦]À³±¹¬I:¶i¦æ¤½§i¡C

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

(1)¥»¤½¥q«e©ó102¦~9¤ë26¤é»P¬ü°êFDA¶i¦æPre-IND meeting¡A·|¤¤FDA©x­û«Øij¥»¤½¥q¥i¿ï¾Ü¶È¥H¦b¼Ú¬w¶i¦æ¤§PROUD-PV trail(§YP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g²Ä¤T´ÁÁ{§É¸ÕÅç)¼Æ¾Úµ²ªG¡A³w°e¬ü°êFDA¥Ó½ÐÃÄÃÒ¡C

(2)PROUD-PV trail«Y¥»¤½¥q±ÂÅv(Out-Licensing)¹Ù¦ñAOP¤½¥q¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡F¸g»PAOP¤½¥q¨ó°Ó«áij©w¡A¥Ñ¥»¤½¥q©e°UAOP¤½¥q¾á¥ôCROÅU°Ý¡A¨ó§U¬ü°êIND¥Ó½Ð°e¥ó¨Æ©y¡C



¶}ª©·|­û¡u¥ý¶i¡v½Ðºô¤Íµo¨¥µÛ­«©ó²z©Ê°Q½×·sÃĶi«×¡AµL¿×¤£²z©Êªº¥´À£¡A½Ð¦Ü¨ä¥Lª©°Ï¡A¤À¬y¬O¬°¤F¦³§Q§ë¸ê¤H·j´M

·|­û¡GLKK10141678  µoªí®É¶¡:2017/3/10 ¤W¤È 01:09:17²Ä 2069 ½g¦^À³
ÃĵØÃÄ©óC¨xÁ{§É¤T´Á¹êÅç³]­p¬° P1101 ¤zÂZ¯À + ¦N¥ß¼w¡]Gilead¡^ªºSovaldi ±Ä¦X¨ÖÀøªk, ¥i¨ÏÀøµ{­°§C¬°8©P, ¨Ã¥B¯à­°§C¤fªAÃĪ«(¦p¦N¥ß¼w¡]Gilead¡^ªºSovaldi)§ÜÃÄ©Ê¡BªvÀøµL®Ä¥H¤Î¨xÀù´_µoªº­·ÀI, Àøµ{¶O¥Î¬Û¸ûÀ³·|¤ñ¶Ç²Îªº¤zÂZ¯ÀÀøªk¥H¤Î¤fªA¤p¤À¤l¥ÎÃÄÀøµ{§C¡C

½Ð°Ý¦U¦ì¤j¤j,¬°¤°»ò²Ä¤G´ÁP1101 ¤zÂZ¯À +¹p¤Ú«ÂªL¨Ö¥Î,¦Ó²Ä¤T´Á§ï¥Î P1101 ¤zÂZ¯À + ¦N¥ß¼w¡]Gilead¡^ªºSovaldi ±Ä¦X¨ÖÀøªk

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gucss10142657  µoªí®É¶¡:2017/3/9 ¤U¤È 10:32:43²Ä 2068 ½g¦^À³
­Ó¤H·Qªk-¥~¸ê«ùÄò¦Y³f¡A5©Î8¤ë¦³¾÷·|¯Ç¤Jmsci¤j«¬¦¨¥÷ªÑ¡A´Á«Ý²Ä¤G©u©³¬ü°êÃÄÃÒ¥Ó½Ð~
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2017/3/9 ¤U¤È 05:37:09²Ä 2067 ½g¦^À³
¤À¨É 2017.03.07 Barbara Bartholomew ¦b Polycythemia Vera support group¥H¤Î 2017.03.09 Cindy Smith ©ó ¦bPolycythemia Vera PV Supportive Friends ªÀ¹Î¤¤¦³ÃöÃĵؤº®e½Ķ»P¹ï¸Ü¤º®eºI¹Ï, ¦]¥²´Iºô®æ¦¡­­¨î, ¹ï¸Ü¹ÏÀɤW¶Ç©ó¦¹, ¥i¦Ü Mobile01 ³sµ²°Ñ¦Ò¡C

www.mobile01.com/topicdetail.php?f=291&t=4919602&p=9¡G

[Polycythemia Vera support group] 2017.03.07

* Barbara Bartholomew :

§Ú¦b«ä¦Ò¦b±µ¤U¨Óªº¤»­Ó¤ë¤º­n¨D¥Îù¤ó¤zÂZ¯ÀPegasys ©Î ÃĵØP1101 ±µ¨üªvÀø¡CÃĵتº¤@¥÷Án©ú´£¨ì¥L­Ì¥¿¦b´M¨DP1101°µ¬°PV¤@½uªvÀø¥ÎÃĪº³\¥i¡C(¥¦¥ç´£¨ì, ¶¶±a¤@´£, PV¦b¬ü°ê¦a°Ïªº²±¦æ²v¬°100,000¤H¤¤¦³48-57¤H, ¦Ó¯f¤H¼Æ«ùÄò¼W¥[¤¤¡C) §Ú«Ü·P¿E¦U¦ìªº¨ó§U¥h¦^À³§Úªº½Ð¨D¨Ã¥B±Ð¨|§ÚªºÂå¥Í(¥]¬A§Ú¦Û¤v)¡CÅý§Ú­Ì¤F¸Ñ¨ì, §Y¨Ï¦b§Ú HU ¥ÎÃĤW¨Ã¥¼¥¢±Ñªº±¡ªp¤U, ¦p¦ó¨ú±o«OÀIµ¹¤áªº¤è¦¡¡C§A­Ì¬Y¨Ç¤H¤]´£¨ì§A­ÌªºÂå¥Í«Ü¾Õªø³oºØ¤è¦¡¡C§Úªº°²³]¬O¤£½×¬Où¤ó¤zÂZ¯À©ÎÃĵØP1101 ³£·|¦b§Úªº­pµe¶}©l¬O³Q§å­ã«OÀIµ¹¥I¡C§Ú´£¤ÎªºPDFÀɮ׬OÃĵتº¤å¥ó, ¦WºÙ¬° ÃĵØP1101 (Ropeginterferon Alfa-2b) ©M PV Polycythemia Vera, ÁÂÁ¡I

* Rob Strause :

HU ¤]¨S³Q®Ö­ã¥Î©óªvÀøPV, ¦ý¥¦»ù®æ¤£¶Q¡C¸ÕµÛ´£¨Ñ¥H¤U¤å¥óµ¹©pªºÂå¥Í¨Ã©M¥L»¡§Aª¾¹D¦b³o­Ó°Q½×¸s²Õ¤º¦³¤H·PÁ¤zÂZ¯ÀÅý¥Lªº¯e¯fÀò±o½w¸Ñ¡C

Âå¥Í¦b«Ü¦hª¬ªp¤U³£·|¥hª§¨ú«OÀIµ¹¥I, ¥u­n¥L­Ì»{¬°³o­Ó¬Û«H³o¼Ëª§¨ú¬O¦³·N¸qªº¡C

* Cori Griswold :

§Ú¤£½T©w§ÚªºÂå¥Í«ç»ò°µ¨ìªº, ¦ý§Ú­Ì¦b²Ä¤@¦¸¥Ó½Ð®É, «OÀI¤½¥q§Y§å­ãù¤ó¤zÂZ¯ÀPegasys ªºµ¹¥I, ¦Ó¥L¦b¨ä¥LÃĪ«ªº¥Ó½Ð¤W¤]¨S¥¢±Ñ¹L, ¯¬ºÖ§A¡I

[Polycythemia Vera PV Supportive Friends] 2017.03.09

* Cindy Smith:

¤µ¤Ñ¥h¨£§Úªº¸~½F¬ìÂå¥Í, ©Ò¦³¦å²G¼Æ¾Ú³£¹L°ª, Âå¥Í´£¨ì¦³¤@­Ó·sªº¤Æ¾Ç¥ÎÃĦb©ú¦~±À¥X, ¬OJakafi ªº§ó·s¶Ü? ¥ô¦ó¤H¦³¬ÛÃö·Qªk¶Ü?

* Christine :

§Ú¨SÅ¥¨ì¦³¬Æ»ò·sÃÄ­n±À¥X, ¥u¦³¤@ºØ·s«¬¤zÂZ¯À(P1101)§Y±N¨ì¨Ó¡C

¥Ø«e³o­Ó·sªº¤zÂZ¯À¤´µLªk¨Ï¥ÎÁÙ¦³¼Ú¬w°Ï¶i¦æÁ{§É¸ÕÅç, ¦Ó§Ú¨SÅ¥¨ì¥ô¦óJakafi ªº§ó·s¸ê°T¡C

* Cindy Smith:

¯uªº¶Ü?§Ú³Q§iª¾¤w¸g¥i¥H¨Ï¥Î¤F¡C

* Claire :

§Ú·Q³oÀ³¸Ó¬O§óªø®Ä§a?

* Alisa :

¬Oªº, ³oºØ·s«¬¤zÂZ¯À(P1101)¶È»Ý­n¨C3-4©Pª`®g¤@¦¸, ¦Ó¥B¥¦¥i¥H¨Ï¥Î«D±`§Cªº¾¯¶q¦Óºû«ùªø®Ä©Ê¥B¦³§ó§Cªº°Æ§@¥Î¡C³oºØ·s«¬¤zÂZ¯À³Q³]­p±Mªù¥Î©ó¦å²G¯e¯f¯f±w(MPNs)¡C

¦b¦å²G¯e¯f¬ã°Q·|¤W³£¦b°Q½×Á{§É¸ÕÅç©M·sÃÄ¡C©Ò¦³ªºPVÁ{§É¸ÕÅç³£¬OJakafi ©M³o­Ó·s«¬¤zÂZ¯À(P1101)¡C°£¤F³o­Ó·s«¬¤zÂZ¯À¥H¥~¨Ã¥¼Å¥¨ì¥ô¦ó·sÃĪº¨¥½×, ¦Ó³o­Ó¤zÂZ¯À¦b¤@¤Á¶¶§Qªº±¡ªp¤UÀ³¸Ó¤@¦~¥ª¥k·|±À¥X¡C¥t¥~ÁÙ¦³¤@­Ó¿E¾`§í¨î¾¯¦bÁ{§É¸ÕÅ礤, ¦W¬°Pacritinib, ¦ý³o­Ó¬O¥Î¦bMF ¦Ó«DPV¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/3/9 ¤W¤È 12:45:51²Ä 2066 ½g¦^À³
¦U¦ì¤j¤j,c¨xªº¥«³õ¨º»ò¤j,¦pªGÃĵتº¤T´ÁÁ{§É¼Æ¾Ú¦nªº¸Ü,¤j®a³£µo¤F,¬O¤£¬O

¤½¶}¸ê°TÆ[´ú¯¸­«¤j°T®§¤½§i

(6446)ÃĵØÃĤ½§i¥»¤½¥q·sÃÄP1101¥Î©óªvÀøC«¬¨xª¢¯f¬r°ò¦]Åé²Ä¤G«¬¤§²Ä¤G´ÁÁ{§É¸ÕÅç¥D­nµû¦ô«ü¼Ð

1.¨Æ¹êµo¥Í¤é:105/06/13

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò(­Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î

5.µo¥Í½t¥Ñ:

105.06.10©ó°ª¶¯¨È¤Ó¨xŦ¬ã¨s¾Ç·|¡]APASL¡^¤§C¨x²Ä¤@¥DÃD·|ij¤¤¥Ñ¥»¤½¥qC«¬¨xª¢¯f¬r°ò¦]Åé²Ä¤G«¬²Ä¤G´ÁÁ{§É¸ÕÅ礧­p¹ºÁ`¥D«ù¤H²ø¸UÀs±Ð±Â¤À¨É·s¤@¥Nªø®Ä«¬¤zÂZ¯À¦b®ÚªvºC©ÊC«¬¨xª¢ªº¬ã¨s¦¨ªG¨ä¤¤¥»¤½¥q·sÃÄP1101¥Î©óªvÀøC«¬¨xª¢¯f¬r°ò¦]Åé²Ä¤G«¬¤§²Ä¤G´ÁÁ{§É¸ÕÅç¥D­nµû¦ô«ü¼Ð¬ÛÃö°T®§¦p¤U:

¤@¡B¬ãµo·sÃĦWºÙ©Î¥N¸¹¡GP1101

¤G¡B¥Î³~¡G

(¤@)¾AÀ³¯g¡GªvÀøC«¬¨xª¢¯f¬r°ò¦]Åé²Ä¤G«¬

(¤G)¥xÆWÃÄ«~Á{§É¸ÕÅç¸ê°Tºô¡G www1.cde.org.tw/ct_taiwan

¤T¡B¹w­p¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G²Ä¤T´ÁÁ{§É¸ÕÅç(¶i¦æ¤¤)

¥|¡B¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G¥»¤½¥q¥»¦¸«Y¨ú±oP1101¥Î©óªvÀøC«¬¨xª¢¯f¬r°ò¦]Åé²Ä¤G«¬¤§²Ä¤G´ÁÁ{§É¸ÕÅç¥D­nµû¦ô«ü¼Ð¡AÁ{§É¸ÕÅç¸ê°T¦p¤U¡G

(¤@)´£¥X¥Ó½Ð/³q¹L®Ö­ã/¤£³q¹L®Ö­ã¡G

¤@¡B ¸ÕÅç­pµe¦WºÙ¡Gµû¦ôP1101¨Ö¥ÎRibavirin¹ï©ó¥¼±µ¨üªvÀø¤§·P¬VC«¬¨xª¢¯f¬r°ò¦]«¬²Ä¤G«¬±wªÌªº§Ü¯f¬r¬¡©Ê»P¦w¥þ©Ê¤§¶}©ñ©Ê¡BÀH¾÷¤À°t¡B¦³®ÄÃĹï·ÓªºÁ{§É¸ÕÅç

¤G¡B ¸ÕÅç¥Øªº¡G

1.µû¦ô¨Ã¤ñ¸û¬I¥´¤TºØ¾¯¶q¤§P1101(¾¯¶q270¡B360¡B450·L§J)¨Ö¥ÎRibavirin¤§¦w¥þ©Ê»P­@¨ü©Ê¡C

2.µû¦ô¨Ã¤ñ¸û¬I¥´¤TºØ¾¯¶q¤§P1101(¾¯¶q270¡B360¡B450·L§J)©MPEGASYSR(¾¯¶q180·L§J)¤§¨ü¸ÕªÌªº«ùÄò©Ê¯f¬r¤ÏÀ³ªº¤ñ²v¡ASVR(Sustained Virologic Response)¡A °lÂÜ24¶g®É¡A°»´ú¤£¨ì

C«¬¨xª¢¯f¬rRNA

¤T¡B ¸ÕÅ綥¬q¤À¯Å¡GPhase II (¬dÅçµn°O¦a°Ï:¥xÆW)

¥|¡B ÃÄ«~¦WºÙ¡GP1101

¤­¡B «ÅºÙ¾AÀ³¯g¡GC«¬¨xª¢¯f¬r°ò¦]Åé²Ä2«¬

¤»¡B µû¦ô«ü¼Ð¡G

1.¥D­nµû¦ô«ü¼Ð¡G¥Î·N¦V¤ÀªR(ITT)¤ÀªR¦UªvÀø²Õ§O¤¤¦³«ùÄò©Ê¯f¬r¤ÏÀ³(SVR(Sustained Virologic Response ))¡A °lÂÜ´Á²Ä24¶g®É¡A°»´ú¤£¨ìC«¬¨xª¢¯f¬rRNA)ªº¨ü¸ÕªÌ¤§¤ñ²v¡A¦UªvÀø²Õ§Oªº¤£¨}¨Æ¥ó¥Í©R¼x¶H(vital sign)¡B¤ß¹q¹Ï¡B¹êÅç«ÇÀËÅç³ø§i

2.¦¸­nµû¦ô«ü¼Ð¡G¥Î¹ê»ÚªvÀø¤ÀªRªk(PP)¤ÀªR¦UªvÀø²Õ§O¤¤¦³«ùÄò©Ê¯f¬r¤ÏÀ³(SVR) °lÂÜ´Á²Ä24¶g®É¡A°»´ú¤£¨ìC«¬¨xª¢¯f¬rRNA)ªº¨ü¸ÕªÌ¤§¤ñ²v¡A¦UªvÀø²Õ§O¤¤¦³§Ö³t¯f¬r¤ÏÀ³(RVR)ªº¨ü¸ÕªÌªº¤ñ²v

¤C¡B ¸ÕÅç­pµe¨ü¸ÕªÌ¦¬¯Ç¤H¼Æ¡G¸ÕÅç­pµe¦¬¯Ç80¦W¨ü¸ÕªÌ¡A¹ê»Ú¦¬¯Ç86¤H

¤K¡B ¥D­nµû¦ô«ü¼Ð¤§²Î­pµ²ªG¤Î²Î­p·N¸q: C«¬¨xª¢¯f¬r°ò¦]Åé²Ä¤G«¬¤HÅéÁ{§É¤G´Á¡A´NÀø®Ä¦Ó¨¥¡AP1101¦U²Õ(¤TºØ¾¯¶q270¡B360¡B450·L§J)¥D­nÀø®Ä«ü¼Ð¤Î¦¸­nÀø®Ä«ü¼Ð»P¦³®ÄÃĹï·Ó²Õ(PEGASYS)¤ñ¸û¤§²Î­pµ²ªG¡A§¡§e²{P­È>0.05¡C

²Î­p¤W¡AP1101¤T²Õ¾¯¶qªºÀø®Ä»PPEGASYS²ÕµLÅãµÛ®t²§¡A¤]´N¬O¸ò¹ï·Ó²ÕÀø®Ä¬Û¦ü¡C

´N¦w¥þ©Ê¦Ó¨¥¡A»PPEGASYS²Õ¬Û¤ñ¡AP1101¤T²Õªº°Æ§@¥Îªºµo¥Í²v§¡¤ñ¸û§C¡A§e²{P­È<0.05¡C²Î­p¤W¡AP1101¦U²Õ°Æ§@¥Îªºµo¥Í²v¤ñPEGASYS²Õ¸û¤Ö¡A§e²{ÅãµÛªº®t²§¡A¤]´N¬O°Æ§@¥Î¦³ÅãµÛªº¸û¤Ö¡C

C«¬¨xª¢¯f¬r°ò¦]Åé²Ä¤G«¬¤HÅéÁ{§É¤G´Á¸ÕÅçµ²ªGÀø®Ä»PPEGASYS¤@¼Ë¡A°Æ§@¥Îµo¥Í²v¦³ÅãµÛÀu¶Õ¡A¥»¤HÅé²Ä¤G´ÁªºÁ{§Éµ²ªG¤w¤ä«ù¤½¥q¶i¤J¤HÅé¤T´ÁÁ{§É¡A¥Ø«e¥»¤½¥q¤w¨ú±o¥xÆWTFDA¤ÎÁú°ê­¹«~ÃĪ«ºÞ²z¸p¥¿¦¡®Ö­ã¦P·N¶i¦æ¤T´ÁÁ{§É¸ÕÅç¨Ã©ó¥xÆW¤ÎÁú°ê¨â¦a¦P®É¶i¦æ¤HÅé¸ÕÅç¡C

(¤G)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¤½¥q©Ò­±Á{¤§­·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î

(¤T)¤w³q¹L¥Øªº¨Æ·~¥DºÞ³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G¤£¾A¥Î

(¥|)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G¥»¤½¥q²Ö¿n¤w§ë¤J¸ÓÁ{§É¸ÕÅ礧¬ÛÃö¶O¥Î¬ù88,894¤d¤¸

¤­¡B±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G

(¤@)¹w­p§¹¦¨®É¶¡¡G¶i¦æ¦h°ê¦h¤¤¤ß²Ä¤T´ÁÁ{§É¸ÕÅç¡A±N©ó¥xÆW¤ÎÁú°ê¨â¦a¦P¨B¶i¦æ¦¬®×¡AÁ`¦¬®×¤H¼Æ¦Ü¤Ö240¤H¡A¹w¦ô©ó2017¦~§¹¦¨¸ÕÅç¡C

(¤G)¹w­pÀ³­t¾á¤§¸q°È¡G¥»¤½¥q±N¤ä¥I°õ¦æÁ{§É¸ÕÅç¤Î¥Ó½Ð·sÃĬdÅçµn°O¤§¬ÛÃö¶O¥Î¡C

6.¦]À³±¹¬I:µo¥¬¥»­«¤j°T®§¡C

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A ¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A¥B³æ¤@Á{§É¸ÕÅçµ²ªG(¥]§t¥D¡B¦¸­nµû¦ô«ü¼Ð ¤§²Î­p¾ÇP­È¤Î²Î­p¾Ç¤W¬O§_¹FÅãµÛ·N¸q)¡A¨Ã¤£¨¬¥H¥R¤À¤Ï¬M¥¼¨Ó·sÃĶ}µo¤W¥«¤§¦¨±Ñ¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³Á§JªL10142093  µoªí®É¶¡:2017/3/8 ¤U¤È 11:09:57²Ä 2065 ½g¦^À³
¶K¤W¤@«h»D¡A½Ð¦Û¦æ¬ã§P

¬°¦óC¨xÃĤ§¤÷¨Ó¥x«ô³Xªº¬OÃĵء]6¦¸¡^¡H

---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

³Q¨üÃöª`ªºJean-Pierre Sommadossi¡A¬O¬ü°êGileadÃļtC¨x·sÃÄSovaldiªºµo©úªÌ¡A¥L³Ð¤U¤@ÁûC¨xÃÄ°â»ù¹F1,000¬ü¤¸¡]¬ù·s¥x¹ô3¸U¤¸¡^ªº¬ö¿ý¡A¥ú³oÁûÃÄ¥h¦~¬°Gilead³Ð³y104»õ¬ü¤¸À禬¡C

Jean-Pierreªí¥Ü¡ASOVALDIÁöµM¦bÁ{§É¸ÕÅç¤ÏÀ³«D±`¨}¦n¡Aªv¡²v±µªñ100¢H¡A¦ý¦b¤W¥««á¡A¹ê»Úªv¡²v«o¥u¦³85¢H¡A±À´ú­ì¦]¥i¯à¬O©ó3­Ó¤ëªºÀøµ{¤Óªø¡A¥[¤W©ù¶QªºÃÄ»ù¡A¨Ï±o¯f¤Hªº¨Ì±q«×¤Ó§C¡C¦]¦¹¡A¥Ø«e¥L¥¿¿n·¥µo®i·s¤@¥NªºC¨xÃĪ«¡A§Æ±æ¯à±NÀøµ{ÁYµu¬°4¶g¡A²{¶¥¬q¬ãµo¶i«×¨}¦n¡A¹w´Á¤µ¦~9¤ë¯à¶i¤JÁ{§É¸ÕÅç¡C

Jean-Pierre ªí¥Ü¡A¥xÆW¥ÍÂå²£·~¥ÍºA°éªºµo®i¤w³vº¥¦¨¼ô¡A¤£ºÞ¬O¬ãµo³æ¦ì¡BÂå°|¡B¥ø·~©Î§ë¸êÀô¹Ò¦b¨È¬w¦a°Ï¬Ò³B©ó»â¥ýªº¦a¦ì¡A¦]¦¹¡A¥L§Æ±æ¯à§ä¨ì¥i«H¿àªº°Ó·~¹Ù¦ñ¦@³Ð°Ó¾÷¡C

¬°¤F´ª¹Î«e¶i°ê»Ú¥«³õ¡AJean-Pierre¥h¦~12¤ë©M³Ìªñ¤w2¦¸¨Ó¥x¡A°£¤F°Ñ³X°ê¤º·s³Ð¤½¥q¥~¡A¥L¦bµuµu¥b¦~¤º¤À§O¦b®ü¥~©M¥xÆW»PÃĵØÂåÃÄ°ª¼h¦³¹L6¦¸¬¢½Í¡A·~¬É»{¬°¡AÃĵػPC¨xÃĤ§¤÷ªº¦X§@¾÷·|¤Q¤À¿@«p¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/3/8 ¤U¤È 10:39:46²Ä 2064 ½g¦^À³
·PÁÂRUSSELL¤jªº¸ÑªR,ÁÂÁÂ
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/3/8 ¤U¤È 10:29:35²Ä 2063 ½g¦^À³
LKK¤j...

­Ó¤H¥H¬°

Âå¾ÇªºªF¦è...¨S¦³Á{§É¹êÅç....½Ö¤]»¡¤£·Ç

©Ò¥H·sÃĬãµo¦¨¥\²v¬O¦Ê¤À¤§­Ó¦ì¼Æ

¤£¹L....¨Ì²{¦bªº¹ê¨Ò¸òÁ{§É¨Ó¬Ý

¤zÂZ¯À½T©w¤ñ¤p¤À¤lÃĨӪº¦w¥þ¦h¤F

¤×¨ä¬OÃĵتºP1101....

¬Y±M·~°]¸g¹Î¶¤½èºÃP1101vsHU¨º½gÁÙ±¾¦b­º­¶ªº¤å³¹

©Î³\¶V¨Ó¶V¦³¥i¯à³Q¹ê»Ú®×¨ÒÃÒ¹ê...¬O­Ó¯º¸Ü

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gucss10142657  µoªí®É¶¡:2017/3/7 ¤U¤È 10:25:42²Ä 2062 ½g¦^À³
·PÁÂRookie¤j¤jÁ¿¸Ñ¡A¤j·§¤F¸Ñ¤F¡AÁÂÁÂ
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/3/7 ¤W¤È 12:00:52²Ä 2061 ½g¦^À³
½Ð°ÝÃĵتºc¨xÁ{§É,¬O¤£¬O©M¤p¤À¤lÃĦX¨ÖÁ{§É ,¨º·|¤£·|¦³²Ä1973½gªº°ÝÃD

,³o´N¬O§Ú·Q½Ð°Ý¦U¦ì¤j¤jªº°ÝÃD?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/3/6 ¤U¤È 10:07:16²Ä 2060 ½g¦^À³
2017-03-06 16:15Áp¦X³ø °OªÌ¾H®Ûªâ¢¬§Y®É³ø¾É

¥»³ø¿W®a³ø¾É¡A©ù¶QªºC¨x¤fªA·sÃÄ©ó1¤ë¤¤¦¯¦³±ø¥óµ¹¥I¡A¦ý¥Ó½Ð¤H¼Æ¤£¦p¹w´Á¡A¥B¦³3¤H¤¤Â_¥ÎÃÄ¡A¨ä¤¤¤@¤HºÃ¦üªA¥Î«á¤Þ°_ÄY­«¨x¬r©Ê¡A¤£©¯©¹¥Í¡C

­¹Ãĸp¤µ¤Ñµo¥¬·s»D½Z¦^À³¡A½T¹ê±µÀò¤@¦W¦º¤`³q³ø®×¨Ò¡A¦ý©|µLªk»{©w¦º¦]»P¨Ï¥ÎC¨x·sÃĪºÃöÁp©Ê¡A¦ý¤´©IÆ~ÂåÀø¤H­û¤Î¥Á²³¡AÃÄ«~½T¹ê¦³¼ç¦b¨x¶Ë®`­·ÀI¡A¥ÎÃÄ´Á¶¡¤@¥¹¦³¤£¨}¤ÏÀ³¡AÀ³¤Î¦­°±ÃÄ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRookie10143115  µoªí®É¶¡:2017/3/6 ¤U¤È 10:01:49²Ä 2059 ½g¦^À³
§Ú¤§«e°Ý¹L¤½¥qÃþ¦ü°ÝÃD¡A¤½¥qµªÂгo¤è­±¦³¨â³¡¥÷¡A·íÃĽ浹AOP·|¦¬¨ú¤@³¡¥÷Àò§Q¡A¥t·|µø¾P°âª÷ÃB¦¬¨ú¤£¦P¤ñ¨ÒªºÅv§Qª÷
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gucss10142657  µoªí®É¶¡:2017/3/6 ¤U¤È 09:43:58²Ä 2058 ½g¦^À³
ÃĵØP1101¦Û¤v¥Í²£¡A¬ü°ê¦Û¤v½æ¡A¨º½Ð°Ý¦U¦ì¤j¤j¡AÁ{§ÉÃÄÃҤ譱AOPÀ°¤F¤£¤Ö¦£¡A¼Ú¬w³¡¥÷¬O¤§«eÁ¿ªº¾P°âÃB20%©O¡HÁÙ¬O¥Í²£p1101¥H°Ó¶q¦nªº»ù¿ú½æµ¹AOPÁȨú©Ò±o©O¡HÁÂÁÂ!
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/3/6 ¤U¤È 01:48:24²Ä 2057 ½g¦^À³
¦Ñ®v³£¦³Á¿,Â\µÛ©ñµÛ´N¦³¤@­Ó°×¤Ú¨à¤lÀ°§AÁÈ¿ú
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦B«B10138946  µoªí®É¶¡:2017/3/6 ¤U¤È 01:32:15²Ä 2056 ½g¦^À³
¤T´LÀYªºÀV½u³ºµM³o»ò§Ö´N¯¸¤W...¬Ý¨Ó¦³¬G¨Æ
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G141210138230  µoªí®É¶¡:2017/3/6 ¤W¤È 09:45:26²Ä 2055 ½g¦^À³
¾a½æÂø»x¯à¹L¬¡¡H¤½¥q­n¤j¤èÂI¡A¥á¨ÇªF¦èÁý³o¨Ç¯³¥Í¡I
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/3/5 ¤W¤È 11:10:03²Ä 2054 ½g¦^À³
»Õ¤U´Nª¾¹D....

¤p§Ì§Ú²{¦b¦³¦h¼¨´c¯S©w´CÅé...¯S§O¬O¼Ðº]±M·~ªº°]¸g´CÅ騺¤@®a

´¿¸g¬O´X¤Q¦~ªºÅªªÌ......

±qªô¥Ãº~®É¥N¨ì²{¦b

±q§â¥¦ªº«Øij·í¿ïªÑ°Ñ¦Ò¨ì°ªÂIĵ°T(«á¨Ó±ÀÂ˪º¤£¬O°ªÂI¤]±µªñ°ªÂI)

ª½¨ì.....ªñ´X¦~

¤£ª¾¥Í§Þ¬É¬O§_¦³¤H±o¸o³o¨Ç¤H??ÁÙ¬O¯uªº¥Í§Þ¬É¦p¦¹¤£³ô???

¥u­n¦³§Q¦h¶Ç¥X....«Ü§Ö´N¥Z¤å¥´À£....§Q¦h³£·|Åܦ¨§QªÅ!!

¤£¬O·R¥xÆW¶Ü???¯uªº¬Ý¤£¥X¨Ó

©Ò¥H....²{¦b©Ú¶R©è¨î

(´¿¸g¬Ý¤F´X¤Q¦~ªº¤ß±o)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°¶¤j¤j10136951  µoªí®É¶¡:2017/3/4 ¤W¤È 11:25:50²Ä 2053 ½g¦^À³

¬Q¤Ñ¡A¸ò¤@¨ÇªB¤Í¥´§¾¡A¥L­Ì¹ï¬Y³ø¾É«D±`®ð¼«¡A»{¬°§Ú­Ì¥Nªí°ê®a¥X¥h¥´¥@¬ÉªM¡A

³ºµM¦³¤H¦b°ê¤º²r§è«á»L¡A¯u¬O¡¨«e¤è¦Yºò¡A«á¤èºò¦Y¡¨¡C

¦ý§Ú»{¬°±´°Q·sÃĬãµoÁÙ¬O­n²z©Ê¡AºÉ¶q¤£­n±a±¡ºü.¨ä¤¤³Ì­«­n¨âÂI¡A§Ú¦³¸Ü­n»¡¡C

1¡B §ä¬v¤H­I®Ñ¡A³õ­±§Ë±o¯E¤j?

§Oªº¤½¥q°µªk§Ú­Ì¤£¤F¸Ñ¡C¦ýÃĵجOº¡¯S®íªº¡A

¥¦¼Ú·ù±ÂÅvAOP¡A¹êÅ窺123´Á³£¬O¥ÑAOP©Ò¥D¾É¡A

¹êÅç¹Lµ{¨C¤@¶¥¬qµ²§ô¡AAOP¤w³sÄò¤T¦~¦~³£·|§ë

ASH(¬ü°ê¦å²G¦~·|)°µ¹êÅç¬yµ{»Pµ²ªG»¡©ú¡A

·íµM¤]Åwªï¥@¬É¦å²G±M®a¨Ó§åµû«ü±Ð¡A

§@¬°§ï¶i¤§°Ñ¦Ò¡C³o´N¬O¬ì¾Ç¡A³o´N¬O­t³d¥ôªºªí²{¡C

¨º§Ú­Ì¦^¾Ð¨º¤@¤Ñ±¡¹Ò¡C12¤ë5¤é¦b²Ä¤T´Áµ²§ô«á¡A

·Ó©¹¦~ºD¨Ò¡A²Ä¥|¦~¤F¡AAOP§ëASH¡A°µ¤fÀYµoªí¡A³o¦³»ò¤£¹ï?

¥xÆW³o¤@ÀY¥Ñ¶À¥¿¨¦³Õ¤h¥D«ù°OªÌ·|¡A®ÇÃä¤@¦ì·|­p¤H­û¡A

ÁÙ¦³¤@¦ì(?)¦@¤T¤H¡A¦n¹³¥u¦³¶À³Õ¤h§@µª¡C

¦pªG¥H§Ú­Ì§ë¸êªÌ­n¨D¤§¼Ð·Ç¡A³õ­±·¥¬°§C½Õ¡A¬Æ¦Ü´H»Ä¡C

Ãø¹D­nÂù¤è¨ìªü¨½¤s¯²¤@¶¡­Ü®w¦@¦Pµoªí¦¨ªG?

¯u¬O­wµÛ¤]·|¤¤ºj¡C

2¡B ¬°¦ó­n­×§ï¼Ð·Ç?

¬ì¾Ç¹êÅç¹Lµ{¥»¨Ó´N¬O¥Rº¡³\¦h¤£¥i¹w´ú©Ê¡A¹êÅç¹Lµ{¥»´NÀ³»P®É­Ñ¶i¡C

¦³¶¡¥sPV¤½¥qªÌ·Q§ä¤@¦ìMiss PV¡A§@¬°¤½¥qªº¤½Ãö¤j¨Ï

¡C¦ý¬Oµ¥¤F¦n¤[¡A³£¨S¦³¤HÀ³¼x¡A²×©ó¦³¦ì¤p¤k¥Í¥sAOP¨Ó¤F¡C

À³¼x¤º®e¬v¬vÅxÅx¼g¤F¤@°ïÀuÂI¡A¨ä¤¤¦³¤@¶µ»¡¦Û¤v¨­°ª¶W¹L165¤½¤À¡C

¤½¥q©Ò¦³ªºµû¼f»¡¦n¡A´N¨Ì¦¹¼Ð·Ç§@¬°¿ý¨ú¼Ð·Ç¡C

¥i¬O¹L¨â¤Ñ³o¤@¦ì¤p¤k¥Í¦^¨Ó¸ò©Ò¦³µû¼f»¡¡A

¨­°ª³o¤@¶µ¥Ø¬O§_¯à§ï¬°¤£¸G©ó165cm

¡A³o¤@¨Çµô§P»¡¡A§ï¬O¥i¥H¡A¦ý©p¥²¶·»¡¥X§ó¦nªº±ø¥ó»¡ªA§Ú­Ì¡A

¨º¤p¤k¥Í»¡¤T³ò¡¨¯ÝÁv³ò¡¨»P¡¨¸y³ò¡¨¶W¹L¤Q¦T¡A

³o®É©Ò¦³µô§P²´·ú³£«G¤F¡A§]¤F§]¤f¤ô»¡:¦n!¦n!§Ú­Ì°¨¤Wñ®Ñ­±¦P·N®Ñ¡C

¤p¤k¥Í¤]®³¨ì©Ò¦³µô§P¦P·N¤§®Ñ­±¡C

²{¦b³o¤@¨Çµô§P¥¿¦b°µ³Ì«á¤§¼f¬d¡A

³o¤@¦ì¤p¤k¥Í¨­°ª¤wªø¨ì177¤½¤À¡A¤T³ò¬O36¡A24¡A35¡K¡K.

¤½¥q³Q¤H­ÞªP¤F¡A¦ý¨­¬°§ë¸êªÌ¡A¨S¥²­n·Å¨}®¥»ü¦Ü¦¹¡AÅý§Ú­Ì¦³³Ûµh¤§ªºÅv§Q¡C

¤½¥q¨C¦¸®Á¤F´e´Ò¡A¤@¦V§Ô®ð§]Án¡AÀqÀq©Ó¨ü¡A

¬O¤£·Q»P´CÅé¯}ÃaÃö«Y?ÁÙ¬O»{¬°®É¶¡Á`·|»¡©ú¤@¤Á¡C

¨º§Ú¤Ò´_¦ó¨¥?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2017/3/4 ¤W¤È 08:40:31²Ä 2052 ½g¦^À³
·PÁ Russell ¤jªº«ü¾É, ¥Ñ©ó¥²´IºôµLªk­«·s½s¿è, ¤w©ó Mobile01 ³sµ²­×¥¿, ­Y¦³¥ô¦óºÃ¸q¤]½Ð¦U¦ì¥ý¶i¤£§[«ü¾É, ÁÂÁ¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/3/3 ¤U¤È 11:35:09²Ä 2051 ½g¦^À³
Alan¤j...

ÁÂÁ¤j¤jªº«ùÄò¥I¥X...

¦ý...¤£¦n·N«ä.....§ÚıªºÀ³¸Ó½Ķ¦¨.....

¥xÆW¤½¥q¥¿¦b...±À¥X....¤@­Ó§ó¦nªº

¥i¯à·|§ó¶K¤Á¨Ç

Ãĵإ[ªo...¥xÆW¥[ªo....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2017/3/3 ¤U¤È 07:16:24²Ä 2050 ½g¦^À³
¤À¨É 2/26 Polycythemia Vera support group ¦³ÃöÃĵؤº®e½Ķ»P¹ï¸Ü¤º®eºI¹Ï, ­­©ó¥²´Iºô®æ¦¡, ¹ï¸Ü¹ÏÀɤW¶Ç©ó¦¹, ¥i¦Ü Mobile01 ³sµ²°Ñ¦Ò¡C

www.mobile01.com/topicdetail.php?f=291&t=4919602&p=9

*Aws Jasib J :

ªB¤Í, §Ú¦³­ÓºÃ°Ý, ¦³¬Æ»ò¤è¦¡Åý§Ú§Ñ±¼©Î§O·Q¨ìÀù¯g³o¦r²´, ³oÅý§Úı±o«Ü´dºG¡C

*Paul:

§Ú²{¦b¤£¦b¾á¤ßPV¤F, ¦]¬°§Úªºªñªp¤w¸gÀò±o±±¨î¡C§Ú±q10­Ó¤ë«e¶}©l¨Ï¥Îù¤ó¤zÂZ¯ÀPegasysªvÀø«á, ¤w¸g«Üªø®É¶¡³B¦b¤@­Ó¡§·L¤p´Ý¯d¯e¯f¡¨ªºª¬ºA, §Ú¥Ø«e¨S¦³¥ô¦óµs¦½¡B¯h³Ò©Îæ±Äoªº¯gª¬, ¦ÓJAK2ªº¸~½F­t¾á¤]±q­ì¥ýªº36%­°¨ì5%¥H¤U¡CHasselbalchÂå¥Í»¡, ·íJAK2 ªº¸~½F­t¾á¦b³o¼ËªºÂàÅܱ¡ªp¤U, ¯e¯f­nÂରMF ©Î AML ªº­·ÀI±N·|­°§C³\¦h¡C

*Jill:

§Ú¤ñ§A±ß´X­Ó¤ë¶}©l, ¦ý·Pı¤Ó´Î¤F¡C©Ò¦³PV¯gª¬§¡´î»´©Î§¹¥þ®ø°£,¦å²G¼Æ¦r³£¬O°£¤FRBC¡BRDW¥H¤ÎMPV¥~, §¡¦b¥¿±`½d³ò¤º¡C

*Paul:

¬Oªº, ³o¤T¶µ¤j¬ù­n1~3¦~®É¶¡«ì´_¥¿±`¼Æ­È, ¦ý¦P®É¤]·N¨ýµÛ³o±N±a»â§Ú­Ì¦^¨ì¨S¦³¯gª¬ªº¥Í¬¡«~½è¡CÃĵطs¤@¥N¤zÂZ¯À¦bPV¾AÀ³¯g·|¦b2017¦~¦~©³Àò±o¬ü°êFDA §å­ã, ET¾AÀ³¯g «h¦b2019¦~¡C

*Jill: Paul, ÁÂÁ¡C

*Barbara:

Paul, §Ú«Ü¿³¾Ä¡I·í³o­ÓÃħå­ã«á, §Ú·Q­n¨D§Úªº¦å²GÂå¥Í¬O§_¥i¥Î³o­ÓÃÄ¡C§Ú·Q¨ì®É¥LÀ³¸Ó·|ª½±µ²¤¹LHU¡C§Ú«D±`ÁÂÁ§A§iª¾§Ú­Ì³o«h¸ê°T¡C

*Gabriele: §Ú¤]¦bµ¥«ÝP1101¤¤¡C³o¬O¤@ºØ§Ú·Q¥ÎªºÃĪ«¡C§Ú¬O¤@­Ó¹ïÃĶW¯Å±Ó·Pªº¤H, ¬G§Ú·Qª¾¹D§Ú¬O§_¯à°÷§Ô¨ü¥L¡C

*Carol: Aws, ¹ï§Ú¦Ó¨¥, ±µ¨ü³o­Ó¨Æ¹ê¡C

*Glynis Homer: ¨º¥u¬O¤@­Ó¦r, ¥¦¤£À³¬O´dºGªº, ¥u¦³©pµ¹¤©¥¦´dºGªº²[¸q¡C¥´°_ºë¯«, §O¦]¬°³o­Ó¦r²´Åý§A¥Í¬¡®ø·¥µLºë¥´ªö¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2017/3/3 ¤U¤È 02:53:52²Ä 2049 ½g¦^À³
Sindel Demers ¬° John ªº¯f±w, ¦b¬Q¤é(3/2) ¤À¨Éµ¹Polycythemia Vera support groupªÀ¹Îªº¸ê°T¤¤¦³´£¤ÎÃĵءCDr. Mascarenhas §Y¬°§Ú­ÌÃĵتk»¡·|ªº¨º¦ì¦å²G¾Ç®aJohn, ÃÄµØ Rescue trial ªº­pµe¥D«ù¤H¡C

Sindel Demers : (03/03 0:30)

Update on Pegasys :

Just spoke to Dr. Mascarenhas

No need to worry about discontinuation of Pegasys , Tawan Company is launching a better one

Keep calm.

­è©M Dr.Mascarenhas ½Í½×¨ìPegasys ªºªñªp§ó·s, ¥L»¡¤£»Ý­n¾á¤ßù¤ó¤zÂZ¯À°±²£, ¥xÆW¤½¥q¥¿¦bµo®i¤@­Ó§ó¦nªº

«O«ù§NÀR¡C

¹ï¸Ü¹ÏÀɤW¶Ç©ó¦¹, ¥i¦Ü Mobile01 ³sµ²°Ñ¦Ò¡C

www.mobile01.com/topicdetail.php?f=291&t=4919602&p=9

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2017/3/3 ¤W¤È 10:06:16²Ä 2048 ½g¦^À³
ªk¤H±q¤½§G¼Æ¾Ú¤§«á~ªÑ»ù195¤¸¤@¸ô¬~¦Ü140¤¸¡Aªk¤H´X¥G§â¤â¤¤«ùªÑ½æ¥ú¡A

±q¶}¬K¶}¥««á¤@¸ô¥[½X¡Aªk¤H±}±}¶R¶iÃĵØ13500±i¡A±q«ùªÑ¤W¨Ó¬Ý¨C¤Ñ³£

¥[½XÃĵءA§ë¸ê¤H¯d·N~~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°¶¤j¤j10136951  µoªí®É¶¡:2017/3/2 ¤U¤È 10:38:04²Ä 2047 ½g¦^À³
ªñ¼q´Û¯«

§Ú«Ü»{¦P½Ñ¦ì¤j¤jªºÆ[¹î¡C

¦í¦b¼q¦tªþªñ¡A¦Ó¹ï¼q¤º¯«©ú¤ß¦s»´µø¤£·qªººA«×

¡C¤Þ¥Ó¬°¹ï¨­®Çªº¤H¡B¨Æªí²{¥X»´©¿¡BºzµøªººA«×¡C

¤Ï¦Ó¶ZÂ÷¦³¤@¬q¸ôªÌ¡A¤Ï¦Ó¤~·|Åã¥X¥Ü¾A·í´L·q¡C

¬Ý¨ì´¿¸g¦³¤@¡B¤G«h³ø¾É¡A°OªÌ¹ï©ó¹ï·Ó²Õ¥~°ê¤H

µo©úªºÃÄHU¦Ê¯ëºûÅ@¡A¦Û¤v°ê¤Hµo©ú¯àÅD¤W¥@¬É»R¥xªºÃÄ«o¬O¦Ê¯ë¬D±§¡C

§ó¥i¯ºªº¬O¡A¦³¨Ç¥»¤gªk¤H¹çÄ@¬Û¤Ö¼Æ¥xÆW°OªÌÁ¿ªº¸Ü¡A¦Ó¤£¬Û«H

¥@¬É³»¦yªº¦å²G±M®a,¡¨Dr. Mesa, Dr. Verstovsek, Dr. Gisslinger, Dr. Kiladjian,¡¨

¥H¨ä¾Ç³N¦a¦ì©Ò§@¤§­I®Ñ¥H¤Î¼Ú·ù©x­û©Ò°µ©x¤èªº¥¿¦¡µô¨M!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/3/2 ¤U¤È 09:10:27²Ä 2046 ½g¦^À³
¥~¸ê±}±}¦Y³f....

¤j¤j´N¤£­n´¦¬ï¥L­Ì¤F

¤p¤ß...Á¿¤F...¥L­Ì´N¤£¶R¤F

«¢«¢.....¶}ª±¯ºªº

¥u¬O·d¤£À´½æ¥Xªº¤H...¦b·Q¤°»ò???

¸Ñª¼«e(©Î³\À³¸Ó»¡¼Æ¾Ú¤½§G«e)....¦N¤¿¥¼©w....

¥Ó½ÐÃÄÃÒ«e.....±M·~¸ÑŪ¦nÃa¤£©ú®Ô......

¤£½æ....

²{¦b¤T´ÁÃÄ®ÄÃÒ¹ê¤F....ÃÄÃÒ¤]¶}©l¥Ó½Ð¤F.....

Â÷¤W¥«¾P°â¥u®t¤@¨B¤F......

©~µM²{¦b½æµ¹.....¥~¸ê

©_³f¥i©~°Ú!!!

ÁÙ¬O¨º¥y¸Ü....·|¶V¨Ó¶Vºëªöªº

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/3/2 ¤U¤È 06:37:44²Ä 2045 ½g¦^À³
¥~¸ê¤µ¤Ñ¶R¶i373±i
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p´²¤á10028616  µoªí®É¶¡:2017/3/2 ¤W¤È 08:28:48²Ä 2044 ½g¦^À³
ÃĵØPV·sÃĥӽФW¥«³\¥i ÀòEMA¨ü²z

ctee.com.tw/News/ViewCateNews.aspx?newsid=142064&cateid=sjce

2017/03/02 | ¥Í§Þ²£·~ | §ù¿·»T¡þ¥x¥_³ø¾É

¡@ÃĵØÃÄ(6446)«Å¥¬¡Aµ¦²¤¹Ù¦ñAOP¤½¥q¦V¼Ú¬wÃÄ«~ºÞ²z§½(EMA)»¼¥æªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)·sÃÄP1101(Ropeginterferon alfa-2b¡A©ÎºÙAOP2014¡A°Ó«~¦WBESREMI)·sÃĤW¥«³\¥i¥Ó½Ð(MAA)¡A¤w¦¬¨ìEMA³qª¾¼f®Öµ{§Ç¥¿¦¡®i¶}¡A±À¦ô³Ì§Ö¥i±æ¦b©ú¦~¤W¥b¦~¨ú±oÃÄÃÒ¡A¨Ã¦b¼Ú·ù°ê®a¤W¥«¾P°â¡C

¡@¬°°t¦XÃÄ«~¤W¥«®Éµ{¡AÃĵؤµ¦~1¤ë¶¡¤]¯SÁܽЫe­^°êÃĪ«»P«O°·²£«~ªk³WºÞ²z§½(Medicines & Healthcare products Regulatory Agency, MHRA)°ª¯Å¼f¬d­ûRichard Funnel¡A¨ì¥x¤¤¼t¶i¦æ¬°´Á¤@¶gªº¼ÒÀÀ¬d¼t¡A¹F¨ì¨S¦³¥ô¦óÄY­«(Critical)ªº¯Ê¥¢¡A¤]¨S¦³¥ô¦óªº­«­n(major)ªº¯Ê¥¢¡A¶È¦³¤K­Ó¦¸­nªº(minor)¯Ê¥¢¥i¥H¶i¦æ§ïµ½ªº¦nµ²ªG¡C

¡@Ãĵظ³¨Æªø¸â«C¬hªí¥Ü¡A2¤ë24¤éÀò±oEMA³qª¾¡A¸Ó·sÃĤå¥ó¤w§¹¦¨±Ò°Ê¡uDay 1¡v¼f®Öªº§¹¾ã©Ê½T®Ä¡A§Y¼f®Ö¥¿¦¡¶}©l¡C¦pÀò®Ö­ã¡AP1101±N·|¬O¥þ²y²Ä¤@­Ó³Q®Ö­ã¥Î©óªvÀøPV¯f±wªº¤zÂZ¯À¡A¦ÓÄ~EMA°e¥ó«á¡AÃĵرN¦b¤T¦Ü¤»­Ó¤ë¤º¦V¬ü°êFDA»¼¥æ·sÃĤW¥«¥Ó½Ð¡C°õ¦æªøªL°êÄÁ¥ç«ü¥X¡A¼Ú·ùEMAªº·sÃĤW¥«¼f®Ö¬yµ{¬Û·í©ú½T¡A±N·|¨Ì·Ó¬yµ{¾¨¥þ¤O°t¦X¡C

¡@EMAªº¶°¤¤¼f¬dµ{§Ç¤j­P¦³´X­Ó¶¥¬q¡A¦ý¦X­p¬ù277¤Ñ¡AEMA´N·|°µ¥X®ÖµoÃÄÃÒªº³Ì²×¨M©w(Final Commission decision)¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G©ú¤ß¨£©Ê10141540  µoªí®É¶¡:2017/3/1 ¤U¤È 07:04:58²Ä 2043 ½g¦^À³
·PÁÂAlan¤j
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2017/3/1 ¤U¤È 01:41:18²Ä 2042 ½g¦^À³
©ú¤ß¨£©Ê ¤j±z¦n, ¦³Ãö©ó±z©Ò¸ß°Ýªº¹ï¸Ü, ¬O¦bÁy®ÑªºªÀ¹Î MPN Interferon Forum - (Myeloproliferative Neoplasm)¤¤ Catherine Rademacher ©ó1/25µo°_ªº°Q½×¤º®e¡C

¦ÓÁy®ÑªÀ¹Î Polycythemia Vera support group ¥ç¥iµo²{³¡¤À¯f¤Í¹ïp1101¦³©ÒµÛ¾¥, ¦ý¤W­zªÀ¹Î§¡³]©w¬°¤£¤½¶}, ¦]¦¹¶·¥Ó½Ð¨Ã¼f®Ö³q¹L¤~¥i¶i¤J¡C

¥H¤W¸ê°T½Ð°Ñ¦Ò, ÁÂÁ±z¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gwu701610136601  µoªí®É¶¡:2017/3/1 ¤U¤È 12:06:13²Ä 2041 ½g¦^À³
ÃĵØÃÄPV·sÃÄÀòEMA¨ü²z¤W¥«³\¥i¥Ó½Ð

MoneyDJ·s»D 2017-03-01 11:24:42 °OªÌ ·s»D¤¤¤ß ³ø¾É

ÃĵØÂåÃÄ(6446)«Å§Gµ¦²¤¹Ù¦ñAOP¤½¥q¤w¦V¼Ú¬wÃÄ«~ºÞ²z§½(EMA)»¼¥æªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)·sÃÄP1101¤§·sÃĤW¥«³\¥i¥Ó½Ð¡]Marketing Authorization Application,MAA¡^¡A¨Ã¤wÀòEMA¤å¥ó§¹¾ã©Êªº½T®Ä¡A¦¬¨ìEMA³qª¾¸Ó¼f®Öµ{§Ç¥¿¦¡®i¶}¡A±µ¤U¨Ó¸Ó·sÃıN¶i¤JEMA¼Ú·ù¤HÅé¥ÎÃÄ©e­û·|¤§¼f®Ö¡A¨Ì¾ÚEMA¶°¤¤¼f®Öµ{§Çªº®É¶¡ªí±À¦ô¡A¦³¾÷·|©ó©ú¦~¤W¥b¦~¨ú±oÃÄÃÒ¡B¦b¼Ú·ù°ê®a¤W¥«¾P°â¡C

¦b¥»¦¸»¼¥æMAA«e¡A¼Ú¬w¹Ù¦ñAOP¤½¥q¤ÎÃĵØÃĪºÂù¤è¹Î¶¤»PEMA¾ú¸g¬ùªñ8­Ó¤ëºò±K·¾³q¡A¥]¬A´£¨Ñ¬ì¾Ç©Ê«Øij¡B°e¥ó«e·|ij¡BÁ{§É¸ê®Æ¼Æ¾Úªº·Ç³Æ¡B¬ÛÃöªºCMCµ¥¡A¤w¨Ì­ì¥ý»PEMA¬ù©w®É¶¡¡A¥¿¦¡§¹¦¨EMA°e¥ó¡CÃĵØÃĸ³¨Æªø¸â«C¬hªí¥Ü¡A·sÃÄP1101©ó¥xÆW2¤ë24¤éÀò±oEMA³qª¾¡A¸Ó¤å¥ó¤w§¹¦¨±Ò°Ê¡uDay 1¡v¼f®Öªº§¹¾ã©Ê½T®Ä¡A¤W¥«¼f®Ö®É¶¡ªí¤w¥¿¦¡±Ò°Ê¡A¥Nªí¦b¼Ú·ùÃÄÃÒªº³\¥i®Éµ{¤W¤w¸ó¥X¤FÃöÁ䪺¤@¤j¨B¡C¦pÀò®Ö­ãP1101±N·|¬O¥þ²y²Ä¤@­Ó³Q¥Î©óªvÀøPV¯f±wªº¤zÂZ¯À¡A¦ÓÄ~EMA°e¥ó«á¡AÃĵØÃıN¦b¤T¦Ü¤»­Ó¤ë¤º¦V¬ü°êFDA»¼¥æ·sÃĤW¥«¥Ó½Ð¡C

ÃĵØÃÄ°õ¦æªøªL°êÄÁ¥ç«ü¥X¡A¼Ú·ùEMAªº·sÃĤW¥«¼f®Ö¬yµ{¬Û·í©ú½T¡A¤½¥q·|¨Ì·Ó¬yµ{¾¨¥þ¤O°t¦X¡A¦b²Ä80¤Ñ©Ò¥X¨ãªºªì¨B·N¨£®Ñ¬Û·íÃöÁä¡A¥Ø«eÁöµM¥u¶i¤J¼f®Öªº²Ä¤@­Ó¬P´Á¡A·|¿n·¥©MAOP¤½¥q¦P¤¯¨F½L¥i¯àªº´£°Ý¡A¨Ã©ó²Ä120¤ÑÀòª¾©Ò¦³°ÝÃD«eÁܽÐAOP¤½¥q¦P¤¯¨ÓÃĵØÃÄ¥x¤¤¼t¤@°_ÀÀ¦n¦^ÂЩҦ³ªº´£°Ý¡A¥H½T«O¦b³Ìµu®É¶¡¤º§¹¦¨©Ò¦³ªº¦^ÂСA¨Ï¦A±Ò°Êªº®É¶¡¾¨¦­¶}©l¡A¥Hª§¨ú¦b³Ìµu®É¶¡¤º¨ú±oÃÄÃÒ¡A¦b¼Ú¬w°ê®a¤W¥«¾P°â¡C

ÃĵØÃÄ·sÃÄ¥þ²yµ¦²¤º[µo®i³B¸ê²`ªk³W¸g²z³¯ª´¦cªí¥Ü¡A¥Íª«ÃÄ«~¥²¶·¨ÌEMA³W©w¸g¹L¡u¶°¤¤¼f®Öµ{§Ç¡v¡A¤j­P¦³´X­Ó¶¥¬q¡G­º¥ý¬O±N·sÃĤW¥«³\¥i¥Ó½Ð¤å¥ó»¼¥æ¦Ü¦b­Û´°ªºEMA§¹¦¨¸ê®Æ§¹¾ã©Êªº½T®Ä¡A¦¹¶¥¬qºÙ¬°»¼¥æ½T®Ä´Á¡C¼Ú¬w¹Ù¦ñAOP¤½¥q¦b2¤ë6¤é«e¤w¦VEMA»¼¥æMAA¥Ó½Ð¤å¥ó¡AEMA¤w¦b2¤ë23¤é³qª¾AOP¤½¥q¸Ó·sÃĤw§¹¦¨¦¬¥ó¡A¥¿¦¡±Ò°Ê·sÃĤW¥«¤§¼f®Öµ{§Ç¡A¶i¤J²Ä¤@¶¥¬qªº¼f®Ö¡A´Á¶¡¬°´Á120¤Ñ¡C

¦o¶i¤@¨B«ü¥X¡A²Ä120¤Ñ®É¡AEMA·|¦C¥X©Ò¦³°ÝÃD¡]LoQ¡^µ¹¥Ó½ÐÃÒÃĪºAOP¤½¥q¡A¦¹®É¼f¬d®É¶¡¬O°±¤î­pºâ¡]Clock off¡^¡A­«·s­p®É¡]Clock on¡^«h­nµ¥¨ìEMA±µÀò©Ò¦³¦^ÂЪº¸ê®Æ«á¡A¦A±Ò°Ê²Ä¤G¶¥¬q¼f®Ö¡A¨Ã±µÄò­p®É¡F¦b¼f®Ö¹F¨ì²Ä210¤Ñ¡AEMA·|¥X¨ã¤W¥«³\¥i·N¨£®Ñ§tCHMP opinion¡A­Y¬°¥¿­±·N¨£¡A«h¥i´£¥æ¼Ú·ù©e­û·|½Æ®Ö¡A¨Ã©ó67¤Ñ¤º§¹¦¨¦U¶µ¦æ¬Fµ{§Ç¡A¥ç§Y²Ä277¤Ñ¡AEMA´N·|°µ¥X®ÖµoÃÄÃÒªº³Ì²×¨M©w¡C¤@¸g®Ö­ã¡A§Y¥i¦b¼Ú·ù¤Î¼Ú¬w¸gÀÙ°Ï©Ò¦³¦¨­û°ê®a¾P°â¡C

ªL°êÄÁªí¥Ü¡A¸g¼Æ¦~¨Óªº²Ä¤@¡B²Ä¤G¤Î²Ä¤T´Á¤HÅéÁ{§É¸ÕÅç©Ò±oÁ{§É¼Æ¾Ú¡A¦p¤µ¤wÃÒ©úP1101¥i¤j´T­°§C°Æ§@¥Î¡B´£¤É¦w¥þ©Ê¥B¾¯¶q½Õ¾ã´T«×¤j¡A¤w¹F·¥°ª¤§ªv¡²v¡A¨Ã¥B±Ä¨C¤G¶gµ¹ÃĤ@¦¸¡A¬Û¸û¨C¶gµ¹ÃĤ@¦¸ªº¶Ç²ÎPEG¤zÂZ¯À¨Ó»¡¡AP1101°£¨ã°ªÀø®Ä¥~¡AÁÙ´£¨Ñ§ó¦nªº­@¨ü©Ê©M¤è«K©Ê¡C¯S§Oªº¬O¡AP1101»P¥Ø«e¥«³õIncyte¤½¥q²Ä¤G½u¥ÎÃÄJakafiªvÀøPV¤§Àø®Ä«ü¼Ð¤ñ¸û¥iª¾¡A¥Ñ©óIncyte¤½¥q¥HJakafiªvÀøPVªºReliefÁ{§É¸ÕÅç¤w½T©wµLªk¹F¨ì³Ì²×Àø®Ä«ü¼Ð¡A¦Ó¨äResponseÁ{§É¸ÕÅ窺³Ì²×Àø®Ä«ü¼Ð¨Ã¤£¨ã²Ä¤@½u¥ÎÃĪº±ø¥ó¡A¦]¦¹P1101¥¼¨Ó­Y¶¶§Q¸gEMA»PFDA®Ö­ã¡A±N¥i°µ¬°ªvÀøPV¯e¯fªº²Ä¤@½uÃĪ«¡A³yºÖ¦³»Ý­nªº¯f±w¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2017/3/1 ¤W¤È 08:41:50²Ä 2040 ½g¦^À³
¥þ³¡³£¥u¦³°ò¨È¸Ñª¼¥¢±Ñªº·s»D,¨S¦³Ãĵذe¥óªº·s»D,¯u¬O¤£¤½¥­
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G©ú¤ß¨£©Ê10141540  µoªí®É¶¡:2017/2/28 ¤U¤È 08:17:43²Ä 2039 ½g¦^À³
Alan Liu¤j±z¦n

·PÁ±z¦b¦¹ª©¤£­Âªº¬°ª©¤Í­Ì¸Ñ´b¡A¤p§Ì¤]Àò¯q¨}¦h¡C

·Q©M±z½Ð±Ð#1982½gªº¯f±w°Q½×­ì¤åºô§}¡A¤p§Ì§ä¤FPV REPORTER©xºôÁÙ¦³Áy®Ñ¡AÁÙ¬O§ä¤£¨ì¦¹¹ï¸Ü¦ê¡C

­Y¤è«Kªº¸ÜÁٽд£¨Ñ¡A¤p§Ì·Q¬Ý¬Ý¯f¤Í­Ì¦³¨S¦³«áÄòÃö©óp1101°Q½×¡AÁÂÁÂ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/2/28 ¤W¤È 06:40:58²Ä 2038 ½g¦^À³
The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU), located in London. It began operating in 1995. The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU.

Questions about medicines

How long does it take for a medicine to be evaluated by the Agency?

In general, the Agency will issue an opinion on its evaluation within 210 ¡¦active¡¦ days. However, the clock may be stopped during the procedure to allow companies to answer questions posed by the Agency¡¦s Committees. This leads to the actual evaluation time being longer.

Can the Agency tell me when a medicine will be approved?

The Agency only releases limited information on medicines that are under evaluation. Once the Agency has completed its evaluation of a medicine, it publishes a document summarising its opinion.

The European Commission follows the opinion of the Agency in almost all cases. It takes around two months for the European Commission to approve a medicine after the Agency has given a positive opinion.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/2/28 ¤W¤È 06:30:56²Ä 2037 ½g¦^À³
ÃĵطsÃħð¼Ú·ù ¹LÀYÃö

2017-02-28 00:01:02 ¸gÀÙ¤é³ø °OªÌ¶À¤å©_¡þ¥x¥_³ø¾É

¼Ú·ùEMA¥¿¦¡»{¥i¥xÆW·sÃĨñµ¯Ç¼f¬d¡AÃĵØÃÄÂô¹L²Ä¤@Ãö¡C

Ãĵثť¬¡A¼Ú¬w¹Ù¦ñAOP¤½¥q¤w¦V¼Ú¬wÃĪ«ºÞ²z§½¡]European Medicines Agency, EMA¡^´£¥XRopeginterferon alfa-2b¡]P1101¡^·sÃĤW¥«³\¥i¥Ó½Ð¡]marketing authorization application, MAA¡^¡A¾AÀ³¯g¬°ªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g¡]PV¡^²Ä¤@½u¼Ð·ÇÃĪ«¡A¨ÃÀòEMA½T»{¥Ó½Ð¤å¥ó§¹¾ã¡A¨ÌEMA³W©w®Éµ{©ó2¤ë23¤é±Ò°Ê·sÃļf®Ö¡C

Ãĵئ¹¦¸Àò¼Ú·ù±µ¯Ç¼f¬dªº·sÃÄP1101¡A¬O·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀÃĪ«¡A¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g¡A¦ÓP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g±wªÌªº¥þ²y©Ê²Ä¤T´Á¤HÅéÁ{§É¸ÕÅç¡]PROUD-PV¡^¡AÁ{§É¸ÕÅç¤w©ó2016¦~4¤ëµ²§ô¡C

¾Ú±x¡A¦¹¦¸ÃĵػPAOP¦X§@¶i¦æªºªºP1101Á{§É¤T´Á¸ÕÅçPROUD-PV¡A©ó¼Ú¬w¶i¦æÁ{§É¸ÕÅç¶O¥Î«Y±x¼Æ¥ÑAOP¤½¥q­t¾á¡F¦¹¥~¡AÃĵئb²£«~¶}µo¤è­±²Ö­p§ë¤J4.35»õ¤¸¡C

°e¼f®Éµ{¤è­±¡AÃĵثü¥X¡A¼Ú·ùEMAªº¼f¬dµ{§ÇÄY®æ¡A±q°e¥ó¨ì¼f¬d³£¦³ÄY®æªº®Éµ{³W©w¡A²Ä¤@¶¥¬q©ó2¤ë6¤é°e¥ó«á¡A2¤ë23¤éÀò±o±µ¯Ç«á¡AEMA±N¹ï·sÃļf¬dªº®É¶¡±Ò°Ê210­Ó¤u§@¤éªº¼f¬d´Á­­¡A±q±µ¨ü»¼¥ó·í¤é°_ºâ¡A²Ä120­Ó¤u§@¤é±N¹ï°e¼f·sÃijæ¦ì´£¥X¬ù400¶µ°ÝÃD¡A°e¼f³æ¦ì¦^ÂаÝÃD´Á¶¡¡u­p®É°±¤î¡v¡]¤£­p¤J¼f¬d®Éµ{¡^¡Aµ¥¨ì°e¼f³æ¦ì¥¿¦¡¦^ÂаÝÃD«á¡A¦A±q²Ä121¤Ñ°_ºâ¡A¨ì²Ä210­Ó¤u§@¤é¥¿¦¡¤½§iÃÄÃÒ¬O§_³q¹L¡C

¦¹¦¸Ãĵذe¼fªºP1101¡A¬O°w¹ï¡u¨u¨£¦å²G¯e¯f¡v¶}µoªº·sÃÄ¡A¦Ó¦¹¯e¯f¦U¦³¤£¦Pªºµo¯f¹Lµ{»P¯e¯f¯S¼x¡F¨ä¤¤°©Åè¨t¼W¥Í¯e¯f¡]Myeloproliferative neoplasms, MPNs¡^¬O°©Åè¨t·F²Ó­Mµo¥Í²§±`ÅܤơA¨Ï¨ä¤À¤Æªº¦å²G²Ó­Mµo¥Í¹L«×¼W¥Í©Ò³y¦¨ªº¤@ºØ¯e¯f¡A¥i¤À¬°¯u©Ê¬õ¦å²y¼W¥Í¯g¡]PV¡^¡B¦å¤pªO¼W¦h¯g¡]ET¡^¡BºC©Ê°©Åè©Ê¥Õ¦å¯f¡]CML¡^©M­ìµo©Ê°©ÅèÅÖºû¯g¡]PMF¡^¡C

¨ä¤¤¡A¯u©Ê¬õ¦å²y¼W¥Í¯g¡]PV¡^¬°¨­Åé²£¥Í¹L¶q¬õ¦å²y²Ó­M¼W¥Íªº°©Åè¯e¯f¡A³q±`±w¦³PV¯e¯fªÌªº¯gª¬µo®i¸û½wºC¡A¦³®É¦n´X¦~³£¨S¦³©úÅã¯gª¬¡Aµo¯f¯f¤H¥H¦Ñ¦~¤H©~¦h¡C¦]¬°¬õ¦å²y¹L¦h¡A¦å²GÂH¸Y¡AÄY­«ªºÁÙ·|³y¦¨µÊŦ¸~¤j¡B¦å®ê¡A¼W¥[¤¤­·¦MÀI¡A¥Ø«e¶È¯à¾a©w´Á©ñ¦å¨Óºû«ù¥¿±`¦å²G¿@«×¡A«o¥i¯à¦]¬°­«½Æ©ñ¦å¤Þµo¨ä¥L¨Öµo¯g¡A¦p¦å¤pªO¹L¦h¯gµ¥¡C

§ïµ½¤zÂZ¯À ­°§C°Æ§@¥Î

Ãĵص¦²¤ªøªL°êÄÁªí¥Ü¡AP1101¬O¬°¤j´T§ïµ½¼Æ¤Q¦~¨Óµu®Ä¤Î¶Ç²ÎPEGªø®Ä¤zÂZ¯À¡A¸g¤HÅéÁ{§É¸ÕÅç©Ò±oÁ{§É¼Æ¾Ú¤wÃÒ©ú¡AP1101¥i¤j´T­°§C°Æ§@¥Î¡B´£¤É¦w¥þ©Ê¥B¾¯¶q½Õ¾ã´T«×¤j¡A¤w¹F·¥°ª¤§ªv¡²v¡A¥¼¨ÓÃĵØP1101¥¼¨Ó­Y¶¶§Q¸g¼Ú·ùÃĺÊÁ`§½¡]EMA¡^»P¬ü°ê­¹Ãĸp¡]FDA¡^®Ö­ã¡A±N¦³¾÷·|°µ¬°ªvÀøPV¯e¯fªº²Ä¤@½uÃĪ«¡C

¾Ú¤F¸Ñ¡A¶Ç²Î¤zÂZ¯ÀÃĪ«°Æ§@¥Î¤j¡B¯f¤H§Ô¨ü«×®t¡A¦Ó¾É­P¾¯¶qÃø¥H½Õ¤É¡A´«¨¥¤§¡A¦]Àø®ÄµLªk´£¤Éªº¯Ê¥¢¦Ó³]­p¬ãµo¦¨¥\¡CÃĵظg¼Æ¦~¨Óªº²Ä¤@¡B²Ä¤G¤Î²Ä¤T´Á¤HÅéÁ{§É¸ÕÅç¡A¤w¸gÃÒ¹êÀu©ó¶Ç²ÎÃĪ«¡A¯à´£°ª¾¯¶q¥Hªv¡¨u¨£¯e¯f¡C

ªL°êÄÁ»¡¡AP1101¬O¦bÂåÃÄ¥v¤W²Ä¤@¦¸ÃÒ©ú¥i¥H¦w¥þ±Ä¨C¤G©Pµ¹ÃĤ@¦¸¡A¬Û¸û¨C©Pµ¹ÃĤ@¦¸ªº¶Ç²ÎPEG¤zÂZ¯À¡]pegylated interferons¡^¨Ó»¡¡AP1101°£¨ã°ªÀø®Ä¥~¡A§ó´£¨Ñ¤F§ó¦nªº­@¨ü©Ê©M¤è«K©Ê¡C

¥t¥~¡AÃĵتºP1101»P¥Ø«e¥«³õªvÀøPVªº°ß¤@²£«~--Incyte¤§²Ä¤G½u¥ÎÃÄJakafi¤ñ¸û«á¡A¨äÀø®Ä«ü¼Ð¤ñ¸û¥iª¾¡AIncyte¤½¥q¥HJakafiªvÀøPVªºReliefÁ{§É¸ÕÅç¡A¤w½T©wµLªk¹F¨ì³Ì²×Àø®Ä«ü¼Ð¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦n¹B10137114  µoªí®É¶¡:2017/2/27 ¤U¤È 09:12:26²Ä 2036 ½g¦^À³
·Æ½ü¤j+1

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·Æ½ü8ªÎ10136452  µoªí®É¶¡:2017/2/27 ¤U¤È 07:58:42²Ä 2035 ½g¦^À³
¤Q¦~¿i¤@¼C, ­È±o¼y¶P! ¤½¥qªº§V¤O¥O¤H´Ü¨Ø.

¤£¹L¦bÁÚ¦V°ê»Ú»R¥x¤§®É,

ª©¤W­Y¦³»P¤½¥q¼ô¦üªº¤j¤j

½Ð°È¥²µ¹¤½¥q¤@¨ÇIR ¤W»Ý­nª`·Nªº¤p«Øij.

1) ¦bEMA©|¥¼½T©w«e, ´N¦³´CÅé¤j´T³ø¾É.

a) ¸ê°T´¦ÅS¤£¤@­P: ³y¦¨¨ä¥L°OªÌ¤£¶}¤ß

b) Åã¥Ü¤½¥q­n¦h¥[±j information flow management.

c) ¤]¥i¯àÅý¦¹­«°T¹ïªÑ»ùªº¼vÅTÅܤp.

2) ­«°T¤½¥¬¦P®É¨Ã¤£¨£»PAOPªº joint announcement ¤]¨S¨£¨ì­^¤åª©ªº·s»D½Z.

¤@ª½»{¬°¥~¸ê¤~¬O¯uÃѳf¾÷ºc§ë¸ê¤H (¤W¶g¤­²b¶R¶W¹L¥b¤w¸gÅã¥X¸ñ¶H¤F), ¤½¥qÀ³¸Ó§óª`­«¯Ñ¯Ð¨Ã·ÓÅU¨ì¥~¸êªÑªF©Î¼ç¦bªÑªFªºÅv¯q.

IR °µ±o¦n¤£¤@©w·|¦³¥ß¬ñ¨£¼v¤§®ÄªG,

¦ý¬Oªø´Á­Y·f°t¤½¥q°ò¥»­±ªºµo®i,

¥HÃĵتºÃD§÷, ¥~¸êªø´Á«ù¦³­Ó50%³£¤£¤ÓÃø,

¦ý¬O¬Ý¬ÝÂi­±¤W³o¨Ç¥~¸ê«ùªÑ«Ü°ªªº¤½¥q,

¤j·§³£¬O¦bIR¤W¤w¸g¯Ñ¯Ð³\¤[ªº¤½¥q.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°¶¤j¤j10136951  µoªí®É¶¡:2017/2/26 ¤U¤È 11:06:02²Ä 2034 ½g¦^À³
¥H«e¡A§Ú­Ì·|»{¬°ÃÄÃÒªº¥Ó½Ð¡A´N¹³¤@¯ëªº¤H¥Á¥Ó½Ð®×¥ó¤@¼Ë¡A

¥h¨ì¬F©²¾÷Ãö¡A»â¤@±iµP¤l´N¥iÂ÷¶}¡Aºâ¬O§¹¦¨¥Ó½Ðµ{§Ç¡A¨ä¹ê¤£µM¡C

³o¤]¬O§Ú³Ìªñ¤~¾Ç¨ì¤§ª¾ÃÑ¡C

¦b°ê¥~ÃÄÃÒªº¥Ó½Ð(EMA)¡A¬O«Ü¥J²Ó¸òÁcº¾ªº¡C

«e«e«á«á´N­nªá¤W¤@­Ó¤ë¡CAOP±q¤ëªì´N¶}©l°e¥ó¡A

¨Ì·ÓEMA¨ä³W½d»P¼Ð·Ç¡A¤@¥ó¥ó­n¨D¨ì¦ì¡A¨ì³Ìªñ20´X¸¹¡A

¤~ºâ§¹¦¨¡A§¹¦¨¡¨³ø¦W¤âÄò¡¨¡C

23¤é¶}©l¼f¡A¨ä¼f®Ö´N¬O°w¹ï§A©Ò§e²{¤§¤º®e¡A

¬O§_¦³¤£À´ªº¦a¤è¡A­n§A¦^µª¡C

©Ò¥H§A¥Ó½Ð©Ò§e²{¤§¤º®e¡A´N¥ý¥²¶·¥ý²Å¦X¨ú±oÃÄÃÒ¤§­n¥ó¡A

§_«h³s³ø¦W³£¤£µ¹§A³ø¦W¡C©Ò¥H¯à¶i¤J¼f¬dµ{§Ç¡A

³£¬O¤w¸g²Å¦X°ò¥»­n¥ó¡A¤Ï«h¤£¥i¯à¥¿¦¡¶i¤J¼f¬dµ{§Ç

¡AEMA©x­û¤]¤£·|®ö¶O®É¶¡¡C©Ò¥H¯à§¹¦¨³ø¦WªÌ¡A°£«D¦³­«¤j·å²«

¡A§_«h³£¬O¯à¹LÃö¡C§Ú©Ò±o¨ìªº«H®§À³¸Ó¨S¿ù¡C

¶X³sÄò°²¤é§Ú·Q¿ìªk¤Wºô§ó²`¤Jªº¤F¸Ñ³Q®Ö­ãÃĪ«ªº¬yµ{¡C

¦]¬°§¹¦¨¡¨³ø¦W¤âÄò¡¨ªº½ÆÂø©Ê¡B¬D¾Ô©Ê»P¦¨´N©Ê¡C

¤½¥q¤£­n¤Ó§C½Õ¡AÀ³¸Ó­±¹ï§ë¸êªÌ¡A§ä®É¶¡»P§ë¸êªÌ²á²á¡AÁ¿²M·¡¡A

¤]Åý¤j®a°Ý­Ó°÷¡C

¤W¯Z®É¶¡¡A¤]¥i¦V¤½¥q¤Ï¬M¡A

³o»ò­«¤jªº¨Æ±¡¡A¤£À³¸Ó¡¨ÀA¦ç©]¦æ¡¨¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRookie10143115  µoªí®É¶¡:2017/2/26 ¤U¤È 09:59:54²Ä 2033 ½g¦^À³
®¥³ß,Ãĵؤw¦¨¥\ÁÚ¥X²Ä¤@¨B,

±µ¤U¨Óªº­«ÀYÀ¸´N¬O4/1¦bªF¨ÊÁ|¿ìªºMPN Asia 2017

°ê»Ú¦å²G¯e¯fÅv«Â,Dr. Mesa, Dr. Verstovsek, Dr. Gisslinger,

Dr. Kiladjian, Dr. Pei-Jer Chen,§¡¨üÁܵoªíºtÁ¿

¨ä¤¤16:00 Dr. Gisslinger ºtÁ¿¥DÃD:Results of the PROUD-PV Study

¥i¯à´N·|¦³PROUD-PV§ó¶i¤@¨Bªº¹êÅç¼Æ¾Ú,§Æ±æ¤£¥u¦b18­Ó¤ë»PHU¶Àª÷¥æ¤e,§ó¯à©Ô¶}®t¶Z

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦n¹B10137114  µoªí®É¶¡:2017/2/26 ¤U¤È 08:38:40²Ä 2032 ½g¦^À³
°¶¤j¤j±z¦n

®¥³ß¡Aªø¤[ªº°í«ùµ¥«Ý¡A²×©ó¤SÁÚ¥X¤@¤j¨B¤F¡C

¤p§Ì¦]¬°¤£¤F¸ÑEMAªº¾ú¥v¡A

¥h¦~¥u­n¬O§¹¦¨EMA(¼Ú¬wÃĪ«ºÞ²z§½)¦¬¥óªº®×¤l¡A¨C¤@¥ó³£³q¹L¡C

¦¹¸Ü·í¯u¶Ü¡H ¨º¯u¬O¶W¯Å¤j§Q¦h

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°¶¤j¤j10136951  µoªí®É¶¡:2017/2/26 ¤U¤È 05:39:35²Ä 2031 ½g¦^À³
¤Ñ¹D¹S¶Ô

§¹¦¨°e¥óªº¥Ó½Ð¡A³o¬O¥Í§Þ¥v¤Wªº¨½µ{¸O¡C

¬Ý¨ì³o·s»D¡A¬Q±ß¡A§Ú¥¢¯v¤F¡A¦³ºØ·Q­úªº½Ä°Ê¡C

§Aª¾¹D³o·s»Dªº·N¸q¡C

¥h¦~¥u­n¬O§¹¦¨EMA(¼Ú¬wÃĪ«ºÞ²z§½)¦¬¥óªº®×¤l¡A¨C¤@¥ó³£³q¹L¡C

³o¤]·N¨ýµÛ²Ä¤@¥ó¥Ñ°ê¤H¦Û¤vµo©ú¡A¦Û¤v»s³yªºÃÄ¡A«Ü¥i¯à¼Ú¬ü¤W¥«¡A¥¿¦¡¥´¶i¼Ú¬ü¤HÅé¡C

¦Ó¥B¬O¤@½u¥ÎÃÄ¡C³o¬O¦h»ò¤£Â²³æªº¦¨´N¡C

³o¹ï©ó§Úªº·N¸q¡C

¡§¦h±¡À³¯º§Ú¡A¦­¥ÍµØ¾v¡¨

¨ä¹ê¡A§ë¸ê³o´X¦~¦~¤F¡A¸òµÛÃĵؤ@¸ô¨«¨Ó¡A§Ú·|¸òµÛ¤½¥qªº¦¨¥\¦Ó³ß®®¡A

®À§é¦Óªq³à¡A§Ú¤w§ëª`¤Ó¦h·P±¡¡A¥i¯à±`±`±¡ºüªº°_¥ñ¡A¥ÕÀY¾v¯uªº¬O¶V¨Ó¶V¦h¡C

¹ï©ó§Ú­Ì³o¨Ç¦­¦~ªº§ë¸êªÌ¡A¦³´X¦ì¤Ï¦ÓªÑ»ù°ª§C¨Ã¤£¬O¨º»ò¦b¥G¡A¤Ï¥¿¤]¤£½æ¡C

©Î³\§Ú­Ì­nªº¬O¤@ºØ¦Û§ÚªÖ©w¡A¤@ºØ§O¤H¹ï§Ú²´¥ú¿W¨ìªºªÖ©w¡C

¹ï©ó³o¤@¨Ç¬ì¾Ç®aªº·N¸q:¤G¤Q¦~«e¨ü¬F©²ªºÁܬù¡AªL³Õ¤h®³µÛ¤@¥ó¥Ö½c¬ü°ê»OÆW¨â¦a­¸¡A

©ÔµÛ¤@¸s§Ó¦P¹D¦Xªº»O¸Ç¬ü°ê¤H¸â³Õ¤h¡B¶À³Õ¤h¸g¹L³o»ò¦h¦~ªº¾Ä°«¤¤©ó¦³¤F¦^õX¡A¯u´À¥L­Ì°ª¿³¡C

¤@¸ô¤W¡A§Ú¯uªº«Ü¥Î¤ß¡B²`¤Jªº¤F¸Ñ¤½¥q¡C³o¤@¨Ç¬ì¾Ç®a¥L­Ì¡A©¹©¹§Ñ°O¦Y¶º¡A

§¤¤U¨Ó¤@¤U¤l´N¬O±ß¤W10ÂI¤F¡A¤~¤ß¤£¥Ì±¡¤£Ä@ªºÂ÷¶}¤½¥q¡C

¦³¤@¨Ç­û¤u«Ü«÷ªº¡A¦^®aÁÙ¬OÄ~Äò«ä¯Á»P¬ã¨s¡C

¥Í©R¤¤¦ü¥G¥u¦³¤u§@»P¬ã¨s¡A¥Í¬¡¬O·¥«×¬\Àê¦Ó¥F¨ýªº¡C

¤½¥q¥«­È¤w¤T¡B¥|¦Ê»õ¡A²{ª÷¦³¤T¡B¥|¤Q»õ¡A¤½¥q°ª¼hÁÙ¬O¾ë¹ê¨Ì¡C

°Ñ¥[»¡©ú·|®É¬ðµM¤@³¡¦Ñ·Ý¨®¥X²{¡A¤U¨Óªº³º¬O³o´X¦ìÅý¥Í§Þ¾Ç¥Í½¤«ôªº¤j®v¡AÁÙ¦@­¼¡C

§Ú¬Ý¹L¸â³Õ¤h¬ï¹L³ÌFashion ªº´N¬O¤WÂdºVÆr®É¬ï¤F¤@¨­¬õ¡C

¨ä¾l®É¶¡¡A¨ì¥x¤j®Õ¶é¬Ý¨ì¨º¤@¨Ç±Ð±Âªº¬ïµÛ´XµL¨â¼Ë¡C

¤W¤Ñ·|À°§U¨º¤@¨Ç¾Äµo§V¤Oªº¤H¡C

´N¬OÃĵسoºØ¾ë¹ê¦Ó¾Äµoªº¤å¤Æ¡AÅý§Ú¸ò¤@¸s§ë¸êªÌ¡A¤£±ó¤£Â÷¡A

¬Æ¦Ü©ÛªB¤Þ¦ñªº§ë¤J¡A¦]§Ú­Ì¬Û«H:¤Ñ¹D¹S¶Ô!

¦A¦¸®¥³ßÃĵءA§A­Ì¯uªº¤F¤£°_!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬ù¿«10143522  µoªí®É¶¡:2017/2/25 ¤U¤È 12:44:42²Ä 2030 ½g¦^À³
¥~¸êºCºC¶R~¤Ñ¤Ñ¶R~·Å¤ôµN«Cµì~
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/2/24 ¤U¤È 08:09:21²Ä 2029 ½g¦^À³
¡i¤½§i¡jÃĵØÂåÃļڬw¹Ù¦ñAOP¤½¥q¤w§¹¦¨±NÃĵØÂåÃÄRopeginterferon alfa-2b¡]P1101¡^¦V¼Ú·ùEMA´£¥X·sÃĤW¥«³\¥i¥Ó½Ð

2017/02/24 18:16 ¤¤¥¡ªÀ

¤é¡@¡@´Á¡G2017¦~02¤ë24¤é

¤½¥q¦WºÙ¡GÃĵØÂåÃÄ (6446)

¥D¡@¡@¦®¡GÃĵØÂåÃļڬw¹Ù¦ñAOP¤½¥q¤w§¹¦¨±NÃĵØÂåÃÄRopeginterferon alfa-2b¡]P1101¡^¦V¼Ú·ùEMA´£¥X·sÃĤW¥«³\¥i¥Ó½Ð

µo¨¥¤H¡G¶À¥¿¨¦

»¡¡@¡@©ú¡G

1.¨Æ¹êµo¥Í¤é:106/02/24

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:

¥»¤½¥q¼Ú¬w¹Ù¦ñAOP¤½¥q¤w¦V¼Ú¬wÃĪ«ºÞ²z§½(European Medicines Agency, EMA)

´£¥XRopeginterferon alfa-2b¡]P1101¡^·sÃĤW¥«³\¥i¥Ó½Ð¡]marketing

authorization application, MAA¡^¡A¾AÀ³¯g¬°ªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)²Ä¤@½u

¼Ð·ÇÃĪ«¡A¨Ã¤w¸gÀòEMA½T»{¥Ó½Ð¤å¥ó§¹¾ã¨Ã¨ÌEMA³W©w®Éµ{©ó2017¦~2¤ë23¤é±Ò°Ê

·sÃĪº¼f®Ö¡C

6.¦]À³±¹¬I:µL

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

¤@¡B¬ãµo·sÃĦWºÙ©Î¥N¸¹¡GRopeginterferon alfa-2b¡]P1101¡^

¤G¡B¥Î³~¡GP1101«Y·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀÃĪ«¡A¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)

¤T¡B¹w­p¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¼Ú·ùEMA·sÃĤW¥«³\¥i¥Ó½Ð (MAA¡^

¥|¡B¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G

(¤@)´£¥X¥Ó½Ð/³q¹L®Ö­ã/¤£³q¹L®Ö­ã¡G·sÃÄP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g

(PV)±wªÌªº¥þ²y©Ê²Ä¤T´Á¤HÅéÁ{§É¸ÕÅç(PROUD-PV)¡AÁ{§É¸ÕÅç¤w©ó2016¦~

4¤ëµ²§ô¡C

ºô­¶¡Ghttps://clinicaltrials.gov/ct2/show/NCT02218047?term=proud-pv-&rank=1

(¤G)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¤½¥q©Ò­±Á{¤§­·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î¡C

(¤T)¤w³q¹L¥Øªº¨Æ·~¥DºÞ³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡GP1101©ó¼Ú¬wÃĪ«ºÞ²z§½´£¥X

·sÃĤW¥«³\¥i¥Ó½Ð¡A±N¥[³tP1101¦b¼Ú¬wªº·sÃĮ֭ã¤W¥«¡A¹ï¥»¤½¥q¥¼¨ÓÀç

¹B¦³¥¿­±¤§¼vÅT¡C

(¥|)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡GPROUD-PV©ó¼Ú¬w¶i¦æÁ{§É¸ÕÅç¶O¥Î«Y±x¼Æ¥ÑAOP¤½

¥q­t¾á¡F¦Ó¥»¤½¥q²Ö¿n¤w§ë¤J¤§¬ÛÃö¶O¥Î¬ù·s¥x¹ô435,028¤d¤¸(¤£§t«e­z

¶O¥Î) ¡C

¤­¡B±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡GÀò±o·sÃĮ֭ã¨ú±oÃÄÃÒ¡C

(¤@)¹w­p§¹¦¨®É¶¡¡G

ÃÄÃÒ¹ê»Ú®Ö­ã®É¶¡¤Î­ã»é»P§_§¡¬°¼Ú·ùEMA¥DºÞ¾÷Ãö¨Ìªk³W¶i¦æ¡A¼f®Ö¶i«×

§¡¨ÌEMA¥DºÞ¾÷Ãö³W©w®Éµ{¶i¦æ¡C

(¤G)¹w­pÀ³­t¾á¤§¸q°È¡G

¼Ú¬w¦a°Ï¥Ñµ¦²¤¹Ù¦ñAOP¤½¥q­t³d¦V¼Ú·ùEMA´£¥X·sÃĤW¥«³\¥i¥Ó½Ð¨ú±oÃÄÃÒ

¡F¥»¤½¥q«h­t³d¦V¬ü°êFDA´£¥XÃÄÃҥӽСC

¤»¡B¥«³õ²{ªp

¨u¨£¦å²G¯e¯f¦U¦³¤£¦Pªºµo¯f¹Lµ{»P¯e¯f¯S¼x¡A±`±`¬O·¥¬°ÄY­«©Î¬O«Â¯Ù¨ì¥Í©R

ªº¡F¨ä¤¤°©Åè¨t¼W¥Í¯e¯f(Myeloproliferative neoplasms, MPNs)¬O°©Åè¨t·F²Ó

­Mµo¥Í²§±`ÅܤơA¨Ï±o¨ä¤À¤Æªº¦å²G²Ó­Mµo¥Í¹L«×¼W¥Í©Ò³y¦¨ªº¤@ºØ¯e¯f¡A¬ù¥i

¤À¬°¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)¡B¦å¤pªO¼W¦h¯g(ET)¡BºC©Ê°©Åè©Ê¥Õ¦å¯f(CML)©M­ìµo

©Ê°©ÅèÅÖºû¯g(PMF)¡C¨ä¤¤¯u©Ê¬õ¦å²y¼W¥Í¯g(PV )¬°¨­Åé²£¥Í¹L¶q¬õ¦å²y²Ó­M¼W

¥Íªº°©Åè¯e¯f¡A³q±`±w¦³PV¯e¯fªÌªº¯gª¬µo®i¸û½wºC¡A¦³®É¦n´X¦~³£¨S¦³©úÅã¯g

ª¬¡Aµo¯f¯f¤H¥H¦Ñ¦~¤H©~¦h¡C¦]¬°¬õ¦å²y¹L¦h¡A¦å²GÂH¸Y¡A¦å²G¦b¬Y¨Ç²Õ´¬y°Ê

½wºC¦ÓµLªk¨ÑÀ³¨¬°÷ªº®ñ®ð¡A·|³y¦¨¯f¤HÀYµh¡B·w¯t¡B·Pıµê®z¡B©I§l§xÃøµ¥µ¥

ªº¯gª¬¡FÄY­«ªºÁÙ·|³y¦¨µÊŦ¸~¤j¡B¦å®ê¡A¼W¥[¤¤­·¦MÀI¡C¤×¨ä¥Ø«e©|¥¼µo²{¦³

®ÄªvÀø¤èªk¡A¶È¯à¾a©w´Á©ñ¦å¨Óºû«ù¥¿±`¦å²G¿@«×¡A¤£¶È¤£¤è«KÁÙ¥i¯à¦]¬°­«½Æ

©ñ¦å¤Þµo¨ä¥L¨Öµo¯g¡A¦p¦å¤pªO¹L¦h¯gµ¥µ¥¡AÄY­«¼vÅT¯f¤H¥Í¬¡«~½è¡Cµu®Ä©Î¶Ç

²ÎªºPEG¤zÂZ¯ÀÃĪ«¤@ª½¥H¨Ó³£³Q»{¬°¯à°÷ªv¡¦å²G¯e¯f¡A¦ý¬O¯ÊÂI¬°°Æ§@¥Î¹L¤j

Ãø¥H³Q¯f¤H¼sªx±µ¨ü¡C

¥»¤½¥qªºP1101¬O¬°¤j´T§ïµ½¼Æ¤Q¦~¨Óµu®Ä¤Î¶Ç²ÎPEGªø®Ä¤zÂZ¯À¡A¨äÃĪ«°Æ§@

¥Î¤j¡B¯f¤H§Ô¨ü«×®t¦Ó¾É­P¾¯¶qÃø¥H½Õ¤É¥H­PÀø®ÄµLªk´£¤Éªº¯Ê¥¢¦Ó³]­p¬ãµo¦¨

¥\¡A¸g¼Æ¦~¨Óªº²Ä¤@¡B²Ä¤G¤Î²Ä¤T´Á¤HÅéÁ{§É¸ÕÅç©Ò±oÁ{§É¼Æ¾Ú¤wÃÒ©úP1101¤w

¥i¤j´T­°§C°Æ§@¥Î¡B´£¤É¦w¥þ©Ê¥B¾¯¶q½Õ¾ã´T«×¤j¡A¤w¹F·¥°ª¤§ªv¡²v¡A¯S§O¦b

ÂåÃÄ¥v¤W²Ä¤@¦¸ÃÒ©ú¥i¥H¦w¥þ±Ä¨C¤G¶gµ¹ÃĤ@¦¸¡A¬Û¸û¨C¶gµ¹ÃĤ@¦¸ªº¶Ç²ÎPEG¤z

ÂZ¯À¡]pegylated interferons¡^¨Ó»¡¡AP1101°£¨ã°ªÀø®Ä¥~¡A§ó´£¨Ñ¤F§ó¦nªº­@

¨ü©Ê©M¤è«K©Ê¡C¥t¥~§ó¯S§Oªº¬O¡A¥H¥»¤½¥qP1101»P¥Ø«e¥«³õIncyte¤½¥q²Ä¤G½u¥Î

ÃÄJakafiªvÀøPV¤§Àø®Ä«ü¼Ð¤ñ¸û¥iª¾¡A¥Ñ©óIncyte¤½¥q¥HJakafiªvÀøPVªºRelief

Á{§É¸ÕÅç¤w½T©wµLªk¹F¨ì³Ì²×Àø®Ä«ü¼Ð¡A¦Ó¨äResponseÁ{§É¸ÕÅ窺³Ì²×Àø®Ä«ü¼Ð

¨Ã¤£¨ã²Ä¤@½u¥ÎÃĪº±ø¥ó¡A¬G¥»¤½¥qP1101¥¼¨Ó­Y¶¶§Q¸gEMA»PFDA®Ö­ã¡A±N¦³¾÷·|

°µ¬°ªvÀøPV¯e¯fªº²Ä¤@½uÃĪ«¡C

¤C¡B·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A ¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI

¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRookie10143115  µoªí®É¶¡:2017/2/24 ¤U¤È 03:44:45²Ä 2028 ½g¦^À³
¤µ¤Ñ¦¨¥æ¶q494±i¡A¥~¸ê¶R¶W257±i¡A¤@¥bªº¦¨¥æ¶q³£¶i¤F¥~¸êªº¤f³U
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2017/2/24 ¤W¤È 10:41:02²Ä 2027 ½g¦^À³
¥xªÑ¶q¯à¼W¥[, ¦ý¸êª÷¨â·¥¤ÆªººA¶Õ§ó©úÅã,6446 ¥Ø«e¶}½L 1¤p®É 40¤ÀÄÁ, ¦¨¥æ¶q¥u¦³67±i, «D±`¸Ø±i
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G·Æ½ü8ªÎ10136452  µoªí®É¶¡:2017/2/23 ¤W¤È 08:48:58²Ä 2026 ½g¦^À³
P1101 ¤T´Á¤½¥¬«á´¿¸g§â¸ê®Æµ¹¤@¦ì¥xÆW¤H¦b¬ü°õ·~ªºÂå¥Í¬Ý,

¨Ã¸ß°Ý¥«³õºÃ¼{¦³Ãö off-lable use & ÃÄ»ù®t²§

¦^µª«Ü²³æ¡G

1) «OÀIcover ¤U½ÖºÞ§AÃÄ»ù®t²§, ¹ï¯g¤UÃij̭«­n

2) ¨S«OÀI­nÂå¥Í¶}«K©yªºÃÄ, ¨º¥L·|½Ð¯f¤Hñ¤Áµ², ¥H§K¤é«á³Q®aÄݧi.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/2/22 ¤U¤È 10:54:40²Ä 2025 ½g¦^À³
¤Í¯¸¦³¤H´£¨ìoff-label use

¦^À³¦p¤U:

¥xÆW³W©w¦p¤U¡]°ê¥~À³¸Ó¤]¤j¦P¤p²§...§Ú­Ì¤j¦h¾ÇFDAªº)¡G

(¤@)ÃÄ«~¥é³æ¼Ð¥Ü¥~¨Ï¥Î(off-label use)ªº¬ÛÃöªk«ß³W½d¡G

Âå®v¦bÂåÀø¤¤¨Ï¥Î½Ã¥Í¸p©Ò®Ö­ã¥é³æ¼Ð¥Ü¥~ªº¥Î³~¨Ï¥ÎÃĪ«¡A±qÂåÀøªk³W¼h­±¨Ó¬Ý¡AÀ³ÄÝ©óÃĨƪk²Ä7±ø©Ò¿×·sÀø®Ä½Æ¤è©Î·s¨Ï¥Î³~®|»s¾¯¤§ÃÄ«~¡C·sÀø®Ä½Æ¤è³¡¤À¡A¬O¨S¦³¥]§t¦b½Ã¥Í¸p©Ò®Ö­ãªº½d³ò¤º¡A¦pªGÂå®v¨Ï¥Î¦¹ÃĪ«ªvÀø¡A§YÄÝÃÄ«~¥é³æ¼Ð¥Ü¥~¨Ï¥Î(off-label use)¡AÀ³¨ü·sÃĤW¥«¤§­­¨î¡A¨Ì¾ÚÂåÀøªk²Ä8±ø¤§³W©w¡A·sÂåÀø§Þ³N¡B·sÃÄ«~»Ý¸g¹LÂåÀø¾÷ºc¨Ì¾ÚÂå¾Ç²z½×¶i¦æ¤HÅé¸ÕÅçµ{§Ç¨ÓÃÒ©ú¡A¨Ã¥t¥~°e¥ó¥Ó½Ð®Ö­ã¤~¯à¨Ï¥Î¡C

¦AªÌ¡A¦pÃÄ«~¥é³æ¤W¥¼®Ö¥i¾A¥Î©ó¬Y¨Ç¾AÀ³¯g¡AµM¸ÓÃÄ«~´¿¼sªx³Q¥Î©ó¥é³æ¾AÀ³¯g¥H¥~¤§¨Ï¥Î¡A¦¹®ÉÂå®v¨Ï¥Î©ó¥é³æ¼Ð¥Ü¥~¨Ï¥Î(off-label use)®É¡A«hÀ³¿í¦u¦æ¬F°|½Ã¥Í¸pÂå¨Æ³B©ó¥Á°ê91¦~¤½§i¡u¥é³æ®Ö­ã¾AÀ³¯g¥~ªº¨Ï¥Î(off -label use)¡v­ì«h(½Ã¸pÂå¦r²Ä0910014830¸¹¨ç)¦p¤U¡G

1.»Ý°ò©óªvÀø¯e¯fªº»Ý­n¡C

2.»Ý²Å¦XÂå¾Ç­ì²z¤ÎÁ{§ÉÃIJz¡C

3.À³¾Ú¹ê§iª¾¯f¤H¡C

4.¤£±o¹H¤ÏÃÄ«~¨Ï¥Î·í®É¡A¤wª¾ªº¡B¨ã¤½«H¤OªºÂå¾Ç¤åÄm¡C

5.¥ÎÃÄÀ³ºÉ¶q¥H³æ¤è¬°¥D¡A¦p¦P®É¨Ï¥Î¦hºØÃÄ«~¡AÀ³¯S§Oª`·N¨äºî¦X¨Ï¥ÎªºÀø®Ä¡BÃÄ«~¥æ¤¬§@¥Î©Î¤£¨}¤ÏÀ³µ¥°ÝÃD¡C

°ò©ó¤W¶}¨ç¤å¡A¦æ¬F°|½Ã¥Í¸p¦ü¥¼¸T¤îÂå®v¬°¡u¥é³æ®Ö­ã¾AÀ³¯g¥~ªº¨Ï¥Î(off-label use)¡AµMĤ¦C¨Ï¥Î¤§­ì«h¡F¶à99¦~6¤ë2¤é½Ã¥Í¸p¥ç¦A«×¥H½Ã¸pÂå¦r²Ä0990262180¸¹¨ç¨çª¾¡u¥é³æ®Ö­ã¾AÀ³¯g¥~ªº¨Ï¥Î(off-label use)­ì«h¡A±j½Õ¡GÂå®v¦p¸g±M·~§PÂ_¡A¦³¥²­n³B¤è®Ö­ã¾AÀ³¯g¥~¨Ï¥ÎÃÄ«~¤§«e¡AÀ³¨Ì¸Ó­ì«hÂÔ·Vµû¦ô¨ä®Ä¯q¤Î­·ÀI¡A¨Ã¥R¤À§iª¾¯f¤H¡A¨ú±o¨ä¦P·N©l±o¨Ï¥Î¡A¥HÁקKµo¥ÍÂåÀøª§Ä³¡C

´«¨¥¤§¡A¥Ø«eÂåÀø¾÷ºc©ÎÂå®v¹ï©óÃÄ«~¥é³æ¼Ð¥Ü¥~¤§¨Ï¥Î(off -label use)¡A¦pÄÝ©ó¡u¥é³æ®Ö­ã¾AÀ³¯g¥~ªº¨Ï¥Î¡v¡A¤£¶È»Ý²Å¦X½Ã¥Í¸pÂå¨Æ³B©Ò¹{¥¬¤§¡u¥é³æ®Ö­ã¾AÀ³¯g¥~ªº¨Ï¥Î(off -label use)¡v­ì«h¡A¾Ú¹ê§iª¾¯f¤H¡B²Å¦XÂå¾Ç­ì²z¤ÎÁ{§ÉÃIJz¡A¨Ã¤£±o¹H¤ÏÃÄ«~¨Ï¥Î·í®É¤wª¾ªº¡B¨ã¤½«H¤OªºÂå¾Ç¤åÄm¥~¡A§óÀ³¥ý¨ú±o¨ü¸ÕÅçªÌ¤§®Ñ­±¦P·N¡A©l²Åªk¨î¡C

ºK¦Ûwww.chainye.com/c_law03_detail.asp?ids=18

³o´N¬O¦h¦ì¤j¤j´£¨ìªº...

¦pªG¦³®Ö­ãªº¤@½u¥ÎÃÄ...¤j¦h¼ÆªºÂå¥ÍÁÙ·|«_ÀI¥Îoff-label use¶Ü??

¦b°ê¥~ÂåÀøªÈ¯É·|½ß¦º¤Hªº!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦n¹B10137114  µoªí®É¶¡:2017/2/22 ¤U¤È 06:36:12²Ä 2024 ½g¦^À³
LKK¤j

ÁÂÁ¡A»¡¤£©w¤µ±ß¼Ú¬w¨ºÃä´N¦³®ø®§¤F¡A

¬Q¤Ñ¤]¦³¬Ý¤@¤UAOPªººô¯¸¡A¤]¬O¨S¦³¤½§i¤°»ò°T®§¡A«ùÄòÆ[¹î¡C

§Ú­Ó¤H¬O§Æ±æ¤½¥q¥i¥H¦bÄÀ©ñ®ø®§µ¹´CÅé®Éµy·L«O¦u¤@ÂI¡A

»¡ªº¨º»ò¦nªÑ»ùÁÙ¤£¬O¨S¦³¤ÏÀ³¡C

·íµM²{¦b§Ú¤£·|ı±o¤½¥q¬O¬G·Nªº¡A

¦ý¦pªG¤½¥q¥ý¸ò´CÅé³zÅS¡A·í¹ê»Ú¡m¸U¤@¡n¨S¦³³q¹L¡A

³o¼Ë¹ï¤½¥q§Î¶H«Ü¶Ëªº¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/2/22 ¤U¤È 04:56:02²Ä 2023 ½g¦^À³
¦n¹B¤j,¯u²Ó¤ß,«Ü¦n
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/2/22 ¤U¤È 04:47:54²Ä 2022 ½g¦^À³
ÃÒ¥æ©Ò­«¤j°T®§¤½§i

(6446)ÃĵØÃÄ-´CÅé³ø¾É»¡©ú

1.¨Æ¹êµo¥Í¤é:106/02/22

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.¶Ç¼½´CÅé¦WºÙ:¸gÀÙ¤é³øC6

6.³ø¾É¤º®e:

¡uÃĵØÃħð¼Ú ±N¶Ç±¶³ø¡v

¼Ú·ùEMAªº¼f¬dµ{§ÇÄY®æ¡A±q°e¥ó¨ì¼f¬d³£¦³ÄY®æ®Éµ{³W©w¡A²Ä¤@¶¥¬q©ó2¤ë6¤é°e¥ó«á¡A2¤ë23¤é±N¦^Âбµ¯Ç¸ê®Æ»P§_¡A®Ú¾ÚAOP¦h¦~ªº°e¼f¸gÅç¡A©ú¤éÀ³¥i¡u¶¶§Q³qÃö¡v¡C

°e¼f¾AÀ³¯g:¬õ¦å²y¼W¥Í¯g¡B¦å¤pªO¼W¥Í¯g¡B°©ÅèÅÖºû¤Æ¤ÎºC©Ê¦åÀù

7.µo¥Í½t¥Ñ:´CÅé³ø¾É»¡©ú

8.¦]À³±¹¬I:

1.¥»¤½¥q»PAOPÂù¤è¤w©ó¤µ¦~2¤ë6¤é¦@¦P§¹¦¨°e¥óEMAµ{§Ç¡A¦³ÃöEMAÃÄÃҥӽаe¥ó¤é¥HEMA¥¿¦¡³qª¾¬°·Ç¡A¬ÛÃö°T®§½Ð¨Ì¥»¤½¥q¤½§i¸ê°T¡A¯Sµo¥¬¦¹­«¤j°T®§¡C

2.°e¼f¾AÀ³¯g¶È¬°¬õ¦å²y¼W¥Í¯g¡C

9.¨ä¥LÀ³±Ô©ú¨Æ¶µ:·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¯à¤@©w¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2017/2/22 ¤U¤È 02:04:04²Ä 2021 ½g¦^À³
¤µ¤Ñ³o¼Ëºâ?

§Q¦h¤U¶^??

¹j¾Àªº¯E­ô«ç»ò¤@ª½º¦?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRookie10143115  µoªí®É¶¡:2017/2/22 ¤W¤È 09:39:35²Ä 2020 ½g¦^À³
©t¨àÃĦ³§Ö³t³qÃö§¹J¶Ü¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/2/22 ¤W¤È 06:20:03²Ä 2019 ½g¦^À³
ÃĵØÃħð¼Ú ±N¶Ç±¶³ø

2017-02-22 00:04:44 ¸gÀÙ¤é³ø °OªÌ¶À¤å©_¡þ¥x¥_³ø¾É

¥xÆW·sÃħð¤J¼Ú·ù¡AÃĵØÂåÃÄ¡]6446¡^¸³¨Æªø¸â«C¬h¬Q¡]21¡^¤éªí¥Ü¡AºX¤Uªø®Ä¤zÂZ¯ÀP1101¡]Ropeginterferon alfa-2b¡^¤w¥¿¦¡°e¥ó¼Ú·ùÃÄ«~¼fÅç³æ¦ìEMA¡]European Medicines Agency¡^¬O¥xÆW¦Û¥D¶}µo·sÃĪº²Ä¤@¨Ò¡C

¸â«C¬h«ü¥X¡AP1101°e¥ó¼Ú·ù«á¡A±N·J¾ã¦³Ãö¬dÅçµn°Oªº¸ê®Æ¡A¦b¤U©u©³°e¥ó¬ü°ê­¹«~ÃĪ«ºÞ²z§½¡]FDA¡^¡A­Y¶¶§Q¥i±æ¦¨¬°¥xÆW¦Û¥D¶}µo¨Ã¦b¬ü¤W¥«ªº­º­Ó·sÃÄ¡A¡u¥xÆWÃÄ«~²×©ó¯à¥¿¦¡¶i­x¼Ú¬ü¡v¡CÃĵØÃĬQ¤éªÑ»ù¦¬160¤¸¡A¤Wº¦1¤¸¡C

¸â«C¬h»¡¡A¦¹¦¸°e¥óªºP1101¬O¥ÑÃĵئۥDµo©ú¡B¶}µo¨Ã¥Ñ¼Ú·ù¦X§@¹Ù¦ñ¦b¼Ú¬w§¹¦¨Á{§É¤T´Á¸ÕÅç¡AÂù¤è©ó¤µ¦~2¤ë6¤é¦@¦P§¹¦¨°e¥óEMAµ{§Ç¡A©ú¤éEMA±N±Ò°Ê¤U¶¥¬q¼fÅçµ{§Ç¡C

¥xÆW¹L¥hÁö¦³ÃÄ«~°e¥ó¼Ú·ù¡A¦ý¨S¦³¤@­Ó¬O¥Ñ¥xÆW¤H¦Û¤vµo©ú¡B¶}µo¨ì°e¥ó¡A¦]¦¹¹ï¥xÆWµo®i¥Í§Þ¡B¥´°ê»Ú¬×¦Ó¨¥¡A¨ã¦³¨½µ{¸O·N¸q¡C

Ãĵسпì¤HªL°êÄÁªí¥Ü¡AP1101¦Û2006¦~¦b¥x¶i¤JÁ{§É«e¶}µo¡A2009¦~¶i¤J¤@´ÁÁ{§É¡A2009¦~¶}©l¤G´ÁÁ{§É¡A¨ì¤F2012¦~©³¶i¤J¤T´ÁÁ{§É¸ÕÅç¡A³ôºÙ¡u¤Q¦~¿i¼C¡v¦³¦¨¡A¥¼¨Ó¡A¬ü°ê¡B¤é¥»¥«³õ¤]±N¥ÑÃĵئۦæ¾P°â¡C

¸â«C¬h«ü¥X¡A¼Ú·ùEMAªº¼f¬dµ{§ÇÄY®æ¡A±q°e¥ó¨ì¼f¬d³£¦³ÄY®æ®Éµ{³W©w¡A²Ä¤@¶¥¬q©ó2¤ë6¤é°e¥ó«á¡A2¤ë23¤é±N¦^Âбµ¯Ç¸ê®Æ»P§_¡A®Ú¾ÚAOP¦h¦~ªº°e¼f¸gÅç¡A©ú¤éÀ³¥i¡u¶¶§Q³qÃö¡v¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2017/2/22 ¤W¤È 04:49:18²Ä 2018 ½g¦^À³
¼f¬d´Á¬O210­Ó¤u§@¤Ñ,¥[¤W¦^ÂÐ

EMA®É¶¡,±À´ú³Ì§Ö¨ú±oÃÄÃÒ¥i¯à·|¦b©ú¦~²Ä¤@©u

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦n¹B10137114  µoªí®É¶¡:2017/2/21 ¤U¤È 11:17:44²Ä 2017 ½g¦^À³
©_©Ç¡A³oºØ®ø®§¤£¬OÀ³¸Ó­n­«°T¤½§G¶Ü¡H

«ç»ò¦n¹³³£¬O¥ýµo´CÅé·s»D½Z

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/2/21 ¤U¤È 11:11:07²Ä 2016 ½g¦^À³
½Ð°Ý¦U¦ì¤j¤j,¦pªG³q¹L¬O¤£¬O´N¦³¥|±iÃÄÃÒ¤F?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµL¹Ð10141268  µoªí®É¶¡:2017/2/21 ¤U¤È 11:01:58²Ä 2015 ½g¦^À³
ªLÁ`»¡¶R¾÷²¼,²Ä¤G´ÁX¤Q¤¸²Ä¤T´ÁXXX,ÃĽæ±o«Ü¦n¦Û¤v·Q
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/2/21 ¤U¤È 10:52:50²Ä 2014 ½g¦^À³
¶Z¤W¥«¤S§ó¶i¤@¨B¤F

¦U¦ìªB¤Í....­@¤ßµ¥«ÝÅo

¥i¯à¨ì¦¬³Î®É....¦^ÀY¤@¬Ý....

160«K©y.....

·íªì........140®É.......¬°¤°»ò¤£¦h¶R¤@ÂI

ǢǢǢ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/2/21 ¤U¤È 10:26:28²Ä 2013 ½g¦^À³
¥xÆW¦Û¥D¶}µo­º¨Ò ÃĵطsÃļڷù°e¼f

2017-02-21 21:16¸gÀÙ¤é³ø °OªÌ¶À¤å©_¢¬§Y®É³ø¾É

¥xÆW¦Û¥D¶}µo·sÃIJĤ@¨Ò¡A±N¥¿¦¡µn³°¼Ú¬w¡CÃĵØÂåÃĺX¤Uªø®Ä¤zÂZ¯ÀP1101¡]Ropeginterferon alfa-2b¡^¤w¥¿¦¡°e¥ó¼Ú·ùÃÄ«~¼fÅç³æ¦ìEMA¡]European Medicines Agency¡^¡A±N¬O¥xÆW¦Û¥D¶}µo·sÃĪº²Ä¤@¨Ò¡C

Ãĵظ³¨Æªø¸â«C¬hªí¥Ü¡AP1101°e¥ó¼Ú·ù«á¡A±N·J¾ã¦³Ãö¬dÅçµn°Oªº¸ê®Æ¡A¦b¤U©u©³°e¥ó¬ü°ê­¹«~ÃĪ«ºÞ²z§½¡]FDA¡^¡A­Y¶¶§Q¡A¤]¥i±æ¦¨¬°¥xÆW¦Û¥D¶}µo¨Ã¦b¬ü¤W¥«ªº­º­Ó·sÃÄ¡C

¼f¬d®Éµ{¤è­±¡A¸â«C¬h«ü¥X¡AEMA¹ï·sÃļf¬dªº®É¶¡­q©w210­Ó¤u§@¤éªº¼f¬d´Á­­¡A±q±µ¨ü»¼¥ó·í¤é°_ºâ¡A²Ä120­Ó¤u§@¤é±N¹ï°e¼f·sÃijæ¦ì´£¥X¬ù400¶µ°ÝÃD¡A°e¼f³æ¦ì¦^ÂаÝÃD´Á¶¡¡u­p®É°±¤î¡v¡]¤£­p¤J¼f¬d®Éµ{¡^¡Aµ¥¨ì°e¼f³æ¦ì¥¿¦¡¦^ÂаÝÃD«á¡A¦A±q²Ä121¤Ñ°_ºâ¡A¨ì²Ä210­Ó¤u§@¤é¥¿¦¡¤½§iÃÄÃÒ¬O§_³q¹L¡C

ÃĵØÂåÃĦ¨¥ß©ó2003¦~¡A¬O¦­¦~¥Ñ¦æ¬F°|§ß´Ó¡B°êµo°òª÷§ë¸êªº«ü¼Ð·sÃĤ½¥q¡A³Ð¿ì¤HªL°êÄÁ¡B¸³¨Æªø¸â«C¬h¬Ò¬O·í¦~¥Ñ¬F©²©µÅó¦^°êµo®i¥Í§ÞªºÂk°ê¾Ç¤H¡A¾ú¸g¤Q¦~§V¤O¡B§ë¤J¶W¹L2»õ¬ü¤¸¡]¬ù·s¥x¹ô62»õ¤¸¡^¡A¸g¾ú¤F¤T´ÁÁ{§É¡B·|¶°¥xÆW³»¦y¬ì¾Ç®a°Ñ»P¡AªL°êÄÁªí¥Ü¡u¥xÆWÃÄ«~²×©ó¯à¥¿¦¡¶i­x¼Ú¬ü¡v¡C

¸â«C¬h»¡¡A¦¹¦¸°e¥óªºP1101¬O¥ÑÃĵئۥDµo©ú¡B¶}µo¨Ã¥Ñ¼Ú·ù¦X§@¹Ù¦ñ¦b¼Ú¬w§¹¦¨Á{§É¤T´Á¸ÕÅç¡AÂù¤è©ó¤µ¦~2¤ë6¤é¦@¦P§¹¦¨°e¥óEMAµ{§Ç¡A©ú¤éEMA±N±Ò°Ê¤U¶¥¬q¼fÅçµ{§Ç¡C

¾Ú±x¡A¥xÆW¹L¥hÁöµM¦³ÃÄ«~°e¥ó¼Ú·ù¡A¦ý¨S¦³¤@­Ó¬O¥Ñ¥xÆW¤H¦Û¤vµo©ú¡B¶}µo¨ì°e¥ó¡A¦]¦¹¹ï¥xÆWµo®i¥Í§Þ¡B¥´°ê»Ú¬×¦Ó¨¥¡A¨ã¦³¨½µ{¸O·N¸q¡C

¦¹¦¸ÃĵتºP1101°eEMA¬dÅçµn°Oªº¾AÀ³¯g¦@¦³¥|ºØ¡A¥]¬A¬õ¦å²y¼W¥Í¯g¡B¦å¤pªO¼W¥Í¯g¡B°©ÅèÅÖºû¤Æ¤ÎºC©Ê¦åÀù¡AÅn¬A¤F¤j³¡¤À´Æ¤âªº¦å²G¯e¯f¡A¨ü¨ì¦å²GÂå¾Ç»â°ìªºÆf¥Ø¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSirius10142542  µoªí®É¶¡:2017/2/21 ¤U¤È 10:26:19²Ä 2012 ½g¦^À³
¥xÆW¦Û¥D¶}µo­º¨Ò ÃĵطsÃļڷù°e¼f

¦¹¦¸ÃĵتºP1101°eEMA¬dÅçµn°Oªº¾AÀ³¯g¦@¦³¥|ºØ¡A¥]¬A¬õ¦å²y¼W¥Í¯g¡B¦å¤pªO¼W¥Í¯g¡B°©ÅèÅÖºû¤Æ¤ÎºC©Ê¦åÀù¡AÅn¬A¤F¤j³¡¤À´Æ¤âªº¦å²G¯e¯f¡A¨ü¨ì¦å²GÂå¾Ç»â°ìªºÆf¥Ø¡C

udn.com/news/story/7240/2298934

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/2/21 ¤U¤È 10:15:06²Ä 2011 ½g¦^À³
Anderson¥S

©Ò¥H©O??µ²ªG½×¶Ü??

ÁÙ¬O¨º¥y¸Ü....·|¶V¨Ó¶Vºë±mªº

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan10136952  µoªí®É¶¡:2017/2/21 ¤U¤È 05:50:31²Ä 2010 ½g¦^À³
¦³«e´ºªº¤½¥q¤£©È±I¹æ¡AªB¤Í¥u·|¶V¨Ó¶V¦h
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRookie10143115  µoªí®É¶¡:2017/2/21 ¤U¤È 05:05:54²Ä 2009 ½g¦^À³
¤µ¤Ñ¥~¸ê¶R¶W167±i¡AªáºXÀô²y+63¡A¼¯®Ú¤j³q+49¡A¼¯®Ú¤h¤¦+29¡A¬ü°Ó¬üªL+25¡A

¦nªB¤Í­Ì³£¦^¨Ó¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/2/21 ¤W¤È 10:19:41²Ä 2008 ½g¦^À³
·íªì§Ú»¡­n¶^¨ì150¤~¯à¶i³õ¡A¬Ý¨Ó150¯uªº¬O­Ó©³¡A¥u¬Oµu©³ªø©³¦³«ÝÅçÃÒ¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/2/21 ¤W¤È 12:02:12²Ä 2007 ½g¦^À³
¬ü°êFDA§å­ã¦N§Q¼w¤½¥qªº¤S¤@´ÚC¨x·sÃÄEpclusa ¤W¥«ªº®ø®§¦b·¥µuªº®É¶¡¤º¶Ç¹M¤j¦¿«n¥_¡C·~¤º´¶¹M»{¬°¡A¦N¤T¥N³o´Ú·sÃĤS±N¬O¦N§Q¼w¥X«~ªº¤@´Ú¤£¨È©ó¦N¤G¥NªºC¨x¯«ÃÄ¡C

¬ü°êFDA§å­ã¦N§Q¼w¤½¥qªº¤S¤@´ÚC¨x·sÃÄEpclusa (¥H¤U²ÎºÙ¦N¤T¥N)¤W¥«ªº®ø®§¦b·¥µuªº®É¶¡¤º¶Ç¹M¤j¦¿«n¥_¡C·~¤º´¶¹M»{¬°¡A¦N¤T¥N³o´Ú·sÃĤS±N¬O¦N§Q¼w¥X«~ªº¤@´Ú¤£¨È©ó¦N¤G¥NªºC¨x¯«ÃÄ¡C´N¦¹¡A¬K«B°ê»ÚÂå¾Ç½s¿è¯S¦a¾ã²z¥XEpclusa¡X¡X³o­Ó¸¹ºÙ¦N¤T¥Nªº·s¤@¥NC¨x¯«ÃĪº¦UºØÀu¶Õ¥HÅWŪªÌ¡C

­ì¤åºô§}¡Gread01.com/emNxdd.html

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/2/20 ¤W¤È 06:34:20²Ä 2006 ½g¦^À³
±M®aÆ[ÂI¡þC¨xÃĻݨDÃzµo ¥x¼t¾÷·|¨Ó¤F

2017-02-20 01:19¸gÀÙ¤é³ø ¤å¡þÆp¥Û¥Í§Þ§ë¸ê¤ÀªR«Ç´£¨Ñ

¤¤°êC¨x±wªÌ¥e¥þ²y¥|¤À¤§¤@¡A2016¦~¦ô¹F5,000¸U¤Hªº¥¨¤jÂåÀø»Ý¨D¡A¨Ï±o¤¤°êC¨x¥«³õ¦¨¬°¤jÃļtªº¥²ª§¤§¦a¡C¤W¤ë©³¬ü°ê¬ã¨sÃÄ«~¦w¥þªº«DÀç§Q²Õ´¡uÃĪ«¦w¥þ±¹¬I¬ã¨s©Ò¡vµo¥¬¤F³ø§i«ü¥X¡A¦N§Q¼w¡]Gilead¡^ºX¤U¨â¶µC¨xºZ¾PÃÄSovaldi©MHarvoni¥X²{ÄY­«°Æ§@¥Î¡A»¡©ú³o¨ÇÃĪ«¾É­P¯f¤H¥X²{¨x°IºÜ¬Æ¦Ü¦º¤`ªº«áªG¡C

¦N§Q¼wªº¨xª¢ÃĦV¨Ó¥HÃÄ»ù©ù¶Q¬°¤H¸á¯f¡A¦b¬ü°ê¨C¿õ°â»ù°ª¹F1,000¬ü¤¸¡A¨C¤H¤@­ÓÀøµ{ªá¶O°ª¹F5.5¸U¦Ü12.5¸U¬ü¤¸¡A¦p¤µ¤SÃz¥XÄY­«°Æ§@¥Î¡A³o¨âÂI¹ï¦N§Q¼w¶i­x¤¤°êC¨x¥«³õ«D±`¤£§Q¡C

¦P®É¡AÀHµÛ¤¤°ê¡u¤Q¤G¤­ÂåÀø§ï­²­pµe¡v¡AC¨x¨¾ªv³Q¯Ç¬°­«ÂI±À°Ê¶µ¥Ø¡A¤j¶}¼f¬d¤§ªù¡C¦Ó¥xÆW½ÃºÖ³¡¤]©çªO¦P·N¡A¤µ¦~«×°_±N¼·20»õ¤¸¨ó§UC¨xªºªvÀø¡A¨â©¤ªº¥¨¤j»Ý¨D¬°¶}µoC¨x·sÃĪº¥xÆW¥Í§ÞÃļt±a¨Ó·¥¤j°Ó¾÷¡C

2013¦~10¤ë¡A¦N§Q¼wºX¤U²Ä¤@¶µªº§ÜC¨x·sÃÄSovaldi¤W¥«¡A¦]ªv¡²v°ª¹F¤E¦¨¥H¤W¡A¥[¤W¨S¦³¤W­z¶Ç²ÎÀøªkªº°Æ§@¥Î¡A¥B¥u»Ý­n¤K¨ì12©PªºÀøµ{¡AÅý¯f±wÁͤ§­Yõ­¡A2015¦~ºX¤U¨â¤ä²£«~Sovaldi¤ÎHarvoni´N¬°¦N§Q¼w±a¨Ó¹O¦Ê»õ¬ü¤¸ªº¶Æ¤H·~ÁZ¡C

2016¦~6¤ë¦N§Q¼w¦A«×¶Ç¥X¨Î­µ¡A¦P®É¥i¥Î©ó¤»ºØ¥D­n°ò¦]¨È«¬ªºC¨xÃĪ«Epclusa¤W¥«¡AÅý¦N§Q¼w¦bC¨x¥«³õ¤Wí©~¥þ²yªº¤ýªÌ¦a¦ì¡C¦ý¦p¤µ³o¨Ç²£«~¶Ç¥XÄY­«ªº°Æ§@¥Î­·ÀI¡AÅý¬Ý¦ü³Q¦N§Q¼wÃbÂ_ªºC¨x¥«³õ¡A¦ü¥G¦³¤F¯}¤f¡C

ISMP³ø§i¤¤ºÊ´ú¤FºI¦Ü2016¦~6¤ë30¤éªº12­Ó¤ë¤º¬ü°êFDA¤£¨}¨Æ¥ó¼Æ¾Ú¡A¥]¬A¤F¨Ó¦Û¦N§Q¼w¡B¦ã§Bºû¡]AbbVie¡^¡B¥²ªv§´¡]BMS¡^©M¼b¥Í¡]J¡®J¡^µ¥ªº¤E¤äª½±µ§@¥Î§Ü¯f¬rÃÄ¡]DAA¡Adirect-acting anti-viral¡^¡C

¦b¦ô­pªº25¸U±µ¨üªvÀøªº¯f¤H¤¤¡A¥X²{¤F524¨Òªº¨x°IºÜ³ø§i¡]0.2%¡^¡A¨ä¤¤165¨Ò³Ì²×¾É­P¦º¤`¡]31.5%¡^¡C¥t¥~¦³761¨Ò³ø§i«ü¥X³o¨ÇC¨xÃĪ«µLªvÀø®ÄªG¡]0.3%¡^¡C¦b¨x°IºÜ¯f¨ÒªºÃĪ«¤¤¡AViekira Pak¡]¼b¥Í¡^¡BSovaldi¤ÎHarvoni¡]¦N§Q¼w¡^¦W¦C«e­T¡C¦Ü©ó¦N§Q¼w³Ì·s¤W¥«ªº¥þ°ò¦]«¬C¨xÃÄEpclusa¡A«h©|µL¨¬°÷¼Æ¾Ú¡C

¶Ç²ÎC¨xªº¼Ð·ÇªvÀø¡A¬Oª`®g¦X¦¨ªº¤zÂZ¯À¨Ö¥Î¤fªA§Ü¯f¬rÃĪ«¹p¤Ú«ÂªL¡]Ribavirin¡^¡A¨C¤H¥­§¡ªá¶O¤j¬ù·s¥x¹ô10¸U¦Ü20¸U¤¸¡A¦ý¤´¦³¦h¶µ°Æ§@¥Î¡A¥]¬Aµo¿N¡Bµo§N¡BÀYµh¡B³h¦å¡B©I§l«æ«P¡B¥Ö½§·kÄoµ¥¡A¦ÓµLªk§¹¦¨¾ã­Ó±Nªñ¤@¦~ªº¤¾ªøÀøµ{¡]48©P¡^¡C

¦b¤¤°ê¡AC¨xªº¦º¤`²v¤w¸g¶W¹L·R´þ¯f¡A¤£¹L¥Ñ©óHCV¡]C«¬¨xª¢¯f¬r¡^ªº·P¬V¨S¦³©úÅã¯gª¬¡A¥Á²³¹ïC¨xªº»{ÃѤ£¨¬¡A¤]ÅýC¨x°ÝÃD¥¼¨ü­«µø¡A¨´¤µ¤¤°ê¥«³õ±µ¨üªvÀøªº¤ñ²v¤´¤£¨ì2%¡C¦¹¥~¡AHCVªº¶EÂ_²v§C¡B¶Ç²ÎªvÀø°Æ§@¥Î°ª¡A³£¬O¾É­P±µ¨üªvÀøªº¯f¤H¤ñ¨Ò¹L§C¡A¨xª¢©~°ª¤£¤Uªº­ì¦]¤§¤@¡C

¥Ñ©ó¤¤°ê¦U¦a°Ï·P¬VHCV°ò¦]«¬¤£¦P¡A¬G¨ã¦³°ò¦]«¬¯S²§©ÊªºDAA¡A¦b¤£¦P¦a°Ï»Ý¦³¤£¦Pªºµ¦²¤¡C¤¤°ê¯f±w¨ü¨ì·P¬V³Ì¼sªxªºHCV°ò¦]¨È«¬¬°1b¡B2a©M3a¡A¥e¨ä¯f¨Ò¼Æ¤ñ²v¬°72.5%¡C

¥Ø«e°£¤F¥xÆW°ê½Ã°|¶}µoªºMB110¡]¤w§ÞÂत¤Ñ¥Í§Þ¥Ó½Ð¬ü°ê¤@´ÁÁ{§É¸ÕÅç¡^¥i¦³®Ä§í¨î1b¡B2a©M3aµ¥HCV°ò¦]¨È«¬¥~¡A°ê»ÚÃļt©Ò¶}µoªº·sÃĦh¬°°w¹ï¼Ú¬ü°ò¦]«¬¡A¶È¦N§Q¼w¥i°w¹ï¥þ°ò¦]«¬ªºEpclusa¡A¬O°ß¤@¦b¤¤°ê¨È«¬C¨x·sÃÄ¥«³õªº³Ì¤jÄvª§ªÌ¡C

¤¤°ê¦Û¡u¤Q¤@¤­­pµe¡v°_¡]2006-2010¦~¡^¡A¶}©l¿n·¥§ïµ½C¨x°ÝÃD¡A¤Q¤G¤­­pµe°_µo®iC¨x·sÃĤά̭]¡CºC©ÊC¨x¯f±w¤@¥¹¨S¦³§´µ½ªvÀø¡A·|³vº¥ÂàÅܦ¨¨xÅÖºû¤Æ¡B¨xµw¤Æ¡B¬Æ¦Ü¬O¨xÀù¡C¦b¤¤°êÂåÀø§Ö³t¦¨ªøªºÁͶդU¡A«Ø¥ß¨ã¦³«e¤©Ê»P«æ­¢©Êªº¨¾ªv¬Fµ¦¶Õ¦b¥²¦æ¡A¤]°ß¦³Åý¯f¤Hªv¡C¨x¡A¤~¯à­°§CC«¬¨xª¢©Ò­l¥Í¥Xªº¨xµw¤Æ©Î¨xÀùµ¥Ãe¤jÂåÀø¤ä¥X¤ÎªÀ·|¦¨¥»¡C¥h¦~¡A¬O¤¤°ê¹ê¬IÀu¥ý¼f¬dªº²Ä¤@¦~¡A´N¤w¸g¦³27­ÓC¨xÃĪ«Àò±oÀu¥ý¼f¬d¡A´X¥G¥]¬A©Ò¦³°ê¤º¥~¤j¼t¡C

¥Ø«e¥þ²y¤jÃļt¤]¯É¯É¸õ¥X¨Ó¥Ê¤ÀC«¬¨xª¢¥«³õ¡A2015¦~¥«³õ³W¼Ò¹F230»õ¬ü¤¸¡A¥H¦N§Q¼w±j¥e80%ªº190»õ¬ü¤¸³Ì¬ð¥X¡C¦p¤µ¡A¦N§Q¼w©ù¶QªºÃÄ»ù¥[¤W¼ç¦bÄY­«°Æ§@¥Î¡AÅý¤j³°C¨x¥«³õ¥X²{Ävª§§½­±¥X²{Âà¾÷¡A¥xÆWÃļt²{¦bÀ³¥[ºò¸}¨B¶}µo§ó¸gÀÙ¹ê´f¦w¥þªºÃĪ«¡A¾¨¦­¥¬§½¡C

¡]°OªÌ¶À¤å©_¡þ¾ã²z¡^

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/2/20 ¤W¤È 05:17:19²Ä 2005 ½g¦^À³
½Ð°ÝÃĵتºc¨xÁ{§É,¬O¤£¬O©M¤p¤À¤lÃĦX¨ÖÁ{§É ,¨º·|¤£·|¦³²Ä1973½gªº°ÝÃD?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/2/18 ¤W¤È 01:03:56²Ä 2004 ½g¦^À³
¥~¸ê¤w³sÄò¤G¤Ñ¶R280±i¤F,¨ä¹ê¥u­n°ò¥»­±¦n,µ¥«Ý®É¶¡,·í¼Q¥X®É,·Q°l³£¤£´±°l
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRookie10143115  µoªí®É¶¡:2017/2/17 ¤U¤È 03:28:15²Ä 2003 ½g¦^À³
­@¤ßÂI¡A§Ú·Q¤j®a³£¦bµ¥«ÝAOP°e¥óªº®ø®§¡Aµ¥®ø®§­±§ó©ú½T¨Ç¡AÀ³¸Ó·|¦³ªí²{
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦n¹B10137114  µoªí®É¶¡:2017/2/17 ¤U¤È 03:06:36²Ä 2002 ½g¦^À³
别¤ß«æ,±µ着©¹¤U¬Ý~~

¤@®Úªø红©Ô¤W¥h,´N¦³ªk¤H­n°l¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2017/2/17 ¤U¤È 02:43:47²Ä 2001 ½g¦^À³
¤Ñ¤Ñ§Q¦h¦ý«o¤£º¦

1.Äw½X¤w¸g«Üí¤F,¦ý®Ú¥»¨S¦³¤HÄ@·N¥Î¥«»ù¶R

2.µLªk§l¤Þªk¤H°l»ù

3.²³æ¨Ó»¡,´N¬O¦P¼ËªºÃþªÑ,¦³¨Ç¨É¦³°ª¥»¯q¤ñ,¦³¨Ç«o¨S¦³

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p´²¤á10028616  µoªí®É¶¡:2017/2/17 ¤U¤È 12:01:04²Ä 2000 ½g¦^À³
¨È¬w¥Íª«»s«~»sµ{¤j·| ¥x¼t¹Ü5¤j¼ú

2017-02-17 §ù¿·»T¡þ¥x¥_³ø¾É

¡@ 2017¥Íª«»s¾¯»s³y¾Ç·|¨È¬w¤j·|(Biologics Manufacturing Asia 2017¡ABMA)¦b·s¥[©Yµn³õ¡I³Ì¨üÆf¥Øªº¹{¼ú¤¤¡AÃĵØÃÄ¡B¥x±d¡BÁp¥ÍÃÄ¡B¥Ã©ý¤À§O©ê¨«5­Ó¤j¼ú¡A¥Ñ©ó¥@¬É¯Å¤jÃļt¬Ò°Ñ»P²±·|¡A¹ï±o¼ú¤½¥q¥¼¨Ó±ÂÅv©Î°ê»Ú¦X§@¥i±æ¦³ª½±µ§U¯q¡C

¡@¦¹¦¸BMA¤j·|¶i¦æ¤T¤Ñ¡]2/14-2/16)¡A¥]¬AAmgen¡BGenetech¡BSumsung Bioepis¡BCelltrion¡BEli Lilly¡BNovartisµ¥°ê»Úª¾¦W¥Í§Þ»sÃĤ½¥q§¡°Ñ»P²±·|¡C

¡@ÃĵØÃĬO¥H­ì³Ð©ÊPEGªø®Ä«¬³J¥Õ½èÃĪ«¬ãµo§Þ³N¥­¥x¶}µo¤@¨t¦C¥Íª«·sÃĦ³¦¨¡AÀò¹{¡u ¥xÆW³Ì¨Î¥Íª«»sµ{ ¨ô¶V¼ú¡v¡Aµ¦²¤ªøªL°êÄÁªí¥Ü¡AP1101¬°PEGªø®Ä«¬¤zÂZ¯À¡A¬O¬ð¯}©Ê¥Íª«·sÃIJ£«~¡A¥i¥Î©óªvÀø¦hºØ¾AÀ³¯g¡A¦p¨u¨£¦å²G¯e¯f¡BºC©Ê¨xª¢·P¬V ¡B¶Â¦â¯À¸~½F»P¤@¨ÇÄY­«Àù¯gµ¥¡C¥L«ü¥X¡AÀHP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)·sÃÄ¡A±N¦b¤µ¦~¥Ó½Ð¼Ú¡B¬üÃÄÃÒ¤U¡A¤º³¡¤]¶}©l¿n·¥¥¬§½¥Í²£½u¡C

¡@¥t¥~¡A¥x±d«hºaÀò¥xÆW³Ì¨Î¥Íª«»sµ{§Þ³N³Ì°ª¼ú¶µ®íºa(Grand Winner of Best Bioprocess Excellence in Taiwan)¡A¦P®É¤]Àò±o¶}µo³Ð·s§ÜÅé½Æ¦XÅé§Þ³N¤Î¥Í²£¥­¥xªºÀu¿ï¼ú¶µ¡C¥x±d²Ä¤@­Ó¥Íª«¬Û¦üÃÄEG12014¡A¦b2015¦~©³¥¿¦¡¦b¼Ú¬w°e¥ó¶i¤J¤HÅéÁ{§É¸ÕÅç«á¡A³Wµe¦b2017¦~¶i¦æ¥þ²y¤HÅé¤T´ÁÁ{§É¸ÕÅç¡A¸Ó¤½¥q¥Ø«e¤]¥¿¦b¦Ë¥_¿³«Ø¥þ·s³J¥Õ½èÃļt¡C

¡@¦Ü©óÁp¥ÍÃÄ«hÀò¹{ ¡u³Ð·s¥Íª«¤À¤l¶}µo¼ú¡v¡AÁ`¸g²z¹ù¬ü§g¤]Àò¹{¡u¦~«×³Ì¨Î¥Íª«»sÃĤ½¥q¸g²z¤H¼ú¡v¡AÅ㨣¨ä»sµ{§Þ³N»P¬ãµoºÞ²z¦¨´N¤wÀò°ê»ÚªÖ©w¡C

bio.ctee.com.tw/index.php?controller=news&action=cont&id=3363

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/2/16 ¤U¤È 11:06:04²Ä 1999 ½g¦^À³
·PÁÂRookie¤j´£¨Ñªº°T®§¡C(¤º®e¤Ó¦h¤F¡A¬Ý¤£§¹)

¥X®u¥xÆWªº¾ÇªÌ¡A¦³´X­Ó¦n¹³¸òÃĵئ³±K¤ÁªºÃö«Y¡C

¦pChen, Pei-Jer ³¯°ö­õµ¥¡C

¤£¹L¤]µLªk½T©wÃĵجO§_¥X®u¡A­Ó¤H¥ç§ä¤£¨ìÃĵØÃÙ§U¤§¸ê°T¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/2/16 ¤U¤È 10:54:30²Ä 1998 ½g¦^À³
APASL Annual Meeting 2017

Moving Towards HCV Elimination in Asia Pacific in the Era of DAAs

Speakers: Jia-Horng Kao,Taipei

Raising the Bar in HCV Care in Asia: Going Beyond SVR

Speakers: Mei-Hsuan Lee,Taipei

Leading the Way to HCV Cure

Speakers: Jia-Horng Kao,Taipei

China-Innovated DAAs: Eliminating HCV in China by 2030

Speakers:Ming-Lung Yu,Kaohsiung

APASL-AASLD Joint Workshop Travel Award

Yu-Han Huang.Taipei

Young Investigator Award

Yi-Chun Chou , Taichung

YI018 Risk and Adverse Outcomes of Fractures in Patients with Liver Cirrhosis: Two Nationwide Studies

APASL - AASLD Joint Workshop:

Real World Data: Phase 4 studies and Registries

Jia-Horng KAO, Taipei

Liver Cancer

Jia-Horng KAO, Taipei

TIPS for Portal Hypertension

Gin-Ho LO, Kaohsiung

Novel Therapeutic Target and Strategy for HCC

Pei-Jer CHEN, Taipei

Evolving Strategies in LDLT for Hepatocellular Carcinoma

Chao-Long CHEN, Kaohsiung

Prevent Tumor Progression and Recurrence after Liver Transplantation

Po-Huang LEE, Taipei

Risk Factors for HBV Mother-to-child Transmission

Chun-Jen LIU, Taipei

Distinct Seromarkers Predict Different Milestones of Chronic Hepatitis B Progression

Hwai-I YANG, Taipei

Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer

Yen-Hsuan NI, Taipei

Targeted Therapy and Immunotherapy

Ann-Lii CHENG, Taipei

Translational Medicine Course 02

HCV - ¡¥Ideal¡¦ HCV Regimen

Ming-Lung YU, Kaohsiung

Countries and Regions Waiting Approval for DAAs - What is the Best

Management Strategies?

Ming-Lung YU, Kaohsiung

Systemic Therapy and Combination Therapy for HCC

Ann-Lii CHENG, Taipei

Updates from REVEAL Study Cohort

Hwai-I YANG, Taipei

Pediatric Chronic Hepatitis B: Management

Yen-Hsuan NI, Taipei

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRookie10143115  µoªí®É¶¡:2017/2/16 ¤U¤È 03:29:49²Ä 1997 ½g¦^À³
²Ä¤G¤Q¤»©¡¨È¤Ó¨x¯f¾Ç·|¦~·|¡]2/15¡ã2/19¡^¦b¤W®üÁ|¦æ¡A¤£ª¾Ãĵئ³¨S¦³°Ñ¥[¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°¶¤j¤j10136951  µoªí®É¶¡:2017/2/16 ¤U¤È 12:19:28²Ä 1996 ½g¦^À³
ÃĵØÃĶ}µo¥Íª«·sÃĦ³¦¨ Àò¹{¨ô¶V¼ú

ÃĵØÃÄ¡]6446¡^¶}µo¥Íª«·sÃĦ³¦¨¡I¬Q¡]15¡^±ß¦b·s¥[©YÁ|¿ìªº2017¥Íª«»s¾¯»s³y¾Ç·|¨È¬w¤j·|

(Biologics Manufacturing Asia 2017)¤¤¡AÀò¹{µo¡u¥xÆW³Ì¨Î¥Íª«»sµ{¨ô¶V¼ú¡v(Best Bioprocessing Excellence in Taiwan)¡A¨Ã¨üÁÜ©ó¤j·|¤W¶i¦æ±MÃDºtÁ¿¡C

2017¥Íª«»s¾¯»s³y¾Ç·|¨È¬w¤j·|¡A±q2¤ë14¨ì2¤ë16¬°´Á¤T¤Ñ¡A

»P·|ªº¤H­û¶W¹L200 ¤H¡A»P·|°ê®a¥]§t¤F¬ü°ê¡B¿D¬w¡B¼Ú¬w¡B¤é¥»¡BÁú°ê¡B¥xÆWµ¥°ê®a¡A

¦P®É¥@¬É¯Å¤jÃļt¬Ò°Ñ»P²±·|¡C

¸Ó·|ij±´°Q¥Íª«»s¾¯»s³yªºµo®i»PÁͶաAÃĵØÀòÁÜ©ó¤j·|¤W¶i¦æ±MÃDºtÁ¿¡A

®i²{¸Ó¤½¥q¦b·sÃĬãµo»P»s³y¥Í²£ªº¨ãÅ馨ªG¡C

¦P®É¡A¦¹·|ij¤]¶i¦æ2017¦~¡u¨È¤Ó¦a°Ï¥Íª«»sµ{¨ô¶V¼ú¡v

(Asia Pacific Bioprocessing Excellence Awards)ªº¹{µo¡A

µû¼f©e­û¬Ò¬°ªA°È©ó¥@¬É¯ÅÃļtªº°ª¶¥¸g²z¤H¡AÃĵØÀò¹{¡u¥Íª«»s¾¯³Ð·s¼ú¡v¡A

Ãĵإx¤¤¤À¤½¥qÀç¹Bªø÷á­l´É¥Nªí±Â¼ú¡C

÷á­l´É´¿¥ô¬ü°ê´f¤ó¡B½÷·ç¤½¥q¡A¦b¥Íª«»sµ{µo®i»P»s³yªø¹F27¦~®È¬ü¸gÅç¡A

¦¹¤@®íºa¹üÅãÃĵئb¥Íª«»s¾¯»â°ì¨ã¦³³»¦y§Þ³N¡B³Ð·s»sµ{»PÀu¨q«~½è¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/2/14 ¤U¤È 10:51:20²Ä 1995 ½g¦^À³
­ì¥»Jakafi¸òPeggasy¾a¯S©w±Ú¸s´N¦Y¹¡¹¡¤F

­Y¯à¦b¼W¥[³o¨Çlow-risk PV±Ú¸s...

¥i±µ¦¬ªº¥«³õ....´N§ó¤j¤F

»°§Ö¥Ó½ÐÃÄÃÒ¤W¥«§a...

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°]°È¦Û¥Ñ¤H10132540  µoªí®É¶¡:2017/2/14 ¤U¤È 03:49:16²Ä 1994 ½g¦^À³
ÂX¤j¾A¥Î¹ï¶H¤£¤@©w·|»Ý­n°µÁ{§É¤T´Á¡C Low Risk PV IIT ªº¦¬®×¶q¤£¤p¡A¼Æ¾Ú¦³¤@©w¦³°Ñ¦Ò©Ê¡C

¤@¯ë¦Ó¨¥ÂX¤j¾A¥Î¹ï¶H¡A³q±`¬O¦bÃÄ«~¤W¥«¤@¬q®É¶¡«á¡A¦¬¶°§ó¦hªº¥ÎÃĸê®Æ«á¨ä¦w¥þ©Ê»P¦³®Ä©Ê¤@¦pÁ{§É¤T´Á®É¡A§Y¥i¥Ó½ÐÂX¤j¾A¥Î¹ï¶H¡C Low Risk PV IIT Á{§É¸ÕÅç¶O®É¬ù¤T¦Ü¥|¦~°t¦X AOP 2018 ¤W¥«¡A¬Û«H·í Low Risk PV IIT Á{§É¸ÕÅçµ²§ô«á¡A­Y¦¨®Ä¨}¦n¡AÀ³¸Ó´N·|¥Ó½ÐÂX¤j¾A¥Î¹ï¶H¡C

¬ü°ê³oÃä¡A¥i¯à»Ý­n¬Ý Rescue IIT ¯à¤£¯àÀ°¤W¤@¨Ç¦£¡A©ÎªÌ FDA ¹ï©ó¼Ú¬wªºIIT¼Æ¾ÚºA«×¦p¦ó¡A³£¬O¥ª¥k¦b¬ü°êÂX¤j¾A¥Î¹ï¶HªºÃöÁä¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p´²¤á10028616  µoªí®É¶¡:2017/2/14 ¤W¤È 09:14:03²Ä 1993 ½g¦^À³
¥H¤U¬OÃĵا¹¾ãªº·s»D½Z¡A½Ð¦U¦ì¤j¤j°Ñ¦ÒÅo!!!

¦U¦ì´CÅé¥ý¶i ±z¦n¡G

ªþ¥ó¬°ÃĵØÂåÃÄ(6446)PV·sÃÄÂX¥R¾AÀ³¯g¯f±w±Ú¸s·s»D½Z¡A·q½Ð°Ñ¾\¡C

¹Ï»¡¡GBarbui³Õ¤h¡]¥k¡^¥X®u2016¬ü°êASH¦~·|¥ÑÃĵØÂåÃÄ¥D¿ì¤§¤ÈÀ\·|ij¡C

¡iÃĵØÂåÃÄPV·sÃÄÂX¥R¾AÀ³¯g¯f±w±Ú¸s·s»D½Z¡j

µo§G¤é´Á¡G2017¦~2¤ë13¤é

ÃĵØÂåÃÄP1101©µ¦ù¦Ü¦~»´PV¯f±w­Ý¤j´TÂX¤j¥ÎÃıڸs

MPN±Ð¤÷Barbui±Ð±Â¥D¾É¡A±Ò°ÊLow Risk PV IITÁ{§É¸ÕÅç

ÃĵØÂåÃÄ¡]¥H¤U²ºÙ¡¨Ãĵء¨¡A¥xÆWÂd¶R¤¤¤ßªÑ²¼¥N½X¡G6446¡^¤µ(13)¤éªí¥Ü¡A³Ì·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀP1101¡]Ropeginterferon alfa-2b¡^¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g¡]PV¡^¤§PROUD-PV²Ä¤T´ÁÁ{§É¸ÕÅçµ²ªG¹F¼Ð¦¨¥\¡A«ùÄò¦b°ê»ÚMPN¡]°©Åè¼W¥Í©Ê¸~½F¡^¯e¯f»â°ìÀò±o¼ö¯P°Q½×¡C¨ä¤¤¯À¦³MPN±Ð¤÷¬üÅAªº¸q¤j§Q¦å²G¾Ç±Ð±ÂTiziano Barbui±Ð±Â¤w¦VEMA¥Ó½Ð¶i¦æLow Risk PV¥ÑÂå¥Í¥D¾Éªº²Ä¤G´ÁÁ{§É¸ÕÅç(IIT)¡A¥»¸ÕÅç±NÂX¤jP1101¥Î©óªvÀø18-60·³¤§¸û¦~»´±Ú¸s¡C¦¹Á|¥Nªí¡AP1101±N¤£¶È¬OªvÀøPV¯e¯f°ª­·ÀIªº60·³¥H¤W²Ä¤@½u¥ÎÃÄ¡A§ó¦³¾÷·|¦¨¬°¨¾¤îPV¯e¯fµo¥Íªº¹w¨¾©ÊÃĪ«¡A¤j´T´£¤ÉP1101¾AÀ³¯gªº¥«³õ³W¼Ò»PÃĪ«¸gÀÙ»ù­È¡A¤]¬O¥xÆW·sÃĬãµo¦¨ªG¦b°ê»Ú¥ÍÂå»R¥x¹ñÅSÀY¨¤»PªÖ©wªº¤S¤@©úÃÒ¡C

Tiziano Barbui±Ð±Â²{¥ô¸q¤j§QOspedali Riuniti di Bergamo¬ã¨s°òª÷·|¦å²G¾Ç±Ð±Â­Ý¬ì¾Ç¥D¥ô¡A¥Lªø´Á­P¤O©óMPN¯e¯f¤§¬ã¨s¡A¤×¨ä±Mª`©óPV»P­ìµo©Ê¦å¤pªO¼W¦h¯g¡]ET¡^¯e¯f¤§ÃĪ«¬ãµo¡A´¿¥ô°ê»Ú¦å®ê»P¤î¦å¨ó·|¡]ISTH¡^ªº¬õ´³¯T½H§Ü¾®¾¯¤p²Õ©e­û·|¥D®u¡B¸q¤j§Q¦å²G¾Ç·|¥D®u¡Aµoªí¶W¹L200½g¥H¤W¬ÛÃö¤åÄm¡A¥Ø«e¨­­Ý¦h¶µ¾Ç³NÁ{§É¸ÕÅç­pµeªº¥D­n­t³d¤H¡C

Barbui±Ð±Â«ùÄòÃöª`ÃĵØÂåÃĪºPROUD-PVÁ{§É¸ÕÅç¶i®i¡A¦]¦¹·íµ¦²¤¹Ù¦ñAOP¤½¥q©ó¥h¦~¬ü°ê¦å²G¯fÂå¾Ç·|¦~·|¡]ASH¡^«e¤iµoªíPROUD-PVÁ{§Éµ²ªGºK­n(Abstract)²Å¦X¹w´Á®É¡A¨ÏBarbui±Ð±Â§ó¥[³t±À°Ê·s¤@½üPV¯e¯fªºÃĪ«Á{§É¸ÕÅç­pµe¡C

PROUD-PVÁ{§É¸ÕÅçÃÒ©ú¡APV±wªÌ¨Ï¥ÎP1101ªvÀø12­Ó¤ë«á¦b¦å²G¾Ç¤W§¹¥þÀø®Ä¤ÏÀ³®Ä²v(Complete Hematological Response, CHR)»P¨Ï¥Î·Rªv½¦Ån(Hydroxyurea,HU) ±wªÌÅã¥Ü®ÄªG¬Û·í¡C¥i³ßªº¬OP1101»·¤ñHU¾Ö¦³·¥¨Îªº¦w¥þ©Ê»P­@¨ü©Ê¡C¦P®É¦b³h¦å¡B¥Õ¦å²y´î¤Ö¡B¦å¤pªO´î¤Ö¡Bäú¤ß¹Ã¦Rµ¥©Ò¦³°Æ§@¥Î¤W¡A¤]ÃÒ©úP1101»PHUªº¤ñ¸û¦bªAÃĦw¥þ©Ê¤W¤j¬°´£°ª¡A¨Ã¨ã²Î­p¾Ç·N¸q¡]P¡Õ0.01¡^¡C

¦¹¥~¡APROUD-PV²Ä¤T´ÁÁ{§É¸ÕÅç§óÃÒ©ú¡A¦b¸g¹L12­Ó¤ë¦Ü18­Ó¤ëªºªvÀø«á¡A¦b¨Ï¥ÎHUªº³o¤@²Õ¨ÃµLªk¨¾¤îPV¯f±wÂà´«¦¨´c©Ê¸~½F¡A¤Ï¦Ó¬OP1101½T¹ê¥i¥H¹F¨ì¨¾¤îPV¯f±wÂà´«¦¨´c©Ê¸~½Fªº®ÄªG¡A³o¤w¬°¼sªxMPNÂå®v©ÒÃÙ³\ªº¦¨ªG¡C

¥Ñ©óPROUD-PV²Ä¤T´ÁÁ{§É¸ÕÅ窺¬ã¨s²Õ»P¹ï·Ó²Õ¥­§¡¦~ÄÖ³£¦b60·³¡AÄÝ©óPV¯f±w¤¤ªºHigh risk±Ú¸s¡ABarbui±Ð±Â»{¬°P1101³s°ª­·ÀI¨ü¸ÕªÌ³£¯à§Ô¨ü¥BÃÒ©ú¦³®Ä¡A¬Û«H¦bªvÀø60·³¥H¤UPV±Ú¸s¤]·|¦³®Ä¡CBarbui±Ð±Â¯S§OÆg³\PROUD-PVªºÁ{§Éµ²ªG¡BÅã¥Ü¥XP1101·¥¨Îªº¦w¥þ©Ê¤Î­@¨ü©ÊÀ³§ó¾A¦X§C­·ÀI±Ú¸s¯f±w¨Ï¥Î¡A¦]¦¹¿n·¥»PAOP¤½¥q¤ÎÃĵØÂåÃĪ§¨úÁ{§É¥ÎÃĨӷ½¡A§Æ±æ¶i¦æ¥ÑÂå¥Í¥D¾ÉªºÁ{§É¸ÕÅç­pµe¡]investigator-initiated trial¡^¡CÃĵØÂåÃÄ»PAOP¤½¥q¸gµû¦ô«á¦P·N¨ÑÃÄ¡ABarbui±Ð±Â¤D¥H°òª÷·|¦W¸q¥¿¦¡¦VEMA´£¥XLow risk PV²Ä¤G´ÁÁ{§É¸ÕÅç¥Ó½Ð¡A¹w­p©Û¦¬150¦ì18·³¦Ü60·³ªºPV¯f±w¡A¹ï·Ó²Õ¬°©ñ¦å(phlebotomy)¥[¤W§C¾¯¶qªºªü´µ¤ÇªL¡]acetylsalicylic acid¡AASA¡^¡A¸ÓÁ{§É¸ÕÅç®É¶¡¹w©w¬°´Á¤T¦~¡C¬ÛÃö¸ê®Æ¦p¥H¤Uºô§}

clinicaltrials.gov/ct2/show/NCT03003325?term=aop2014&rank=3

ÃĵØÂåÃĶi¤@¨B«ü¥X¡A¥h¦~12¤ë¶¡¥l¶}ªºASH¦~·|¡AMPN¯e¯f¥«³õ³Ì¨üÆf¥ØªºµJÂI¡A²ö¹L©óªvÀøPV¯e¯f¤G¤j¤zÂZ¯À·sÃĦP®É¤½¥¬Á{§É¸ÕÅçµ²ªG¡C¤@­Ó¬OÃĵØÂåÃĵ¦²¤¹Ù¦ñAOP¤½¥q°õ¦æªºPROUD-PV²Ä¤T´ÁÁ{§É¼Ï¯Ã¸ÕÅçµ²ªG¡A¥t¤@­Ó¬OMNP¬ã¨s°òª÷·|ºX¤UMPD¬ã¨sÁp·ù¥D¾ÉªºMPD-RC 112²Ä¤T´Á¸ÕÅç´Á¤¤¤ÀªR¡A¨ä¹êÅç·sÃĬ°Ã¹¤ó¥Í²£ªºPEGASYS¡C¹ï¤ñ¤G¤jÁ{§Éµ²ªGÅã¥Ü¡AÁöP1101»PPEGASYS¤£¬OÀY¹ïÀY¤ñ¸û¡A¦ý³£¬O©MHU°µ¹ï·Ó¡A¥H¦¹Ãþ±ÀµL½×¦bÀø®Ä¡B¦w¥þ©Ê¡A¥H¤Î°Æ§@¥Î¤è­±¡AP1101¬Ò»·Àu©óPEGASYS¡C

¦Ü©ó¦bPV¯f±w³ÌÃö¤ßªº°Æ§@¥Î¡A¦p³h¦å¡B¥Õ¦å²y´î¤Ö¡Bªq³à¡B·w¯t¡B¯h³Ò¡Bäú¤ß¹Ã¦Rµ¥¡A¸g¹LªvÀø¤@¦~«á«hµo²{¡A¨Ï¥ÎPEGASYS¯f±wªºµo¥Í¾÷²v¡A¤£¦ý»·¤j©ó¨Ï¥ÎHUªº¯f±w¡A¬Æ¦ÜÁÙ¤ñ¨Ï¥ÎP1101¯f±w°ª¥X¼Æ­¿¡C¥t¥~¡A¤zÂZ¯À¦bÂå¬É©ÒÃö¤ßªº°Æ§@¥Î¤ñ¦p¼~Æ{¯g¤Î­Â«å¯gµ¥µ¥¡AP1101³£ÃÒ©ú»·¤ñPEGASYS§ó¬°¦w¥þ¡C¼~Æ{¯g¡GP1101(1.6%¡A2/127)¡APEGASYS(28%¡A10/36)¡F­Â«å¯g¡GP1101(12.6%¡A16/127)¡APEGASYS(50%¡A18/36)¡C

¥Ñ©ó¤G¤j¤zÂZ¯À·sÃĹï·ÓHUªº¤T´ÁÁ{§É¸ÕÅç¥X²{ºIµM¤£¦Pªº®t²§¡A¤Þµo»P·|±M®a¾ÇªÌªº¼ö¯P°Q½×¡AÃĵØÂåÃĤDÁܽХ]¬ABarbui±Ð±Â¦b¤ºªº30¾l¦ì°Ñ»PMPD-RC 112Á{§É­pµe¸ÕÅç¥D«ù¤H¡]PI¡^Á|¿ì¤ÈÀ\·|ij¡A¶i¦æ¥æ¬y¡A®u¶¡°µ¤Fµ²½×¥HP1101¨ú¥NPEGASYS IITÁ{§É¸ÕÅç¡A¨Ã´£¥X¦W¬°¡uRESCUE¡vªºÁ{§É¸ÕÅç¡A§â°Ñ»PÁ{§É¸ÕÅçªÌ¥ÎÃÄ¥ÑPEGASYSÂà´«¬°¨Ï¥ÎP1101¡]Ropeginterferon alfa-2b¡^¡A¹w­p¦b2017¦~¤U¥b¦~®i¶}RESCUEÁ{§É¸ÕÅç¡A©¡®É·|¶i¤@

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2017/2/14 ¤W¤È 07:37:18²Ä 1992 ½g¦^À³
Rookie¤j¡A

Proud-PV»PLow-PV¡A¬O¥H¾AÀ³¯gªºÄY­«µ{«×§@¬°Á{§É¹ï¶H¡A¨Ã«D¥H¦~ÄÖ§@¬°°Ï¤À¡C

Proud-PVªºinclusion criteria¬°18·³¥H¤W(18 years or older)¡A¥B¤w¸gÄY­«¨ì»Ý­n±Ä¥Î´î²Ó­MÀøªkªÌ(For previously cytoreduction untreated patients - documented need of cytoreductive treatment)¡A³q±`¯f±w¦~ÄÖ¤w¸g°¾°ª(Proud-PV¯f±wªº¦~ÄÖ¤¤¦ì¼Æ¬ù60·³)¡C¥Ñ©óPV¯f±w¦b¦­´Á¯gª¬¸û»´·L®É¡A¥i±Äªü´µ¤ÇÆF©Î©ñ¦å°µ»´«×ªvÀø¡A¦]¦¹¥H»Ý­n±Ä¥ÎHUªvÀøªº°ª­·ÀI¯f±w§@¬°¾AÀ³¯g±Ú¸sªºProud-PV¡A­ì¥»¦U®a¤ÀªR³ø§i´N¤w¦X²zµû¦ô¥¼¨Óº¯³z²v¬°5~10%¡C

Low-PVªºinclusion criteria¥u¬O±N¦~ÄÖ­­©w¬°60·³¤º(Age 18-60 years)¡A­«ÂI¬O»Ý­n¬°PV¦­´Á(¤T¦~¤º)ªº§C­·ÀI¯f±w(Diagnosis of Polycythemia Vera performed within 3 years prior inclusion in the study and never treated with cytoreductive drugs)¡A¦]¦¹Low-PV study½T¹ê¬O©¹ÂX¤j¾AÀ³¯g±Ú¸s¥hµû¦ô¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSirius10142542  µoªí®É¶¡:2017/2/14 ¤W¤È 12:38:56²Ä 1991 ½g¦^À³
­è¤~¬d¤F¤@¤UClinicalTrials.gov³o­Óºô¯¸¡Aµo²{P1101¥t¥~ÁÙ¦³¨â­ÓÁ{§É¦b°µ(¼x¨D¯f±w¤¤)¡A¤@­Ó¬OCML(ºC©Ê°©Åè©Ê¥Õ¦å¯f)¤@´Á¡A¥t¤@­Ó¬OPMF(°©ÅèÅÖºû¤Æ)¤G´Á¡A¦A¥[¤W¤½¥q¹w­p¥Ñ¬ü°ê¤À¤½¥q°µET(¦å¤pªO¼W¥Í)¤T´Á¡Aµ¥©ó¦bMPN»â°ìªº¥|­Ó¥D­n¯gª¬(PV¡BET¡BPMF¡BCML)³£¤w¸g¦b±À¶i¤¤¡A¤½¥q¦ü¥G»¡ªº¤ñ°µªº¤Ö¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSirius10142542  µoªí®É¶¡:2017/2/13 ¤U¤È 11:41:52²Ä 1990 ½g¦^À³
To: Rookie¤j

²Ä¤@±iÃÄÃÒ³q±`·|±q­«¯g¶}©l®³¡A³o¼ËÁ{§É©Ò»Ý®É¶¡µu¡A¥i¥H¦­ÂI®³¨ìÃÄÃÒ¡A¥ý¦³²{ª÷¶i±b¡A¤§«á¦A©¹«e°µ¡AÂX¤j¾A¥Î±Ú¸s¡C¦Ó¥B»´¯g»P­«¯gªº¹ï·Ó²Õ³B²z¤è¦¡¤£¦P¡A»´¯g¬O¥Î©ñ¦å¥[ªü´µ¤ÇªL¡A­«¯g¬O¥ÎHU¡AµLªk©ñ¦b¤@°_°µ¡C

µ¥ÃÄÃÒ¨ì¤â«á¡A»´¯gªº¤H¦pªG·Q­n¤Î¦­®Úªv¡A·íµM¤]¥i¥Hª½±µ´N¦YP1101¡A¥u­n¸gÀÙª¬ªp¤¹³\©Î¬O¦³«OÀIµ¹¥I¡A¬Û«HÂå®v¤£·|¤Ï¹ï¡C

Ãĵرq¤@­Ó¤ë«e¶}©l³]¥ß¬ü¡B¤é¤À¤½¥q¥[³t·sÁ{§É¡A¨ì²{¦b©¹«eÂX®i¾A¥Î±Ú¸s¡A¤½¥q«ùÄò©¹«e±À¶i¡A«Ü§Ö·|¶}©l¦¬³Î¦¨ªG¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRookie10143115  µoªí®É¶¡:2017/2/13 ¤U¤È 11:09:06²Ä 1989 ½g¦^À³
¥u¬O«Ü¯Ç´e­ì¨ÓªºÃÄÃÒ³W¹º¬O¥u¦³°w¹ï60·³¥H¤W¶Ü¡H

¦b¤½¥q¬ÛÃöªº·s»D½Z¤Îªk»¡·|¦n¹³³£¨S´£¤Î¡A

¨º·íªì¦b°µ¤T´Á®É¡A¬°¦ó¤£¦h¯Ç¤@¨Ç18-60·³ªº¯f±w¡A¤@¦¸¸Ñ¨M

¦Ó¥BÁÙ­n¦Aµ¥¤T¦~¡A¦A¥[¤WÃÄÃÒ¼f²z¡A®£©È¨S­Ó¥|¤­¦~¡A

¤~®³ªº¨ìÃÄÃÒ¡]18-60¡^¡A¨S­@¤ßªº¤H®£©È«ÜÃø®Á

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/2/13 ¤U¤È 10:22:36²Ä 1988 ½g¦^À³
§Q¦hºCºC¯B²{...

·|¶V¨Ó¶Vºë±m!!

60·³¥H¤H¤H¦h?ÁÙ¬O60·³¥H¤U¤H¦h?

µª®×À³¸Ó«Ü®e©ö....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/2/13 ¤U¤È 06:22:20²Ä 1987 ½g¦^À³
¯À¦³MPN±Ð¤÷¬üÅAªº¸q¤j§Q¦å²G¾Ç±Ð±ÂTiziano Barbui±Ð±Â¤w¦VEMA¥Ó½Ð¶i¦æLow Risk PV¥ÑÂå¥Í¥D¾Éªº²Ä¤G´ÁÁ{§É¸ÕÅç(IIT)¡A±NÂX¤jP1101¥Î©óªvÀø18¡ã60·³¤§¸û¦~»´±Ú¸s¡A§ó¦³¾÷·|¦¨¬°¨¾¤îPV¯e¯fµo¥Íªº¹w¨¾©ÊÃĪ«¡C

¤£ª¾¥«³õÂX¤j¦h¤Ö?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gucss10142657  µoªí®É¶¡:2017/2/13 ¤U¤È 05:17:50²Ä 1986 ½g¦^À³
¡i°]°T§Ö³ø¡þ¦ó¬ü¦p³ø¾É¡jÃĵØÂåÃÄ(6446)¤µ(13)¤éªí¥Ü¡A³Ì·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀP1101(Ropeginterferon alfa-2b)¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)¤§PROUD-PV²Ä¤T´ÁÁ{§É¸ÕÅçµ²ªG¹F¼Ð¦¨¥\¡A«ùÄò¦b°ê»ÚMPN(°©Åè¼W¥Í©Ê¸~½F)¯e¯f»â°ìÀò±o¼ö¯P°Q½×¡C¨ä¤¤¯À¦³MPN±Ð¤÷¬üÅAªº¸q¤j§Q¦å²G¾Ç±Ð±ÂTiziano Barbui±Ð±Â¤w¦VEMA¥Ó½Ð¶i¦æLow Risk PV¥ÑÂå¥Í¥D¾Éªº²Ä¤G´ÁÁ{§É¸ÕÅç(IIT)¡A±NÂX¤jP1101¥Î©óªvÀø18¡ã60·³¤§¸û¦~»´±Ú¸s¡A§ó¦³¾÷·|¦¨¬°¨¾¤îPV¯e¯fµo¥Íªº¹w¨¾©ÊÃĪ«¡C

Tiziano Barbui±Ð±Â²{¥ô¸q¤j§QOspedali Riuniti di Bergamo¬ã¨s°òª÷·|¦å²G¾Ç±Ð±Â­Ý¬ì¾Ç¥D¥ô¡A¥Lªø´Á­P¤O©óMPN¯e¯f¤§¬ã¨s¡A¤×¨ä±Mª`©óPV»P­ìµo©Ê¦å¤pªO¼W¦h¯g(ET)¯e¯f¤§ÃĪ«¬ãµo¡A´¿¥ô°ê»Ú¦å®ê»P¤î¦å¨ó·|(ISTH)ªº¬õ´³¯T½H§Ü¾®¾¯¤p²Õ©e­û·|¥D®u¡B¸q¤j§Q¦å²G¾Ç·|¥D®u¡Aµoªí¶W¹L200½g¥H¤W¬ÛÃö¤åÄm¡A¥Ø«e¨­­Ý¦h¶µ¾Ç³NÁ{§É¸ÕÅç­pµeªº¥D­n­t³d¤H¡C

Barbui±Ð±Â«ùÄòÃöª`ÃĵØÂåÃĪºPROUD-PVÁ{§É¸ÕÅç¶i®i¡A¦]¦¹·íµ¦²¤¹Ù¦ñAOP¤½¥q©ó¥h¦~¬ü°ê¦å²G¯fÂå¾Ç·|¦~·|(ASH)«e¤iµoªíPROUD-PVÁ{§Éµ²ªGºK­n(Abstract)²Å¦X¹w´Á®É¡A¨ÏBarbui±Ð±Â§ó¥[³t±À°Ê·s¤@½üPV¯e¯fªºÃĪ«Á{§É¸ÕÅç­pµe¡C

¥Ñ©óPROUD-PV²Ä¤T´ÁÁ{§É¸ÕÅ窺¬ã¨s²Õ»P¹ï·Ó²Õ¥­§¡¦~ÄÖ³£¦b60·³¡AÄÝ©óPV¯f±w¤¤ªºHigh risk±Ú¸s¡ABarbui±Ð±Â»{¬°P1101³s°ª­·ÀI¨ü¸ÕªÌ³£¯à§Ô¨ü¥BÃÒ©ú¦³®Ä¡A¬Û«H¦bªvÀø60·³¥H¤UPV±Ú¸s¤]·|¦³®Ä¡CÃĵØÂåÃÄ»PAOP¤½¥q¸gµû¦ô«á¦P·N¨ÑÃÄ¡ABarbui±Ð±Â¤D¥H°òª÷·|¦W¸q¥¿¦¡¦VEMA´£¥XLow risk PV²Ä¤G´ÁÁ{§É¸ÕÅç¥Ó½Ð¡A¹w­p©Û¦¬150¦ì18·³¦Ü60·³ªºPV¯f±w¡A¹ï·Ó²Õ¬°©ñ¦å(phlebotomy)¥[¤W§C¾¯¶qªºªü´µ¤ÇªL¡C

ÃĵØÂåÃĶi¤@¨B«ü¥X¡A¥h¦~12¤ë¶¡¥l¶}ªºASH¦~·|¡AMPN¯e¯f¥«³õ³Ì¨üÆf¥ØªºµJÂI¡A²ö¹L©óªvÀøPV¯e¯f¨â¤j¤zÂZ¯À·sÃĦP®É¤½¥¬Á{§É¸ÕÅçµ²ªG¡C¤@­Ó¬OÃĵØÂåÃĵ¦²¤¹Ù¦ñAOP¤½¥q°õ¦æªºPROUD-PV²Ä¤T´ÁÁ{§É¼Ï¯Ã¸ÕÅçµ²ªG¡A¥t¤@­Ó¬OMNP¬ã¨s°òª÷·|ºX¤UMPD¬ã¨sÁp·ù¥D¾ÉªºMPD-RC 112²Ä¤T´Á¸ÕÅç´Á¤¤¤ÀªR¡A¨ä¹êÅç·sÃĬ°Ã¹¤ó¥Í²£ªºPEGASYS¡C¹ï¤ñ¨â¤jÁ{§Éµ²ªGÅã¥Ü¡AÁöP1101»PPEGASYS¤£¬OÀY¹ïÀY¤ñ¸û¡A¦ý³£¬O©MHU°µ¹ï·Ó¡A¥H¦¹Ãþ±ÀµL½×¦bÀø®Ä¡B¦w¥þ©Ê¡A¥H¤Î°Æ§@¥Î¤è­±¡AP1101¬Ò»·Àu©óPEGASYS¡C

¥Ñ©ó¨â¤j¤zÂZ¯À·sÃĹï·ÓHUªº¤T´ÁÁ{§É¸ÕÅç¥X²{ºIµM¤£¦Pªº®t²§¡A¤Þµo»P·|±M®a¾ÇªÌªº¼ö¯P°Q½×¡AÃĵØÂåÃĤDÁܽХ]¬ABarbui±Ð±Â¦b¤ºªº30¾l¦ì°Ñ»PMPD-RC 112Á{§É­pµe¸ÕÅç¥D«ù¤H(PI)Á|¿ì¤ÈÀ\·|ij¡A¶i¦æ¥æ¬y¡A®u¶¡°µ¤Fµ²½×¥HP1101¨ú¥NPEGASYS IITÁ{§É¸ÕÅç¡A¨Ã´£¥X¦W¬°¡uRESCUE¡vªºÁ{§É¸ÕÅç¡A§â°Ñ»PÁ{§É¸ÕÅçªÌ¥ÎÃÄ¥ÑPEGASYSÂà´«¬°¨Ï¥ÎP1101(Ropeginterferon alfa-2b)¡A¹w­p¦b2017¦~¤U¥b¦~®i¶}RESCUEÁ{§É¸ÕÅç¡A©¡®É·|¶i¤@¨BÂX¤jP1101¦bªvÀøPV¯e¯f»â°ìªºº¯³z²v¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2017/2/13 ¤U¤È 04:23:17²Ä 1985 ½g¦^À³
ÃĵØP1101ÂX¤j¥ÎÃıڸs ©µ¦ù¦Ü¦~»´PV¯f±w

2017¦~02¤ë13¤é 15:24 §ù¿·»T

ÃĵØÂåÃÄ¡]6446¡^¤µ(13)¤éªí¥Ü¡A³Ì·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀP1101¡]Ropeginterferon alfa-2b¡^¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g¡]PV¡^¤§PROUD-PV²Ä¤T´ÁÁ{§É¸ÕÅçµ²ªG¹F¼Ð¦¨¥\«á¡A±NÂX¤jP1101¥Î©óªvÀø18-60·³¤§¸û¦~»´±Ú¸s¡C

¦¹¥~¡A¯À¦³MPN±Ð¤÷¬üÅAªº¸q¤j§Q¦å²G¾Ç±Ð±ÂTiziano Barbui±Ð±Â¡A¤w¦VEMA¥Ó½Ð¶i¦æLow Risk PV¥ÑÂå¥Í¥D¾Éªº²Ä¤G´ÁÁ{§É¸ÕÅç(IIT)¡C

¸Ó¸ÕÅç±NÂX¤jP1101¥Î©óªvÀø18-60·³¤§¸û¦~»´±Ú¸s¡C¦¹Á|¥Nªí¡AP1101±N¤£¶È¬OªvÀøPV¯e¯f°ª­·ÀIªº60·³¥H¤W²Ä¤@½u¥ÎÃÄ¡A§ó¦³¾÷·|¦¨¬°¨¾¤îPV¯e¯fµo¥Íªº¹w¨¾©ÊÃĪ«¡A¤j´T´£¤ÉP1101¾AÀ³¯gªº¥«³õ³W¼Ò»PÃĪ«¸gÀÙ»ù­È¡A¤]¬O¥xÆW·sÃĬãµo¦¨ªG¦b°ê»Ú¥ÍÂå»R¥x¹ñÅSÀY¨¤»PªÖ©wªº¤S¤@©úÃÒ¡C

Tiziano Barbui±Ð±Â²{¥ô¸q¤j§QOspedali Riuniti di Bergamo¬ã¨s°òª÷·|¦å²G¾Ç±Ð±Â­Ý¬ì¾Ç¥D¥ô¡A¥Lªø´Á­P¤O©óMPN¯e¯f¤§¬ã¨s¡A¤×¨ä±Mª`©óPV»P­ìµo©Ê¦å¤pªO¼W¦h¯g¡]ET¡^¯e¯f¤§ÃĪ«¬ãµo¡A´¿¥ô°ê»Ú¦å®ê»P¤î¦å¨ó·|¡]ISTH¡^ªº¬õ´³¯T½H§Ü¾®¾¯¤p²Õ©e­û·|¥D®u¡B¸q¤j§Q¦å²G¾Ç·|¥D®u¡Aµoªí¶W¹L200½g¥H¤W¬ÛÃö¤åÄm¡A¥Ø«e¨­­Ý¦h¶µ¾Ç³NÁ{§É¸ÕÅç­pµeªº¥D­n­t³d¤H¡C

Barbui±Ð±Â«ùÄòÃöª`ÃĵØÂåÃĪºPROUD-PVÁ{§É¸ÕÅç¶i®i¡A¦]¦¹·íµ¦²¤¹Ù¦ñAOP¤½¥q©ó¥h¦~¬ü°ê¦å²G¯fÂå¾Ç·|¦~·|¡]ASH¡^«e¤iµoªíPROUD-PVÁ{§Éµ²ªGºK­n(Abstract)²Å¦X¹w´Á®É¡A¨ÏBarbui±Ð±Â§ó¥[³t±À°Ê·s¤@½üPV¯e¯fªºÃĪ«Á{§É¸ÕÅç­pµe¡C

PROUD-PVÁ{§É¸ÕÅçÃÒ©ú¡APV±wªÌ¨Ï¥ÎP1101ªvÀø12­Ó¤ë«á¦b¦å²G¾Ç¤W§¹¥þÀø®Ä¤ÏÀ³®Ä²v(Complete Hematological Response, CHR)»P¨Ï¥Î·Rªv½¦Ån(Hydroxyurea,HU) ±wªÌÅã¥Ü®ÄªG¬Û·í¡C¥i³ßªº¬OP1101»·¤ñHU¾Ö¦³·¥¨Îªº¦w¥þ©Ê»P­@¨ü©Ê¡C¦P®É¦b³h¦å¡B¥Õ¦å²y´î¤Ö¡B¦å¤pªO´î¤Ö¡Bäú¤ß¹Ã¦Rµ¥©Ò¦³°Æ§@¥Î¤W¡A¤]ÃÒ©úP1101»PHUªº¤ñ¸û¦bªAÃĦw¥þ©Ê¤W¤j¬°´£°ª¡A¨Ã¨ã²Î­p¾Ç·N¸q¡]P¡Õ0.01¡^¡C

¦¹¥~¡APROUD-PV²Ä¤T´ÁÁ{§É¸ÕÅç§óÃÒ©ú¡A¦b¸g¹L12­Ó¤ë¦Ü18­Ó¤ëªºªvÀø«á¡A¦b¨Ï¥ÎHUªº³o¤@²Õ¨ÃµLªk¨¾¤îPV¯f±wÂà´«¦¨´c©Ê¸~½F¡A¤Ï¦Ó¬OP1101½T¹ê¥i¥H¹F¨ì¨¾¤îPV¯f±wÂà´«¦¨´c©Ê¸~½Fªº®ÄªG¡A³o¤w¬°¼sªxMPNÂå®v©ÒÃÙ³\ªº¦¨ªG¡C

¥Ñ©óPROUD-PV²Ä¤T´ÁÁ{§É¸ÕÅ窺¬ã¨s²Õ»P¹ï·Ó²Õ¥­§¡¦~ÄÖ³£¦b60·³¡AÄÝ©óPV¯f±w¤¤ªºHigh risk±Ú¸s¡ABarbui±Ð±Â»{¬°P1101³s°ª­·ÀI¨ü¸ÕªÌ³£¯à§Ô¨ü¥BÃÒ©ú¦³®Ä¡A¬Û«H¦bªvÀø60·³¥H¤UPV±Ú¸s¤]·|¦³®Ä¡CBarbui±Ð±Â¯S§OÆg³\PROUD-PVªºÁ{§Éµ²ªG¡BÅã¥Ü¥XP1101·¥¨Îªº¦w¥þ©Ê¤Î­@¨ü©ÊÀ³§ó¾A¦X§C­·ÀI±Ú¸s¯f±w¨Ï¥Î¡A¦]¦¹¿n·¥»PAOP¤½¥q¤ÎÃĵØÂåÃĪ§¨úÁ{§É¥ÎÃĨӷ½¡A§Æ±æ¶i¦æ¥ÑÂå¥Í¥D¾ÉªºÁ{§É¸ÕÅç­pµe¡]investigator-initiated trial¡^¡C

ÃĵØÂåÃÄ»PAOP¤½¥q¸gµû¦ô«á¦P·N¨ÑÃÄ¡ABarbui±Ð±Â¤D¥H°òª÷·|¦W¸q¥¿¦¡¦VEMA´£¥XLow risk PV²Ä¤G´ÁÁ{§É¸ÕÅç¥Ó½Ð¡A¹w­p©Û¦¬150¦ì18·³¦Ü60·³ªºPV¯f±w¡A¹ï·ÓÃĬ°§C¾¯¶qªºªü´µ¤ÇªL¡]acetylsalicylic acid¡AASA¡^¡A¸ÓÁ{§É¸ÕÅç®É¶¡¹w©w¬°´Á¤T¦~¡C

(¤u°Ó)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/2/12 ¤U¤È 09:58:07²Ä 1984 ½g¦^À³
¬Ý¼Ë¤l...

¥i¯à¶}©l­nºë±m¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/2/12 ¤U¤È 12:04:49²Ä 1983 ½g¦^À³
³Ì­«­nªº¬OÁÈ¿ú,ÁȤj¿ú
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°¶¤j¤j10136951  µoªí®É¶¡:2017/2/8 ¤U¤È 10:09:11²Ä 1982 ½g¦^À³
¤@¥»­È±o¤@¦A¾\ŪªºÃĵؾÇ

¤j¾ÇÁp¦Ò¡¨Âå¾Ç¨t¡¨¥Ã»·³ÌÃø¦Ò¡C

¥ÍÂå¬É¡A·sÃĬãµo¤]¬O³Ì³»¦y¡A§ë¸êªÌ­n·dÀ´¤]¬O³Ì§xÃøªº¡C

1¥²¶·­n¦³«Ü±jªº¥~¤å¯à¤O¡A¦Ü¤ÖÅ¥»P¾\Ū³£­n«Ü±j¡C

2°ò¥»Âå¾Çª¾ÃÑ

3²Î­p¾Ç¡B¤W¥«ªº¬yµ{¡K.

4«Ü¦nªº¤ß²z¯À½è

§Ú¡A¶W¹L¤Q¦~¨Ó¡A¥u¬ã¨s¡§Ãĵؾǡ¨³o¤@¥»Á}ÀßÃøÀ´ªº®Ñ¡A´N¤w¸g¥ÎºÉ¤ß¤O¡A

·PıÁÙ¬OÃø¥Hµn°ó¤J«Ç¡A¦ü¥G¥Ã»·³£¦³¸Ñ¤£§¹ªºµª®×¡C

¦³®À§é¡A¦³Åå©_¡A¤]·PÁ¦U¦ì¤j¤j¡AÅý§Ú¤@ª½¦¨ªø¡C

§Ú«Üºa©¯¦­¦­·f¤WÃĵسo¤@¯Z¦C¨®¡A¦]§Ú¤@ª½¬Û«H:

¶V°ªÃø«×¡A¶VÁ}²`ªº»â°ì¡A¤~­È±o§Ú­Ì¶Vªøªº¾Ö¦³¡A

»Ý¥I¥X§ó±oªº®É¶¡¡A¥Î¤ß°l¨D¡C

¥¦ªº¦^õX§ó­È±o´Á«Ý¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦¿¤p¶¢10142793  µoªí®É¶¡:2017/2/8 ¤U¤È 09:33:26²Ä 1981 ½g¦^À³
¦³¨S¦³¤j¤jª¾¹D¡AÃĵؤ°»ò®É­Ô·|¶}©ñ«H¥Î¥æ©ö©O¡Hºâ¤@ºâ«Ü¹³º¡¤»­Ó¤ë¤F¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GArthur121110143792  µoªí®É¶¡:2017/2/8 ¤U¤È 09:07:31²Ä 1980 ½g¦^À³
Alan ¤j:

·PÁ¼ö¤ß½Ķ¤Î¹L©¹´£¨Ñ¸ê°T¡A·PÁÂ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦n¹B10137114  µoªí®É¶¡:2017/2/8 ¤U¤È 08:01:24²Ä 1979 ½g¦^À³
°]°È¤j Alan¤j

ÁÂÁ»¡©ú¡A¤G´Á¹êÅ窺°h¥X¤£¤@©w¬O¥Nªí¯f¤H­@¨ü©Ê¤£¨Î¡C

¤F¸ÑÅo¡C·PÁÂ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2017/2/8 ¤U¤È 04:15:20²Ä 1978 ½g¦^À³
¦n¹B¤j±z¦n¡G

¦³Ãö±zªº´£°Ý, ¸Õ¦^À³¦p¤U, P1101 Á{§É¸ÕÅçI/II´Á N ­È(¯f¤H¼Æ)­°§C¤£À³³æ¯Â§@¬°¯f¤H¹ïP1101­@¨ü«×µ²ªG¡C­ì¦]¸Ô­z¦p¤U¡G

(¤@)¤½¥q¦^À³, ¥Ø«eP1101Á{§ÉI/II´ÁªvÀø®É¶¡¬°2.5¦~(¬°´Á¦@130©PªºÁ{§É¸ÕÅç), ¦Ó¤½¥q³¡¤À¥çµLªvÀø´Á¶¡¯f±w°h¥Xªº¬ö¿ý, ¶È»¡©ú9¦W¯f±w(§Y±z´£¨ìªº W130- 9¦W¯f±w) ¬O§¹¾ã°Ñ»P¬°´Á130©PªºªvÀø¡C¦Ó«á´Á°h¥XÁ{§É¸ÕÅç¯f¤H¦h¬°¹ï P1101 µLªk²£¥Í¦å²G¾Ç¤ÏÀ³ªº¯f±w (§Y±z©Ò¨£¹Ïªí¤¤§e²{¦Ç¶¥Non-responders)¡C

(¤G)¸g­pºâ«á¬Ý¨ì, ­Y¥HÁ{§ÉI/II ´ÁÁ`¨ü´ú¤H¼Æ51¦W¯f±w¨Ó¬Ý, Week 50 (¬ù¤@¦~ªvÀø)©Ò°Ñ»PªvÀø¤§29¦WPV¯f±w, µ¥¦P°h¥XªvÀø¤ñ²v56.86%¡C¦¹¼Æ¾Ú©MÁ{§É¤T´Á©Ò¤½¥¬¤§16.5% ®t¶Z·¥¤j, ­Ó¤H§PÂ_¬Y³¡¤ÀÀ³»PÁ{§ÉI/II ´ÁÁ{§É¸ÕÅç»Ý©w¸q³Ì¤j­@¨ü¾¯¶q(MTD)©Ò¶i¦æ¸ÕÅç¾É­P³¡¤À¯f±wµLªk©Ó¨ü³Ì¤j¾¯¶q¦Ó°h¥XªvÀø, ¦¹³y¦¨¯f±w°h¥X¤H¼Æ¥¢¯u¡C

(¤T)¦¹¥~, ®Ú¾ÚKiladjian Âå¥Í¦b2016¦~5¤ë´¿¤À¨É¤F¤T­Óªø®Ä«¬¤zÂZ¯ÀÁ{§É¤G´ÁÀ³¥Î¦bMPNs ªº¹êÅçµ²ªG(¼v¤ù¦p¤U¡Gwww.oncologytube.com/video/update-on-long-acting-interferons-for-mpn/1038272), ¦b¦¹³ø§i¤¤¥]§t¨â­Óù¤óPegasys Á{§É¤G´Á¸ÕÅç ¥H¤Î ÃĵتºP1101ªºÁ{§ÉI/II´Á¸ÕÅç, ¦b¸Ó³ø§i¤¤¦³°w¹ï°h¥XªvÀøªº¯f±w°µ¬ÛÃö¤ÀªR¡C

±q¼v¤ù¤¤±oª¾, ¨ä¤¤¤@¶µÃ¹¤óPegasys ªºÁ{§É¸ÕÅç(PVN1 Study) Åã¥Ü¥X,

¦³11¦ì¯f±w(30%) ©ó70­Ó¤ëªvÀø«á¤´Â¨ϥÎù¤óPegasys ªvÀø,

¦Ó°h¥XªvÀøªº¤ÀªR¤¤, 14¦ì¯f±w(38%) ¬O¦]¬°¹F¨ì§¹¥þ¦å²G¾Ç¤ÏÀ³¡F10¦ì¯f±w(27%) ¬O¦]¬°¬r©Ê¤ÏÀ³(°Æ§@¥Î¤j)¦Ó°h¥XªvÀø¡C

¦]¦¹, ÃĵØÁ{§ÉI/II ´ÁÁ{§É¼Æ¾ÚN(¯f±w¼Æ)¤U­° ÁöµL©ú½T°h¥XªvÀø­ì¥Ñ, ¦ý´N¥Ø«e P1101 »P ù¤óPegasys¤zÂZ¯À Àø®Ä¤@­P, °Æ§@¥Î¸û§Cªºµ²ªG¨Ó¬Ý¡C±À½×PV¯f±w¦b¨Ï¥ÎÃĵØP1101ªºªø´Á¥ÎÃĪvÀø«á, ¯f±w°±ÃĦӰh¥XªvÀøªº¤ñ¨ÒÀ³±µªñù¤óPegasys ªº38%, ¦Ó°Æ§@¥Î¦Ó°h¥XªvÀøªº¤ñ¨ÒÀ³§C©ó27% ªº¤ñ¨Ò¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2017/2/8 ¤U¤È 03:38:24²Ä 1977 ½g¦^À³
¤p¥¿¥¿ ¤j²Ä1987½g¨â¬q³X½Í¼v¤ù ºK­n½Ķ¦p¤U¡G

(¼v¤ù¤@) DR. Heinz Gisslinger: A discussion about the results of the Phase III PROUD-PV study - part 1

www.youtube.com/watch?v=hCviV-bdtwU&t=209s

µo§G¤é´Á¡G2017¦~1¤ë13¤é

# °OªÌ:

³o¦¸ASH ¦³³\¦h¥O¤HÅåÆvªº¦¨ªG, ¥]§t«Ü¦h§K¬ÌÀøªk¡B¦X¨ÖÀøªkÀ³¥Î¦b¸~½F»â°ì¡B¦å²G¾Ç»â°ìªºªvÀø¤W, ±z²³ø¤FPVªºÁ{§É¤T´Á¦¨ªG, ¥i¥H¤À¨É±zªº¬ã¨s¥H¤Î¦³¦óµo²{¶Ü?

# Dr. Gisslinger:

§Ú­Ì¥Î¤@ºØ·s«¬ªø®Ä«¬¤zÂZ¯ÀºÙ¬°RopegInterferon£\-2b (P1101), ¥¦¦³¸ûªøªº¥b°I´Á, ¥i¥H¨C¨â©Pª`®g¤@¦¸¨ú¥N­ì¦³ªº¨C©Pª`®g, ¯f¤H­@¨ü«×¨}¦n¨Ãºû«ù¤@¼ËªºÀø®Ä¡C³o¦¸ªºÁ{§É¤T´Á¸ÕÅç§Ú­Ì¥ÎP1101 ©MHU ¬Û¤ñ¡C¤zÂZ¯À§A»Ý¤F¸Ñ, ¥¦»Ý­nªø´Á¨Ï¥Î¥H²£¥ÍÀø®ÄªºÃĪ«, ²Ä¤@¦~ªºÀø®Ä¬°¤£¦H©ó HU, ¸Û¦p§Ú­Ì©Òª¾, ¤zÂZ¯À(P1101)ªºÃĮĸûºC, µM¦Ó§Ú­Ìµo²{¦b¤ñ¸ûªøªº¥ÎÃĮɶ¡«á, P1101 ¤£½×¦b¯f±w¦å²G¾Ç¤ÏÀ³¡B¦w¥þ©Ê¡B°Æ§@¥Î¡BJAK2µ¥¦ì°ò¦]­t¾á¤W§¡¥X²{Àu©óHUªºµ²ªG, ¤]¦]¦¹¨Ï¥ÎP1101¶i¦æªvÀøªºPV¯f±w¥i¥H¤ñHU ´£¦­´î¤Ö¾¯¶q¡C¦¹¥~, §ó­«­nªº¬O, §Ú­Ì¦bHUªºªvÀø¹Lµ{¤¤, ¬Ý¨ì5¦ì¯f±wµo²{Àù¯gªº²£¥Í¡F2¦ì¯f±w¥X²{«æ©Ê¥Õ¦å¯f(AML), 2¦ì¯f±w¥X²{´c©Ê¸~½F, 1¦ì¯f±w¥X²{¶Â¦â¯À½F¡C

(¼v¤ù¤G) DR. Heinz Gisslinger: A discussion about the results of the Phase III PROUD-PV study - part 2

www.youtube.com/watch?v=Iu-Q2CTdPFM

µo§G¤é´Á¡G2017¦~1¤ë13¤é

# Dr Gisslinger:

¥Ø«eªø®Ä«¬¤zÂZ¯ÀªvÀø¬O¨C©Pª`®g¤@¦¸, ¦Ó·s¤@¥Nªø®Ä«¬¤zÂZ¯À(P1101) «h¥i¥H¨C¨â©Pª`®g¤@¦¸, ¦ÓÀHµÛªvÀø®É¶¡ªº±À²¾, ¯f±w¥i¥H¥|©Pª`®g¤@¦¸¡C¦Ó¤zÂZ¯À¾A¦X¦­´ÁPV¯f±wªºªvÀø, 90%ªº¯f±wªºµÊŦ¬O¥¿±`¤j¤p¡C

# °OªÌ: ¤U¤@¶¥¬q³W¹º?

# Gisslinger:¦bÁ{§É¤T´Á¸ÕÅç«á, ¤U¤@¶¥¬q§Ú­Ì±N¬Ý¥X§óªø´ÁªvÀø®É¶¡¤U»PHUªº¤ñ¸û, ¨Ãµoªí³o¨Ç¦¨ªG, ±µµÛ¨ú±o¼Ú¬üÃÄÃÒ®Ö¥i, ¦b2018¦~´¶¹M³Q¨Ï¥Î§@¬°PVªvÀøÃĪ«¡C

# °OªÌ: ¦b±zªº¬ã¨s»â°ì, ¦³µL¬Ý¨ì¥O¤HÅåÆvªº¦¨ªG?

# Dr Gisslinger: ¦b¹L¥h¤Q¦~, JAK2§í¨î¾¯³Q¦¨¥\ªº¬ãµo¥H¤Î¥Î¦bMF¤ÎPVªº±ß´ÁªvÀø»â°ì, ¦Ó§Ú­Ì¤]±N«ùÄò¬ãµo, ¥h¹ï§Ü³o¨Ç¬ðÅÜ°ò¦]¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2017/2/8 ¤U¤È 03:34:26²Ä 1976 ½g¦^À³
¤p¥¿¥¿ ¤j²Ä1986½gµoªí¤å³¹ ½Ķ¦p¤U¡G

www.pvreporter.com/

¤@¡BPV Reporter interviews Dr Kiladjian at ASH 2016(December 18, 2016 By David Wallace )

Dr Kiladjian at ASH 2016 Reviews Outcomes of MPN Patients after Interferon therapy discontinuation

PV reporter ªºDavid Wallace¦b2016¦~12¤ë18¤é°w¹ïKiladjianÂå¥Í¶i¦æ2016¦~ASH±M³X, ¥D­n°w¹ï¤¤Â_¤zÂZ¯ÀªvÀø«áªºMPN ¯f±wªºµ²ªG¶i¦æ»¡©ú¡C

ºK­n¦p¤U¡G

(¦b¦¹¸É¥R, ¥»¦¸ªº¤zÂZ¯À¦¨ªG»¡©ú¬°¤@¯ë¤zÂZ¯À¤Îªºªø®Ä«¬¤zÂZ¯À, «D«ü ÃĵØP1101 ·s¤@¥Nªø®Ä«¬¤zÂZ¯À¡C)

(¤@)333¦W¯f±w¤¤¡A¦³149¦W¯f±w¤w°±¤î¤zÂZ¯ÀªvÀø¡C50%¤¤Â_ªvÀøªº¯f±w­ì¦]¦b©ó¬YºØ¬r©Ê¡]¦Û¨­§K¬Ì©Ê©Î¥Òª¬¸¢°ÝÃD¡^¡C

(¤G)35%ªº¯f±w¤¤Â_ªvÀø¦b©ó¦å²G¾Ç½w¸Ñ¡]¦å²y¼Æ¶q«ì´_¥¿±`¡^, ¦Ó¨ä¤¤ªº20-25%°±¤î¨Ï¥Î¤zÂZ¯ÀªvÀø«á¤´ºû«ù¦å²G¾Ç½w¸Ñªº®ÄªG, ºû«ùªº¤¤¦ì¼Æ¬°3¦~, ³Ìªøªº¥i¥Hºû«ù¦Ü11¦~¡C

(¤T)¯àºû«ù³Ìªø®É¶¡°±ÃĪº¯f±w¥B«ùÄò¦å²G¾Ç½w¸Ñªº¯f±w¦b¹L¥hªvÀø¹Lµ{¤¤ÀHµÛªvÀø®É¶¡ªº±À²¾, ¾¯¶q­°§C¥B¥ÎÃÄÀW²v¤]­°§C¡C

(¥|)¦b³o¨Çºû«ù¦å²G¾Ç½w¸Ñªº¯f±w¤¤, ¤]¥]§tµÛ¸û§Cªºµ¥¦ì°ò¦]­t¾á(¬ù¤p©ó5%-10%), ¥L­Ì³£¦³´¶¹M¸û¦­¥Î¤zÂZ¯ÀªvÀøªº±¡ªp¡C

(¤­)¤À¤l¤ÏÀ³¡]µ¥¦ì°ò¦]­t¾á­°§C¡^ªº¦n³B¥]¬A§ó¤Ö¦¸ªºªvÀø¡B°±ÃÄ¡B¸û¤Öªº¦å®ê¨Æ¥óµo¥Í¥H¤Î§ó¤ÖªºÂà¤Æ(¦¹À³«üMF)¥i¯à©Ê¡C

(¤»)¥¼¨Ó¶i¤@¨Bªº¬ã¨s±N¥]§t¥Î¤@­Ó«e¤©Ê¬ã¨s¨Ó½T»{°±¤î¤zÂZ¯ÀªvÀø(°±ÃÄ)ªºµ²ªG¡C¯f±wÀ³¦Ü¤Ö¶i¦æ¨â¦~ªº¤zÂZ¯ÀªvÀø¡Bµ¥¦ì°ò¦]­t¾á»Ý­°¨ì< 5¢H ¤~¯à¤¤Â_ªvÀø¡C

(¤C)¯f±wÆ[ÂI¡]David Wallace ­Ó¤Hµ§°O¡^¡G¤zÂZ¯À¬O¤@ºØ·¥Ãø¥Î©óªvÀøªºÃĪ«¥D¦]¦b©ó°Æ§@¥Î·|ÀHµÛ¾¯¶q¼W¥[¦ÓÅܤj¡C¦ý¬Û¤Ïªº¬O, ³\¦hPV¯f±w¦b¤zÂZ¯À¤Wªí²{¨}¦n¦Ó¨S¦³²£¥Í³\¦h°Æ§@¥Î¤ÏÀ³¡C¦Ó±q¨Ó¦ÛProud PV¬ã¨s¸ê®Æ«ü¥X, Ropeginterferon alfa 2b¡]P1101, ¬OÃĵجãµoªº·s¤@¥N¤zÂZ¯À¡^, ¥¦¥i¥H´£¨Ñ§ó¦nªº¦å²G¤ÏÀ³²v¡B§C¬r©Ê¤ÏÀ³¥H¤Î§ó§CÀW²vªº¥ÎÃÄ¡C

ªþµù: ¼v¤ù±M³X¬ù16:00³B, David ¦³´£°ÝKiladjian Âå¥Í¦³ÃöÃĵØP1101ªº¬Ýªk, ¸`¿ý¦p¤U¡C

P1101 ¬O¤@­Ó«D±`·Å©Mªº¤zÂZ¯À, ¶È»Ý2©P¬I¥´¤@°w©Î¬Æ¦Ü¥|©P¬I¥´¤@°w, ¦p¦P Pegasys ¦ý¾ãÅé¤W¯f¤H­@¨ü«×§ó¨Î¡C

¦ý§ó­«­nªº¬O, ¦bPROUD-PV¦¨ªG»¡©ú·|ij«á, §Ú­Ì§Æ±æ¥¦¦¨¬°²Ä¤@­Ó¤zÂZ¯Àªº¦å²G¯e¯f¥ÎÃÄ, ³o¤£ºÞ¹ïÂå¥Í¡B¹ï¯f¤H¦Ó¨¥³£¬O¤@­Ó·¥¤jªº¶i®i, ¤]¥i¥H´£¨Ñ¯f±w¤@­Ó¦w¥þ¡B¦³®Äªº¥ÎÃÄ¡C§Ú¨Ã«D»¡©Ò¦³¯f±w³£¸Ó¥Î¤zÂZ¯ÀªvÀø, §Ú¬O«ü³o¬O¤@­Ó­@¨ü«×¥i±±¨îªº¡B¥i¥H§@¬°ªø´Á¥ÎÃĪºÃĪ«¡C

¤G¡BInterview with Dr Heinz Gisslinger

PV reporter ªºDavid Wallace¦b2017¦~1¤ë19¤é¹ï2016 ASH ¹ï©óGisslingerÂå¥Í©Ò§@ªºPROUD-PV Á{§É¤T´Áµ²ªG³X½ÍºK­n¡C

(¤@)§@ªÌ´£¨ì¥Ñ©ó½Õ«×²V¶Ã, ¶ÈÁ`µ²±q±Ä³Xªº´X­Ó«GÂI¡C

(¤G)P1101 ¦b²Ä¤@¦~ªºªvÀø¼Æ¾Ú¤£¦H©ó HU¡C©M¨C¤Ñ¤@Áû©Î¨C©P¤@°wªºÃ¹¤óPegasys ¬Û¸û, P1101 ¤¹³\2-4©Pªº¥ÎÃĶ¡¹j¡C¤zÂZ¯À¬O¤@­Ó»Ý¸ûªø®É¶¡¤~¯à²£¥Í®ÄªGªºªvÀø, ¦ÓHU ¥iª½±µ¹ï¯f¤H¦å²G¼Æ¶q²£¥Í®ÄªG¡C

(¤T)¥O¤HÅåÆvªº¬O, ¤zÂZ¯Àªº­@¨ü«×ÁÙÀu©óHU¡C¾¨ºÞ¨Ï¥ÎHUªvÀøªº¯f±w²£¥Í°Æ§@¥ÎÁÙ¤ñ¤zÂZ¯ÀªvÀø¯f±w§ó¦h¦Ó»Ý­n´î¤Ö¾¯¶q, ¦ý¥Ø«e¦å²G¾Ç¤ÏÀ³¤@¦~ªº¼Æ¾Ú©MHU¤@­P¡C¦Ó³q±`¤zÂZ¯À¬ÛÃöªº¯S®í©Ê°Æ§@¥Î¡B¦Û¨­§K¬Ì¯e¯f©Îºë¯«¯e¯fªºµo®i¨Ã¥¼¨£¨ì¡C¤zÂZ¯ÀÀ³¦bPV¦­´Á¶¥¬q§Y¶i¦æªvÀø¡C

(¥|)§Ú­Ì´M¨D¦b2017¦~Àò±o¼Ú·ù¡]EU¡^ªºÃÄÃÒ®Ö¥i§å­ã, ±µµÛ«Ü§Ö¬ü°êFDAÀ³¸Ó«Ü§Ö´N·|§å­ã¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2017/2/8 ¤U¤È 03:28:15²Ä 1975 ½g¦^À³
ÁÂÁ¤p¥¿¥¿ ¤jªº¤À¨É, ¬ÛÃö¤å³¹Â½Ä¶¦p¤U¨Ñ¦U¦ì§ë¸ê¥ý¶i­Ì°Ñ¦Ò¡G

²Ä 1985 ½g

PROUD-PV and MPD-RC 112 trials of interferon alpha vs hydroxyurea for MPNs

youtu.be/0wUNZNSAZrs

µo§G¤é´Á¡G2017¦~2¤ë2¤é

Jean-Jacques Kiladjian, MD, PhD of Saint-Louis Hospital & Paris Diderot University, Paris, France discusses the results of two randomized trials on interferon alpha in patients with myeloproliferative neoplasms (MPNs) presented at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA. Prof. Kiladjian highlights the results of the randomized, Phase III PROUD-PV trial comparing ropeginterferon alfa-2b to hydroxyurea in polycythemia vera (PV) patients (NCT01949805).

He explains that the first step was to prove non-inferiority of ropeginterferon compared to hydroxyurea in the short-term. The study will continue with the name CONTINUATION-PV and in the longer follow-up, he hopes to see superiority of ropeginterferon. Further, he discusses the preliminary results shown by the Myeloproliferative Disorders Research Consortium (MPD-RC) on pegylated interferon alpha-2a vs hydroxyurea in high-risk polycythemia vera and essential thrombocythemia (ET) (MPD-RC 112 trial, (NCT01258856).

Jean-Jacques Kiladjian¬° ¸t¸ô©öÂå°| ¥H¤Î ¤Ú¾¤²Ä¤C¤j¾ÇÂå¾Ç³Õ¤h¡A±´°Q¥»¦¸¦b2016¦~¬ü°ê¦å²G¦~·|(ASH)¤¤¨â­Ó¤zÂZ¯À¥Î©óMPNs(°©Åè¼W¥Í©Ê¸~½F)ªºÁ{§ÉÀH¾÷¸ÕÅçµ²ªG¡C

Kiladjian ±Ð±Â¯S§O±j½Õ ÃĵØÃÄ PROUD-PV ÀH¾÷¤T´Á¸ÕÅ礤 P1101·s¤@¥N¤zÂZ¯À ©M HU ¥Î¦b PV¯f±w¤WªºÁ{§Éµ²ªG¡C¥L¸ÑÄÀµu´ÁªvÀø¤U¤wÃÒ©ú·s¤@¥Nªø®Ä«¬¤zÂZ¯Àµ²ªG¤£¦H©óHU¡C¦Ó³o¶µÁ{§É¹êÅ礴·|«ùÄò¶i¦æºÙ§@CONTINUATION-PV, ¦bªø´ÁªvÀøªº°lÂܤU, ¥L´Á«Ý¥i¥H¬Ý¨ìP1101 Àu©ó HUªº¦¨ªG¡C

¦¹¥~¡A¥L¤]»¡©ú¤F¥Ñ°©Åè¼W¥Í©Ê¯e¯f¬ã¨sÁp·ù¡]MPD-RC¡^©Ò®i¥Ü¥Xªº ù¤ó¤zÂZ¯ÀPegasys v.s. HU ¦b°ª­·ÀI PV ©M ET ¯f±w¤UªºÁ{§Éªì¨Bµ²ªG¡C

ªþµù: ¦b±M³X¼v¤ù³Ì«á, Kiladjian ±Ð±Â´£¨ì¥Ø«e PROUD-PV ¸ÕÅç¦bµù¥U¬yµ{¤¤, §Ú­Ì§Æ±æÃÄÃÒ®Ö¥i³Q±µ¨ü, ¦p¦¹¤@¨Ó¤zÂZ¯À±N¦¨¬°²Ä¤@­Ó³Q®Ö­ã¥Î©óMPNs ªvÀøªºÃĪ«, ¥Ø«eªº¯f±w¶È¬°¥é³æ¥~ªvÀø(Off-Label Use)¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°]°È¦Û¥Ñ¤H10132540  µoªí®É¶¡:2017/2/8 ¤W¤È 11:24:38²Ä 1974 ½g¦^À³
P1101 Á{§É¤T´Á°hªº¤ñ¨Ò¬O 16.5%, HU °h¥X¤ñ¨Ò¬O 12.6% ¡A³æ¬Ý¼Æ¦r¡A¦n¹³ P1101 ¤£¬O«Ü¦n¡A¦ý³o¥u¬OÀY¤@¦~ªº¥ÎÃĤÀªR¡AP1101 ¥HÁ{§É¤G´Áªºª¬ªp¼Æ¾Ú¨Ó¬Ý¡A°Æ§@¥Î¬OÀHªº®É¶¡¦Ó¤U­°¡C

¦¹¦¸Á{§É¡A¦]¬°°Æ§@¥ÎªºÃö«Y¡A HU ²Õ¨Ã¥¼¹F¨ì¹w©wªºµ¹Ãľ¯¶q¡C HU ¦]¬°¦³§ÜÃÄ©Ê¡A¾¯¶q¥u·|¦h¡A¾¯¶qÅܦh°Æ§@¥Î´N·|¤j¡A¤@¦ýµLªk©Ó§Ô¨ü´N¥²¶·§ï¦Y¤G½uÃÄ¡Cªø´Á¥ÎÃĦӨ¥¡A P1101 ªº°h¥X²vÁÙ¬O·|§C©ó HU ªº¡C

Conti-PV ¹ï·Ó²Õ¬O Best available therapy (BAT) ¡A­ì¦]´N¬O«á´Á®É¡AªA¥Î HU ¾¯¶qµLªk¦A¥[¤j¡A¥²¶·­n´«ÃÄ¡A§_«h³oÁ{§É¦³¥i¯à¦] HU ²Õ°h¥X¤H¼Æ¤Ó¦hµLªk¹F²Î­p»Ý­nªº¼Ë¥»¼Æ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦n¹B10137114  µoªí®É¶¡:2017/2/7 ¤U¤È 01:38:10²Ä 1973 ½g¦^À³
¤£¦n·N«ä,¦]¬°µLªk¶K¹Ï¥i¯à´y­z¤£¤Ó²M·¡

´«­Ó¤è¦¡ªí¹F, ¬O§_¦³¸ê®Æ¥i¥HÅã¥Ü¤§«eÁ{§É¤G´Á, Ä~Äò¯d¦b¹êÅ窺¯f¤H¤ñ¨Ò.ªø®É¶¡(¶W¹L¨â¦~)

P.S ³o¦¸Á{§É¤T´Á 12­Ó¤ë °hP1101¥XÁ{§Éªº¤ñ¨Ò¬O 16.5% , HU°h¥X¤ñ¨Ò¬O12.6%

¥H¤W¸ê®Æ¬°¤½¥qªk»¡¸ê®Æ´£¨Ñ.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦n¹B10137114  µoªí®É¶¡:2017/2/7 ¤U¤È 01:05:19²Ä 1972 ½g¦^À³
¦U¦ìª©¤W¤j¤j, ÁÂÁ§A­Ì´£¨Ñªº¸ê°T, ¨¯­W¤F

¤µ¤Ñ¦b½Æ²ßÃĵإH«eªº¸ê®Æ,µo²{¤@­Óª¼ÂI·Q½Ð±Ð¤j¤j

¦bP1101ªºPV¤G´ÁÁ{§É¤W, ¦³¤@¸ê®ÆÅã¥Ü¥ÎÃĶV¤[, §¹¥þ¤ÏÀ³(CR)¯f±w¤ñ¨Ò·|¼W¥[

¦ý¬O¹Ïªíªº¤U¤è¦³ N ­È(À³¸Ó«ü¯f¤H¤H¼Æ),«o±qW10 ªº42 ¤@¸ô¤U­°¦Ü W50 ªº 29 ¦Ü W130 ªº 9

¦pªGÃĪº­@¥Î©Ê¨Î, ¬°¦óN·|¤U­°¦p¦¹ªº¦h? ³o¤p§Ì¯uªº¤£¬O«Ü¤F¸Ñ

­YAlan ¤j©Î¤p¥¿¥¿¤j ¦³¬Ý¨ìªº¸Ü, ¬O§_¥i¥HÀ°¦£»¡©ú¤@¤U, ÁÂÁ¤F.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦B«B10138946  µoªí®É¶¡:2017/2/5 ¤U¤È 06:37:04²Ä 1971 ½g¦^À³
¨º¦ì¤j¤j½¦¨¤¤¤å¦n¶Ü??

¦³¬Ý¨S¦³À´....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/2/5 ¤W¤È 10:23:02²Ä 1970 ½g¦^À³
DR. Heinz Gisslinger: A discussion about the results of the Phase III PROUD-PV study - part 1

https://www.youtube.com/watch?v=hCviV-bdtwU&t=209s

µo§G¤é´Á¡G2017¦~1¤ë13¤é

DR. Heinz Gisslinger: A discussion about the results of the Phase III PROUD-PV study - part 2

https://www.youtube.com/watch?v=Iu-Q2CTdPFM

µo§G¤é´Á¡G2017¦~1¤ë13¤é

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/2/4 ¤U¤È 05:19:20²Ä 1969 ½g¦^À³
http://www.pvreporter.com/

¤@¡BPV Reporter interviews Dr Kiladjian at ASH 2016(December 18, 2016 By David Wallace )

Dr Kiladjian at ASH 2016 Reviews Outcomes of MPN Patients after Interferon therapy discontinuation

Summary of Key Points:

(¤@)Out of the 333 patients, 149 had discontinued interferon treatment. 50% of those discontinued because of some kind of toxicity (autoimmune or thyroid problem).

(¤G)35% of patients discontinued because of hematological remission (normal blood counts).

20-25% remained off interferon successfully (hematological remission) for a median of 3 years and a maximum of 11 years.

(¤T)Patients that attained hematological remission and stayed successfully off interferon the longest had typically tapered their dose down over time to a low amount, given less frequently.

(¥|)Patients who had a lower allele burden (preferably < 5-10%) after treatment were more successful staying in remission. They also had typically started treatment earlier.

(¤­)Benefits of a molecular response (lowered allele burden) include less treatment, including discontinuation of medication, less thrombotic events and lower likelihood of transformation.

(¤»)Further research would include a prospective study to confirm the results of discontinuation of interferon. Patients would likely have at least two years of interferon treatment, to try to reduce the allele burden down to <5% and discontinue treatment.

(¤C)Patient Perspective (author¡¦s note):  Interferon can be a difficult drug to take, due to the side effect profile particularly with increasing dosage.  Conversely, many patients do well on interferon without many side effects.  The introduction of Ropeginterferon alfa 2b (P1101 ¡V a new generation interferon by PharmaEssentia, from the Proud PV study) should provide better response rates, a lower toxicity profile and less frequent dosing.  PharmaEssentia plans to apply for its approval as first line treatment in PV in a number of markets, including the USA.  If approved, it is expected to be the first interferon approved for PV and the only FDA approved first-line treatment for Polycythemia Vera (PV).

¤G¡BInterview with Dr Heinz Gisslinger

Interview with Dr Heinz Gisslinger on final results from the PROUD-PV study, A Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in PV patients.(January 19, 2017 By David Wallace )

(¤@)Due to a scheduling snafu, my previously reserved interview room was given to another reporter.  Dr Gisslinger and I were booted to the noisy convention halls, which were not conducive to my very basic ¡§consumer video equipment,¡¨ a Sony handycam with a built-in mic and the soft-spoken doctor.  So I will summarize a few highlights from the interview.  It should be noted PV Reporter covered Dr Gisslinger¡¦s work at ASH 2014, see that video here.

(¤G)Ropeginterferon (P-1101) was generally equivalent (¡§not inferior¡¨) to HU in the first year of treatment.  P-1101 allows for prolonged intervals of dosing, every 2 to 4 weeks vs daily pills or weekly injections with Pegasys (the interferon currently used in the U.S. and around the world).  Interferon is a slow acting agent for long term treatment, while HU (hydroxyurea) causes almost immediate impact on a patient¡¦s blood counts.

(¤T)Surprisingly, the tolerability of Interferon was superior to HU.  The hematological response of Interferon treated patients for 1 year was the same as HU, although HU patients needed dosing reductions due to side effects more frequently than Interferon patients.  Typically Interferon related specific side effects, development of auto-immune disease or psychiatric disorders did not occur.  Interferon should be started in the early stages of PV

(¥|)We should look for EU (European Union) approval sometime in 2017 and U.S. FDA approval should follow relatively soon thereafter.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/2/4 ¤U¤È 04:57:19²Ä 1968 ½g¦^À³
PROUD-PV and MPD-RC 112 trials of interferon alpha vs hydroxyurea for MPNs

https://youtu.be/0wUNZNSAZrs

µo§G¤é´Á¡G2017¦~2¤ë2¤é

Jean-Jacques Kiladjian, MD, PhD of Saint-Louis Hospital & Paris Diderot University, Paris, France discusses the results of two randomized trials on interferon alpha in patients with myeloproliferative neoplasms (MPNs) presented at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA. Prof. Kiladjian highlights the results of the randomized, Phase III PROUD-PV trial comparing ropeginterferon alfa-2b to hydroxyurea in polycythemia vera (PV) patients (NCT01949805). He explains that the first step was to prove non-inferiority of ropeginterferon compared to hydroxyurea in the short-term. The study will continue with the name CONTINUATION-PV and in the longer follow-up, he hopes to see superiority of ropeginterferon. Further, he discusses the preliminary results shown by the Myeloproliferative Disorders Research Consortium (MPD-RC) on pegylated interferon alpha-2a vs hydroxyurea in high-risk polycythemia vera and essential thrombocythemia (ET) (MPD-RC 112 trial, (NCT01258856).

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/2/3 ¤W¤È 08:33:15²Ä 1967 ½g¦^À³
¥Ø«e6446³B©óªÅÀY,¦ý¥ç¥i¯à¥´©³,µM¦]µLÀ禬Àò§Q,¤£§Q¤jº¦,¥u¯àµ¥«Ý¤j§Q¦h
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G275810143547  µoªí®É¶¡:2017/2/2 ¤U¤È 08:57:08²Ä 1966 ½g¦^À³
¤µ¤é¶}¬õ½L?

¹ê¦b¤£´±·Q¹³ªÑ»ù³º¦A«×IJ¤Î141§CÂI¡A

­Y©ú¤é°_«ùÄò¯}©³¡A

ªÑ»ù¬O§_·|¥ì©ó­J©³?

«ùªÑ«H¤ß¦­¤w§Ö³t±Y¼ì¤¤......

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2017/2/2 ¤U¤È 06:03:52²Ä 1965 ½g¦^À³
¤À¨É¬ü°ê®É¶¡1/25 PV¯f¤Í¹ÎÅé°Q½×ª©¤¤¤T¦ìPV¯f¤Í°Q½×¤º®e¾ã²z¨Ã½Ķ¦p¤U, «ª©ó¥²´IºôµLªk¤À¨É¹ÏÀÉ, ½Ð¦U¦ì§ë¸ê¥ý¶i¦ÜMobile 01 °Q½×ª©Æ[¬Ý§¹¾ã¤º®e, ­­©ó¯f±wÁô¨p, ©Ò¦³¯f±w¤H¦W§¡°µ¶î©Ù³B²z, ÁÂÁ¡C

Mobile01°Q½×ª©¡G(6446) ÃĵØÂåÃĪº§ë¸ê»ù­È¤ÎÄ@´º

www.mobile01.com/topicdetail.php?f=291&t=4919602&p=8

¥H¤U¬°¹ï¸Ü§¹¾ã¹ï¸Ü¡G

* Catherine¡G

¦b³o13¤ÀÄÁªº¼v¤ù¤¤, MascarenhasÂå¥Í´£¨ìPegasys »P HU²Ä¤@¦~´Á¤¤¬ã¨sªºµ²ªG, ¨Ã´£¿ôÅ¥²³µ¥«Ý§¹¾ã¬ã¨sªºªø´Áµ²ªG¡C

Åý§Ú·Ð´oªº¬O, ¦b¼v¤ù²Ä8¤ÀÄÁ, ¥L´£¨ì, ù¤ó¤½¥q¦b2017¦~¦~¤¤±N¤£¦A´£¨ÑPegasys§@¬°«áÄòªº¬ã¨s, §Ú¬Û«H³o¥u¬O¶i¦æ¨ì¤@¥bªº¬ã¨s¶¥¬q¡C§Ú§x´bªº¬O¡A¦pªG³o»¡©ú¡Aù¤óªºPegasys ·|´î¤Ö¨Ï¥Î©Î¬O¦b¨º®É°±²£¡C§@¬°¤@­Ó·sªºÃ¹¤óPegasysªº¯f±w¡A³oÅãµM§xÂZ§Ú, ¦ý³o¤]³\¶È¬O¤@­Ó¬ã¨s¤Wªº¸êª÷ijÃD¡A³o¼v¤ùªº¸ê°T¤£°÷§@¬°¨M©w¡C

¦ýMacarenhasÂå¥Í½T¹ê´£¨ì¤F°Ñ»PRESCUE trial ªºÁ{§É¸ÕÅçªÌ±NÂà´«¬°¨Ï¥ÎP1101 (ropeginterferon£\-2b)¡A¦ý³o©|¥¼ÃÒ¹ê, ³o¬q¼v¤ù¦b2016¦~12¤ëµoªí¡C

* Paul¡G

¤zÂZ¯À¤w¸g¦b«Ü¦hªø´ÁÁ{§É¬ã¨s¤¤ÃÒ©ú¤ñHUÀu²§¤F¡AKiladjian Âå¥Í¦b¥H¤U¼v¤ù°µ¤F·J¾ã»¡©ú¡G

Update on Long-acting Interferons for MPN

youtu.be/vuhwGEi4Y_k

¦Ó Silver Âå¥Í»¡©ú³o¨Çªø´Á¬ã¨s¦¨ªG¥H¤ÎÁ{§É¸gÅç¦p¥H¤U¼v¤ù¡C

Update on Long-acting Interferons for MPN

www.youtube.com/watch?v=lp58hdmZTIE&feature=youtu.be

¦Ó Gisslinger «h¬O°w¹ï³Ì·s«¬ªºªø®Ä«¬¤zÂZ¯ÀP1101 »¡©úªø´Áµ²ªG

An Update From ASH 2016: Interferon Therapy for MPNs

youtu.be/d2U4tNqCX7o

* Donna¡G

¦³½ìªº¬O¡A±q2016¦~·|ij¤W´£¥Xªì¨B¬ã¨sµ²ªGªí©ú¡AHU¯à°÷²£¥Í¤À¤l½w¸Ñ, ¯à°÷´î¤ÖJAK2 °ò¦]ªº­t¾á¡C§ÚªºÂå¥Í»¡¡A³o¦³ÂI¥X¥G¤j®aªº¹w®Æ¡C¥L­Ì³£¦b´Á«Ý¤µ¦~¦~©³ªºªø´Á¬ã¨sªº¦¨ªG

¡A¤]³\³o±N¬O¤@­Ó³Q©Ò¦³«OÀI¤½¥q©w¸q¬°³Ì¦nªºÀøªk¡I±qYouTube ¬Ý¨ì³\¦h°w¹ï12¤ë¦å²G¦~·|ªº±M³X¡I

* Paul¡G

Donna¡A¦b2016¦~·|ij¤¤´£¥Xªº¬ã¨s¼Æ¾Ú¨Ã¥¼´£¨ÑHU ¥ô¦ó·sªº¸ê°T¡A±z»¡ªº¸ê°T¬O Silver Âå¥Í´X¤Q¦~«e§Yª¾¹Dªº¸ê°T¡C

¥u¦³¤zÂZ¯À¥i¥H»¤¾É¡]¦b1-3¦~¤zÂZ¯ÀªvÀø¤U¡^JAK2 °ò¦]«ùÄòªº½w¸Ñ¡A¨ÃÅý¤j³¡¤À¯f±w¤¤°©Åèµ²ºc¥¿±`¤Æ¡C¥Ñ©ó´c©Ê½Æ»s³Q·¥¤j¦a®ø°£¡A¥¼¨ÓPV­nÂন°©ÅèÅÖºû¤Æ(MF)©M «æ©ÊÅè©Ê¥Õ¦å¯f(AML- ¦åÀù)ªº¾÷·|³Q¤j¤j¦a®ø°£¡C

¦b¹F¨ì³o¨Ç²`«×¤À¤l½w¸Ñ¤§«á¡A¯f±w¥i¥H±N Pegasysª`®gªº¾¯¶q©ÎÀW²v­°§C¦Ü¨C2-4©P¦Ü 22.5mcg- 45mcg¡A³o¥NªíµÛ¤zÂZ¯Àªº°Æ§@¥Î¤]±NÀH¤§´î¤Ö¡C

Donna,¤]³\¬O§Ú¿ù¤F, ¦ý¦b§Ú¬Ý¨Ó¡A§Aªº¥v¤¦¦ò¤j¾ÇÂå¥Í¨Ã¥¼¸ò¤WSilver, Hasselbalch, Kiladjian ¥H¤Î Gisslinger Âå¥Íªº³Ì·s¬ã¨s¦¨ªG¡C¦Ó«OÀI¤½¥q§_»{¦³¥]§tù¤óPegasysªº«OÀI, ¥L¦ü¥G¤]¤£ª¾¹D¦p¦ó´£¥X¦³®Äªº¤W¶D¡C ¹ï¦b¤j¦h¼Æ¦å²G¾Ç®a¦Ó¨¥, PV¬O§CÀu¥ý¶¶¦ìªº¯e¯f¡A¦]¬°¶È¦³¤Ö³¡¤À±wªÌ±o¨ì¦¹¯e¯f¡A¨Ã¥B¥¦¤£¬O¤@ºØ«I²¤©Ê¡A­¢¦b¬Ü·ûªº¦M¤Î¥Í©Rªº¦åÀù¡C

* Donna¡G

Paul ·PÁ§A¦A¦¸¬°§Ú´£¨Ñ³o¨Ç¸ê°T¡C§ÚªºÂå¥Í«ùÄò§ó·s¸ê°T¡C¨Æ¹ê¤W¡A·í§Ú¤@¦~«e²Ä¤@¦¸¶}©l°Ñ»PªvÀø®É, ´N¬O¥L«ü¤Þ§Ú¥h¨£ SilverÂå¥Í©M¼Ú¬wÁ{§É¬ã¨s¡C¦b¥L°Ñ¥[12¤ë¥÷ªº·|ij«á¡A§Ú¦b§Ú­Ì³Ìªñ¤@¦¸ªº·|­±´N¦³²á¨ì³o¨Ç¥DÃD¡C§A¦ü¥G¹ï¥v¤¦¦ò©Î¨ºùتºÂå¥Í¦³¤@­Ó«D±`¤£¦nªº¸gÅç¡C

* Paul¡G

Jeremy Smith ¤wĵ§i³o­Ó¥@¬ÉÃö©ó¥v¤¦¦ò¥H¤Î¥L­Ì°w¹ï¤zÂZ¯Àªº¦Ñ«ä·Q¡C¦ý³o¦b2018¦~±N·|³QÃÒ©ú, ¨ì®É¥v¤¦¦ò±N·|¾Ö©ê·s¤@¥Nªø®Ä«¬¤zÂZ¯À P1101(Ropeginterferon)¡A¦]¬°¥¦±N³QFDA§å­ã¥Î©óPV±wªÌ¡A¦Ó³o¬Où¤óPegasys©Ò°µ¤£¨ìªº¡C

* Donna¡G

§Ú¤£ª¾¹D¥L¬O¹J¨ì Schrier-i Âå¥Í, §Ú´¿³Q¥Lĵ§i¡C¦b³o­ÓÂå¥Í¤§«e, ¨â­Ó¥v¤¦¦òªº¦å²G¾Ç®a±ÀÂˤzÂZ¯ÀªvÀø¡C¦b·í¤U¡A§Ú°µ¤F¯«¸Ü¯ëªºHU¶i¦æªvÀø¡A¦ý¥u¦³¥Î¥¦3­Ó¤ë¡C¨S¦³°Æ§@¥Î¡A¦å²G¼Æ¾ÚÀu²§¡C§Ú¥Ø«e³Q«OÀI¤½¥q©Ú«O¡C§Ú¦U¤è¥h¸ß°Ý¡A¥Ø«e¤´ºû«ù¤W¶D¬yµ{¡C²{¦b, ¦b¤@¦~ªvÀø«á, §Ú¦³¥i©Èªº¯h³Ò, ¤f½H©M¨â­Ó©ñ¦åªvÀø¡A¦b§Ú§¹¦¨¤úÂåÀË´ú«á, §Ú¤ÏÀ³Åܱo«Ü¤£¦n, ½Ð°Ýù¤óPegasys ¬O¤ñ P1101 (Ropeginterferon) §ó¦nªº¤zÂZ¯À¶Ü¡H

* Paul¡G

Donna, ù¤óPegasys©MP1101 (Ropeginterferon) ¹ïPVªºªvÀø®ÄªG¬Û¦P¡A¦ý¬OP1101 ¬O¤@ºØ§ó¯Âªº¤zÂZ¯À»s¾¯¡A¦]¦¹°Æ§@¥Î§ó¤Ö¡A¤]¶È»Ý­n¨C2-4©P¦Ó¤£¬O¨C¶g¤@¦¸¡C²{¦b§A¥¿¦b¸g¾úHUªºÄY­«°Æ§@¥Î¡A§Aªº«OÀI¤½¥qÀ³¸Ó§å­ãPegasysµ¹¥I¡C¦pªG§A¤´µM¤£¯à±o¨ì§å­ã¡A¥i¥H¨p¤H¦^À³§Ú, §Ú¥i¥H§i¶D§A¦³¨ä¥L¤è¦¡±o¨ì«OÀIµ¹¥I¡C

* David Wallace¡G

¤£¥Î¾á¤ß¡A§Y¨Ï Pegasys¤£¦A¥i¥H¥Î©óªvÀøPV®É, P1101 (Ropeginterferon alfa-2b) §Y±N­n³Q§å­ã¡]¼Ú¬w·|¬O²Ä¤@­Ó¡A¨ä¦¸¬O¬ü°ê©M¨ä¥L°ê®a¡^¡A¨Ã¥BÀ³§@¬°PVªº¤@½uªvÀø¤è¦¡¡C

Note. David Wallace ¬°PV Reporter ºô¯¸³Ð¿ì¤H, ¨ä2009¦~½T¶E¿©±wPV, «á´£­Ò¯f¤H ª¾ÃѬO³Ì¦nªºªvÀø, ³Ð¥ß¥H¤Uºô¯¸¨ÑPV ¯f±w¶i¦æª¾ÃѤÀ¨É¡C

# PV reporter

www.pvreporter.com/

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°]°È¦Û¥Ñ¤H10132540  µoªí®É¶¡:2017/2/2 ¤U¤È 12:20:39²Ä 1964 ½g¦^À³
¡yÃĵعï·Ó²Õ HU ·|­PÀù?¥þ²y³ÌÅv«ÂFDA Say NO ¡z³o­Ó¼ÐÃD¤Ó¹LªZÂ_¡A¤£¹L³o¬O´CÅé¤@ºD¾½¦å¥Îªk¡C

FDA ¥u»¡¤£²M·¡¯u¹êªº­ì¦]¬O¤°»ò¡A¨ÃµL¶i¤@¨Bªº»¡·|»P¤£·|¡C­Y¬O³Q FDA ª¾¹D¡A¥xÆW´CÅ馳¼g FDA »¡ªA¥Î HU ¤£·|±oÀù¯g¡A·d¤£¦n¥i¯à·|³Q§i¡C¦P®É¡A¤]¦]ÁÙ¤£²M·¡­ì¦]¡AÂå¥Í¬É¤@ª½¦³ºÃ¼{¦s¦b¡C¦³¤@»¡¬O¡APV ±wªÌ¥»¨­´N¦s¦b±o AML ªº¾÷²v¡C¦b³o¦¸ªºÁ{§É¤¤¡AHU ²Õ½T¹ê¦³¯f±w­PÀù¡A³o¬O¤@­Ó¨Æ¹ê¡A¦ý¦b¦¹Á{§ÉµLªkÃÒ©ú HU ¬O§_·|­PÀù¡A¦]¬°Á{§Éªº³]­p¤£¬O¥hÃÒ©ú HU ·|¤£·|­PÀù¡C

PV ªvÀø¡A»´«×ªº¸Ü´N¬O©ñ¦å¥[¦Yªü´µ¤ÇÆF¡A¦ý³Ì«á¤´·|´c¤Æ¨ì»ÝªA¥Î HU¡C³o½g¤å³¹³Ì«áªº³¡¥÷¡A¦³´£¨ì HU ¥­§¡¤­¦~´N·|¦³§ÜÃÄ©Ê¡A¶·ªA¥Î²Ä¤G½u¥ÎÃÄ(§ÜÃĩʲ£¥Íªº®É¶¡¤´¶·¨DÃÒ¡A¦ý¿ð¦­·|¦³¬O½T©wªº)¡CP1101 ¯à¹F§¹¥þ½w¸Ñ(¤G´ÁÁ{§É¼Æ¾Ú)¡A¼Æ¦~«á¬Æ¦ÜÁÙ¦³¥i¯à°±ÃÄ(»Ýµ¥ conti-PV ³Ì²×¼Æ¾Ú)¡A¬°¦ó­nÅý¯f±w¦Y HU µM«á´c¤Æ¦Ü»Ý­n¦Y©ù¶Qªº¤G½uÃĤ@½ú¤l¡A³o¼ËªºÅÞ¿è¦n¹³©Ç©Çªº¡C(JAKAFI ªº°Æ§@¥Î¨ä¹ê¤]¤£§C¡A¦ý¨S¦³¿ï¾Ü¤F¡C)

¸Ü»¡¦^¨Ó¡A·í P1101 ®³¨ì²Ä¤@½u¥ÎÃĤ§«á HU À³·íµLªk¦A³Q®³¨ÓªvÀø PV ¨Ï¥Î¤F¡C FDA ¦³©ú½Tªº³W½d off label use ®É¾÷ ¡CÂå¥Í­Y¬O¶}¥ß HU µ¹¯f±w¡A¬O®³¦Û¤vªºÂ¾·~¥Í²P¦b«_ÀI¡AÀ³¸Ó¨S¦³Âå¥ÍÄ@·N³o¼Ë°µ¡C

ºô¯¸ªº¤å³¹¡A­Y¬O³ø¾É²£·~ªº·s»D´NÁÙ¦n¡A¦ý¨ä¤¤ºUÂø¤Ó¦h¼¶½Z¤Hªº·Qªk»P±À½×¡A¬Ýªº®É­Ô­n¤p¤ß¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pÃÄ®v10142475  µoªí®É¶¡:2017/2/2 ¤W¤È 11:54:36²Ä 1963 ½g¦^À³
½Ð°Ý¡AAOP¬O¥»¤ë¹w©w´£¥X¥Ó½ÐÃįg¶Ü¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p´²¤á10028616  µoªí®É¶¡:2017/2/2 ¤W¤È 11:00:06²Ä 1962 ½g¦^À³
·PÁ°]°È¤jªº»¡©ú

INCY·í®É¤]¬ORelief trial ¥¢±Ñ¤F(¤ñ¹ïHU)

¤~¥HResponse Trial¥Ó½Ð¤G½u¥ÎÃÄ

¦ý³o½g

¡uÃĵعï·Ó²ÕHU·|­PÀù?¥þ²y³ÌÅv«ÂFDA Say NO¡K.¡v

§Ú·Q­n§ó¦hªº¼Æ¾Ú¨Ó»¡©ú¤F~~

www.genetinfo.com/investment/featured/item/4993.html

¬Ý°_¨Ó°]°T¨t²Î¹ïÃĵتº¦^À³ÁÙ¬O¦³¤£¦Pªº¬Ýªk

¬Ý°_¨Ó¤½¥qÀ³¸Ó§ó­n§V¤O¨ú±o¤@½uÃÄÃÒ¥H§ù±y±y²³¤f¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°]°È¦Û¥Ñ¤H10132540  µoªí®É¶¡:2017/2/2 ¤W¤È 10:42:13²Ä 1961 ½g¦^À³
¡yÃĵظѪ¼¦¨¥\¡AÄvª§ªÌINCY¤£¶^¤Ï¦Ó¤jº¦¡z¡C³o½g¤å³¹¬O¦b½èºÃ´CÅ骺¤£±M·~¡A¤£¸Ó®³¤GªÌ¬Û´£¨Ã½×¡A²¦³º¬O¤£¦P©w¦ìªº¥«³õ¡AÄvª§¦³­­¡A¥[¤W Incyte ¦³±j¤j¦æ¾P¥ë¦ñ¿ÕµØ¡A¤£¸Ó®³¤GªÌ¬Û´£¨Ã½×¡C

¤£¹L¡A¨ä¤¤¤å³¹¦³´£¨ì¡APV ²Ä¤@½u¥ÎÃĦ³¤Ó¦hªº¿ï¾Ü¡H ³oÀ³¬O¤£¥¿½Tªº¡CPV ²Ä¤@½u¥ÎÃĥثe¨Ã¨S¦³ÃÄ¥i¥Î¡A¥u¦³¶Ç²ÎÀøªk©ñ¦å¸ò Off-label use ªº HU ¥~¡A¨S¦³¨ä¥LªºÂåÀø¤èªk¤F¡C·íªìªº JAKAFI ¤]¬O·Q§ð²Ä¤@½u¥ÎÃÄ¡A¦ý¦]¬°Á{§É¥¢±Ñ¤~°h¦Ó¨D¨ä¦¸¡A¤G½u¥ÎÃĬO¤£±o¤£ªº¿ï¾Ü¡A¤£¬O¦]¬° HU «K©yªºÃö«Y¡C

¤£¦H©ó(non-inferiority)ªºÁ{§É¤T´Áµ²ªG¡A¤@ª½¬O³Q½a°l²r¥´ªºµJÂI¡C³o¥u¯à´Á±æ«áÄòªº conti-PV ¨ÓÃÒ©ú¡Aªø´Á¦Ó¨¥¨ä¹ê¬OÀu©ó (superior) ªº HU¡C

¦æ¾P¤W´N¬Ý«ç»ò¾Þ§@¤F¡A KOL ªºÂå¥Í¸s¬O¤£¬O¯à¦³®Ä«Å¶Ç¡A¤j®a³£¥i¥H¬Ý¡Cªì´Á¦Ó¨¥¡A§Ú­Ó¤H¬Oı±o¥ýµ²·ù

­Ó¤Hı±o¡A´CÅé©Î³\¸Ó¥h«ä¦Ò¡A¬°¤°»ò EMA ·|¦P·N AOP ­×§ïÁ{§É¤T´Áªº¹F¼Ð±ø¥ó¡H ¦Ó¤£¬O¤@ª½¦b¡y¤£¦H©ó¡zªºµ²ªG¤W¥´Âà¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p´²¤á10028616  µoªí®É¶¡:2017/2/2 ¤W¤È 09:58:28²Ä 1960 ½g¦^À³
¦U¦ìª©¤W¤j¤j

³o½g³ø¾É¬O¤£¬O¦³°ÝÃD?¦X²z¶Ü?

¡uÃĵظѪ¼¦¨¥\¡AÄvª§ªÌINCY¤£¶^¤Ï¦Ó¤jº¦¡v

www.genetinfo.com/investment/featured/item/5039.html

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p´²¤á10028616  µoªí®É¶¡:2017/2/2 ¤W¤È 08:39:10²Ä 1959 ½g¦^À³
¤t´¶ºÙÃÄ«~»ù®æ¦p¡u¤Ñ»ù¡v ©Ó¿Õ±N§ïÅܳo¤@§½­±

¬ü°êÁ`²Î¤t´¶©P¤G¦b¥Õ®c¥l¶}ªº·|ij¤W¹ï»sÃÄ°Óªí¥Ü¡A»sÃÄ°ÓªºÃÄ»ù¤Ó°ª¡A¦b´M¨D¤è¦¡Åý·sÃħó§Ö¤W¥«¥H¥~¡A©Ó¿Õ±N¬°¬F©²ªºÂåÀø°·«O­pµeÀò±o§ó¦nªº»ù®æ¡C

¡u©w»ù¦p¤Ñ»ù¤@¯ë°ª¡A¡v¤t´¶¦bµØ²±¹y¹ï¤@¨Ç¥þ²y³Ì¤jªº»sÃÄ°Ó°ªºÞªí¥Ü¡C¤t´¶¥»¤ë¦­¨Ç®É­Ô¹ï»sÃÄ·~ªº§åµû«P¨ÏÃÄ«~Ãþ©M¥Íª«¬ì§ÞÃþªÑ»ù­«®À¡C¡u¹L¥h´X¦~¡A¤j®aªº¤u§@¨ô¶V¡A¦ý¬O§Ú­Ì¥²¶·±o§âÃÄ»ù­°¤U¨Ó¡C¡v

¤t´¶¤w¸gªí¥Ü¥i¯àÅý¬F©²¥Nªí¬ü°êÂåÀø«OÀI (Medicare) ©MÂåÀø¸É§U­pµe (Medicaid) ª½±µ»P»sÃÄ·~½Í§P»ù®æ¡CMedicare ©M Medicaid ­pµe¥]¬A¥þ²y³Ì¤jªº°·±d°·«OÃþ²£«~©MªA°Èªº±ÄÁʪ̡A¨Ã¥B²[»\¼Æ¤d¸U¬ü°ê¥Á²³¡C¡uÄvª§¬O­°§CÃÄ»ùªºÃöÁä¡A¡v¤t´¶»¡¡C

¦P®É¡A¤t´¶©Ó¿Õ«d´îºÊºÞ¡A¥[§Ö¬ü°ê­¹«~ÃÄ«~ºÊ·þºÞ²z§½ (FDA) ¹ï·sªºªvÀø¤è®×ªº¤W¥«¼f§åµ{§Ç¡A¥[¤j°ê»ÚÄvª§¡C¤t´¶»¡¡G¡u§Ú­Ì±Nºë² FDA¡v¡A¨Ã¥B±N«Ü§Ö«Å¥¬»â¾É¸Ó¾÷ºcªº³Ç¥X¤H¿ï¡C¥LÁÙ©Ó¿Õ«d´î¥ø·~µ|¦¬¡A§l¤Þ¤½¥q­«·s¦^¨ì¬ü°ê¡C

§ë¸êªÌ¹ï³o¨Çµû½×ªº¤ÏÀ³¿n·¥¡AºI¦Ü¯Ã¬ù®É¶¡ 10:07¡A¨º´µ¹F§J¥Íª«¬ì§Þ«ü¼Æ¤Wº¦ 1%¡A¼Ð´¶ 500 ªº»sÃÄ¡B¥Íª«¬ì§Þ©M¥Í©R¬ì¾Ç«ü¼Æ¤Wº¦ 0.8%¡C

news.cnyes.com/news/id/3700528

¨ºÃĵØPV¤T´ÁªºFDA¼f¬d·|³Q¥[³t§a~~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°¶¤j¤j10136951  µoªí®É¶¡:2017/2/1 ¤U¤È 09:08:16²Ä 1958 ½g¦^À³
¸ô»»ª¾°¨¤O

Solvaldi µo©ú¤H¦­¤wª¾¹D¤p¤À¤lÃĪº¤@¨Ç°ÝÃD

©Ò¥H«æ©ó¼Æ«×¨Ó¥x¨D´¼¼z?­n¦X§@!

ªø®Ä¤zÂZ¯Àª½±µ¶i¨ì¦å²G¡A¥¦¬OÄÝ©ó¤HÅé­ì¦³ªºªF¦è¡A¦Ó¥B¥¦¤£ª½±µ±þ¼Ä¡C

¥¦¬Oĵ§i¡B³ê¿ô§Y±N¨ü¨ì·P¬Vªº¥¿±`²Ó­M¤Àªc¡¨§Ü¬r³J¥Õ¡¨¡C

©Ò¥H¥¦¬O

1,´X¥GµL¬r©Ê¡A¦pªG¥¦°÷¯Âªº¸Ü

2,°£¤F¨x¥H¥~¡A¨ä¾l¥i¯à¨ü·P¬Vªº¾¹©x¡A¥i¥H¶¶«Kªv¤@ªv¡C

¯ÊÂI¬O¡A³o¤@ºØ§K¬ÌÀøªk¡A¤ÞÀº¼ö¾÷ªº®É¶¡ªø¡A¦ý¤@¥¹µo°Ê°_¨Ó°Ê¤O¬O²Ó¤ôªø¬y¡A·½·½¤£Â_¡C

¸ô»»ª¾°¨¤O°Ú!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°¶¤j¤j10136951  µoªí®É¶¡:2017/2/1 ¤U¤È 08:42:15²Ä 1957 ½g¦^À³
³o¤@¨Ç¤p¤À¤lÃĪ«ªvÀø¡A³°Äò¥X²{ªº°Æ§@¥Î«áªG¡A

¹ï©ó¦³¤@¯ëÅÞ¿è±`ÃѪº¤H³£ª¾¹D¡A¥Î¸}½¥»\·Q¤]ª¾¹D¡C

¯à¨³³tªº§â¯f¬r±þ¦º¡A¦bµu®É¶¡´N¥i¥H®³¥X«GÄR¦¨ÁZ³æ¡A

¥¦­Ì©Ò¿×ªv¡ªº©w¸q¡A´N¬O§â¯f¬r¼ÆÀ£¨ì¤@©w§C¶q¡A¨Ãºû«ù´X­Ó¤ë®É¶¡¡C

§Ö³t±þ¦º¯f¬r®Ú¥»³£¬O¼@ÃÄ¡A©¹©¹¼@Ãij£¬O¬rÃÄ¡C

±þ¼Ä¹Lµ{¡A¸g¹L­G¸z®ø¤Æ¨t²Î¡AÅ餺¦U¾¹©x¡A¦A¨ì¦å²G´`Àô¨t²Î¡A

¨C¤Ñ¦Y¡A¤@¦¸Àøµ{´N¬O¦n´X­Ó¤ë¡C¬°¤F¹F¨ìªv¨x¤§¥Øªº¡AÅ餺¦³¦h¤Ö¾¹©x¨ü³Ð?

¤×¨ä­ì¥»¯Ü®zªº¾¹©x¡A§ó¥[¯Ü®z¡A­ì¥»°·±dªº¾¹©xÅܦ¨¯Ü®z¡C

©Ò¥H³o¤@ºØªvÀø¤è¦¡¡A¬O¤£¹ïªº¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2017/1/26 ¤W¤È 11:43:19²Ä 1956 ½g¦^À³
# (6446) ÃĵØÃÄ P1101 ·s¤@¥Nªø®Ä«¬¤zÂZ¯À¬O®Ú¥»ªvÀøC¨x¡BB¨x³Ì¨Î¿ï¾Ü¡C

Breakthrough hep C meds carry risk for liver failure, death: report

goo.gl/qoI9kt

µo²{C¨x¥ÎÃĦñÀH¨x¥\¯à°IºÜªº­·ÀI¾É­P¦º¤`¡G³ø§i

2017/1/25 11:13 am

A new report has documented adverse events for a new class of hep C meds, Gilead¡¦s Harvoni among them.

¤@¥÷·sªº³ø§iÅã¥Ü, ³o¤@Ãþ«¬ªºC¨x¥ÎÃÄ·|±a¨Ó¤£¨}¤ÏÀ³, Gilead ªº Harvoni ¤]¥]§t¨ä¤¤¡C

As financial challenges loom for Gilead, a new report highlighted safety concerns for two of its stalwart hepatitis C meds¡XHarvoni and Sovaldi¡Xalong with other rivals in the class.

¦ñÀHµÛ¦N§Q¼wªñ´Á­±Á{¨ìªº°]°È¬D¾Ô, ¤@¥÷·sªº³ø§iÅã¥Ü, ¤½¥q±j¤O±À¥Xªº¨â´ÚC¨x¥ÎÃÄ- Harvoni ¥H¤ÎSovaldi »P¦PÃþ¨ä¥L¹ï¤âªºÃĪ«¦³¦w¥þ°ÝÃDªººÃ¼{¡C

The costly new drugs, which have been lauded for their ability to cure hep C, could be associated with severe side effects such as liver failure, according to an analysis by the Institute for Safe Medication Practices set to be released Wednesday.

®Ú¾Ú¥ÎÃĦw¥þ¨ó·|¶g¤T©ÒÄÀ¥X©ñ¥X°T®§´£¨ì, ³o¨Ç³QÆg´­¨Ã¼Ðº]¥i¥Hªv¡C¨xªº©ù¶QÃĪ«, ¥i¯à¦ñÀHµÛÄY­«ªº°Æ§@¥Î¦p¨x¥\¯à°IºÜ¡C

Aside from the Gilead drugs, the ISMP report included other direct-acting antivirals from AbbVie, Merck & Co., Bristol-Myers Squibb and Johnson & Johnson.

°£¤F¦N§Q¼wªºC¨x¥ÎÃĤ§¥~¡AISMP³ø§iÅã¥Ü¥]¬A¨Ó¦Û¦ã§Bºû(AbbVie)¡BÀq§J(Merck)¡B¬I¶QÄ_¤½¥q(Bristol-Myers Squibb)©M±j¥Í¤½¥q(Johnson & Johnson)µ¥¤fªA¥ÎÃij£¦³¬Û¦PºÃ¼{¡C

By looking at FDA adverse event data for the 12 months ending on June 30, 2016, ISMP found 524 cases of liver failure around the world associated with the drug class and 1,058 reports of severe liver injury. In another 761 cases, the antivirals failed to work. More than 30% of the patients who experienced liver failure died.

±q2016¦~6¤ë30±Àºâ12­Ó¤ë¥H¨Ó, FDA¤£¨}¤ÏÀ³ªº¸ê®Æ¬Ý¨ì, ISMP µo²{524²[»\¥@¬É¦U¦aÃĪ«ÃöÁpªºªº¨x¥\¯à°IºÜ®×¨Ò©MÄY­«¨x¥\¯à¨ü·lªº1058¯f¨Ò³ø§i¡C¦¹¥~¦³761­Ó®×¨Òµo¥Í¦b³o¨Ç¤fªAC¨x¥ÎÃĵL®Ä¡C¶W¹L30%ªº¯f±w«h¬O¨x¥\¯à°IºÜ¦Ó¦º¤`¡C

Gilead said in a statement that its meds were approved for patients already experiencing liver problems, adding that it¡¦s ¡§seen no evidence of a causal relationship between sofosbuvir-based regimens and liver failure.¡¨

Gilead µoªí¤@¥÷Án©ú´£¨ì, ¥¦­ÌªºÃĪ«¬O³Q§å­ã¥Î©ó¦³¨xŦ°ÝÃDªº¯f±w, ¨Ã¸É¥R»¡©ú ¨S¦³¬Ý¨ì³o­ÓªvÀø¤è®×©M¨x¥\¯à°IºÜ¤§¶¡¦s¦b¦]ªGÃö«YªºÃÒ¾Ú¡C

Drug failures aren¡¦t unexpected given the numbers of patients treated, a Gilead spokesperson added. Based on the company¡¦s experience and published articles, occurs as relapse in a small proportion of patients after treatment completion.

Gilead¤½¥qµo¨¥¤H¸É¥R»¡©ú, ³o¨Ç¥ÎÃÄ¥¢±Ñ¯f±w¼Æ¦r¬O«D¹w´Áµ²ªG¡C°ò©ó¤½¥qªº¸gÅç©Mµoªí¤å³¹Åã¥Ü, ¦³¤@¤p³¡¤À¯f±w¦b§¹¦¨ªvÀø«áªvÀø¥¢±Ñ¨Ã¾É­P´_µoªº®×¨Ò¡C

Speaking to ISMP, J&J¡¦s Janssen unit noted that it considers its med¡¦s adverse event profile as consistent with those seen in clinical trials and reflected in the prescribing information, according to the report authors.

§@ªÌ³ø§i´£¥X, ®Ú¾ÚISMP »¡©ú, Johnson & Johnson ¤½¥qªºJanssen³æ¦ì´£¨ì, ÃĪ«§e²{ªº¤£¨}¨Æ¥óª¬ªp©MÁ{§É¸ÕÅ礤ªºµ²ªG¤@­P¡A¨Ã¤w§e²{¦bÃĪ«³B¤èªº¸ê°T¤W¡C

However, the authors said ¡§90% of cases were reported by healthcare professionals as a drug-related adverse event and not the natural progression of hepatitis C.¡¨ While not definitive, the report said the data ¡§show the need for further investigation into the negative consequences of these expensive and important new drugs.

µM¦Ó, §@ªÌ«ü¥X, ±qÂåÅ@±M®aªº³ø§i´£¥X, 90%ªº®×¨Ò¬O©MÃĪ«¬ÛÃöªº¤£¨}¤ÏÀ³¦Ó«D¦ÛµMªºC¨x¶i®i¡CÁöµM©|¥¼½T©w, ¦ý³o¥÷³ø§i«ü¥X»Ý­n§óªø»·ªº½Õ¬dÂÇ¥HÅã¥Ü³o¨Ç©ù¶Q·sÃĪº­t­±«áªG¡C

As ISMP noted, the drugs come with a hefty price tag ranging from $55,000 to $125,000 per patient, citing QuintilesIMS, and account for more in spending than drugs with patient populations ¡§measured in the tens of millions.¡¨ About 250,000 patients took direct-acting antivirals in 2015.

¥¿¦pISMP©Ò«ü¥X, ³o¨ÇÃĪ«ªº»ù®æ¼ÐÅÒ±q55,000¬ü¤¸¨ì125,000¬ü¤¸¤£µ¥¡C¤Þ¥ÎQuintilesIMSªº¸ê°T¬Ý¨ì,³o¨ÇÃĪ«¤ä¥X

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/1/22 ¤U¤È 09:52:56²Ä 1955 ½g¦^À³
¯E¹©¶Ç¥X¤T´Áªº¦n®ø®§¤F

§Æ±æ¥xÆW¥Í§Þ¤µ¦~¶}©l¨¦©³Â½´­

§Q¦h¤£Â_

Ãĵؤ]¤@°_¥[ªo

¤G¤ë¥Ó½Ð¼Ú·ùÃÄÃÒ....²Ä¤T©u¥Ó½Ð¬ü°êÃÄÃÒ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2017/1/18 ¤U¤È 02:50:50²Ä 1954 ½g¦^À³
µLµß®ñ¤j±z¦n, °w¹ï±zªº»¡©ú´£¥X¤@¨Ç¸É¥R¤À¨É¡G

# ÃÄµØ P1101 Conti-PV Á{§É³]­p¦p¤U¡G

AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (CONTI-PV)

°w¹ï¹L¥h°Ñ»P PROUD-PV Á{§É¸ÕÅ窺PV¯f±w¦b AOP2014 (P1101) »PBATªº¤ñ¸û¡C

clinicaltrials.gov/ct2/show/NCT02218047?term=CONTI-PV&rank=1

# Incyte ¡V Jakafi (ruxolitinib) ©óPV¾AÀ³¯g¤G½u¥ÎÃÄÁ{§É³]­p¦p¤U¡G

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

°w¹ïHU¦³§ÜÃÄ©Ê¥H¤Î¤£­@¨üªºPV¯f±w, ¨Ï¥Î ¡§Jakafi¡¨ »P ¡§BAT (³Ì¨ÎÀøªk)¡¨ ªº¦³®Ä©Ê»P¦w¥þ©Ê¤ñ¸û¡C

clinicaltrials.gov/ct2/show/NCT01243944?term=Response+trial&rank=5

¦b Jakafi Response trialªº¸ÕÅ礤, ¹ï©ó BAT ©w¸q¦³¸Ô²Óªº»¡©ú, ºK¿ý½Ķ¦p¤U¡G

Best Available Therapy (BAT) ³Ì¨ÎÀøªk©w¸q¬°¬ã¨sªÌ©Ò¿ï¾Ü, BAT (³Ì¨ÎÀøªk) ¤£¥]§t©|¥¼§å­ã¥Î©óªvÀø¨ä¥L¾AÀ³¯gªº¥ÎÃÄ¥H¤Î¤Ö¼Æ¦³³Q³W½d­­¨îªºÃĪ«¡C

¦]¦¹, ¦b¦¹¹êÅ窺 BAT ³Ì¨ÎÀøªk ¥]§t¡G

* Hydroxyurea HU

* IFN/PEG-IFN ¤zÂZ¯À/ªø®Ä«¬¤zÂZ¯À

* Pipobroman §ÜÀù¥ÎÃÄ

* Anagrelide ©ñ¦å

* Lenalidomide ·ç´_¬ü¡AªvÀø¦hµo©Ê°©Åè½F¥ÎÃÄ

* Pomalidomide ªvÀø¦hµo©Ê°©Åè½F

* Observation only ¶ÈÆ[¹î

¥Ñ¦¹¥i¨£, ÁöµM ¹ï·Ó²Õ³£¬O BAT (³Ì¨ÎÀøªk), ¦ý¹ê»Ú·N²[¤j¤£¦P, »¡©ú¦p¤U¡G

ÃĵØP1101¦bConti-PV Á{§É³]­p, ¨ä¹ï·Ó²ÕÅܧó¬°BAT (³Ì¨ÎÀøªk) ¥D¦]¬°·í®ÉPROVD-PV ­ì¥ý¨Ï¥ÎHUªº¯f¤H, ¦bHU §ÜÃÄ©Ê/¤£­@¨ü±¡ªp¤U, »ÝÅܧóªvÀø¤è¦¡¥H§Q«áÄòÁ{§É°lÂÜ, §_«h­ì¹ï·Ó²Õ HU ªº¯f±w°h¥XªvÀø¼Æ¶q·|³vº¥Ãk¤É¾É­P»P¹êÅç²Õ®t²§©Ô¤j¡C

¦ÓJakafi Á{§É³]­p«h¤w²M·¡»¡©ú, ¡§°w¹ïHU¦³§ÜÃÄ©Ê¥H¤Î¤£­@¨üªºPV¯f±w¡¨, ¯f±w±Ú¸s¤w¸g­­ÁY¬° PV ¤G½u¥ÎÃįf±w, ¦b¦¹½d³ò¤U©M¥Ø«ePV ¤G½u¥ÎÃĪvÀø»{©w¤§ BAT ³Ì¨ÎÀøªk¤ñ¸û¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2017/1/18 ¤W¤È 01:02:06²Ä 1953 ½g¦^À³
¥H¤U¶È¨Ñ°Ñ¦Ò

www.valuewalk.com/2017/01/taiwan-heavy-sell-analysts/

Consensus Target Prices: Taiwan

The target price expected return over the next 12 months is at 7% vs 4% in August. Analysts seem to have turned more positive soon after TAIEX¡¦s 5% gain in the past three months.

Among companies with the highest estimated upside, PharmaEssentia¡¦s drug P1101, used to treat a rare blood disorder called Polycythemia Vera, is expected to hit the market in 2017-2018 and drive earnings.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/1/17 ¤U¤È 10:54:04²Ä 1952 ½g¦^À³
¬Ý¤F¤@¤U¤µ¤Ñ¦U¦ì¤j¤jªº°Q½×...¤p§Ìı±o....

¨ä¹êµL½×¤l¤½¥q»P¤À¤½¥q³£¦³¨äÀu¯ÊÂI...

¨Ì¸ó°ê¥ø·~¸gÀçºÞ²z­±¨Ó¬Ý¡A¦b®ü¥~¦¨¥ß¾ÚÂI¤@©w·|¸ò·|­p®v¡B«ß®v°Q½×¹L¬ÛÃöªºµ|°È¡Bªk侓°ÝÃD«á¨Mij¡CÃĵؿï¾Ü¦b¬ü¡B¤é¦¨¥ß¤l¤½¥q¤@©w¦³¨ä¹D²z¡A­Ó¤H²q·Q¡A°£¤Fµ|°È¦Ò¶q¥~¡A¤é«á­Y¦³¦X§@¥ë¦ñ©ó¾A·í®É¾÷¤JªÑ©ÎªÑ²¼©ó·í¦a¤W¥«¡A«h¥u»Ý³æ¯Â¼W¸ê¤JªÑ/ÄÀªÑ§Y¥i¡A¬Û¹ï«K§Q¡C»¡¤£©w¦­´N»P¤jÃļt½Í¦n¦X§@¼Ò¦¡¡A¥u¬O®É¾÷ÁÙ¨S¨ì¡A¤£¯à«Å§G(­Ó¤HµL®Ú¾Úªº²q´ú)¡C­«ÂI¬OµL»Ý½èºÃ¤½¥q¡A³o¤£¬O¤@­Ó¤H¯à¨Mµ¦ªº¡C

¦Ü©óP1101¤W¥««áªº¦æ¾P°ÝÃD¡A³ßÅw´£¥XµL¨Ó¥Ñ½èºÃªº¦U¤j¤ÀªR®v³£¥G²¤¤F¤@ÂI...

ÃĵتººÞ²z¶¥¼h¦h¦ì¬Ò¦³¦U¤jµÛ¦WÃļt¦h¦~°ª¶¥¤u§@¸gÅç©ÎFDA©x­û¸g¾ú!!!

ÃĵتººÞ²z¶¥¼h¦h¦ì¬Ò¦³¦U¤jµÛ¦WÃļt¦h¦~°ª¶¥¤u§@¸gÅç©ÎFDA©x­û¸g¾ú!!!

ÃĵتººÞ²z¶¥¼h¦h¦ì¬Ò¦³¦U¤jµÛ¦WÃļt¦h¦~°ª¶¥¤u§@¸gÅç©ÎFDA©x­û¸g¾ú!!!

«ç»ò¥i¯à¹ï¤W¥«¾P°âªººÞ¹D©Î­q»ùµ¥¤è­±¤£ÁA¸Ñ¡C¤ÀªR®v«ç»ò¥i¯à¤ñ¥L­ÌÁÙÁA¸Ñ???

«ç»ò¥i¯à¹ï¤W¥«¾P°âªººÞ¹D©Î­q»ùµ¥¤è­±¤£ÁA¸Ñ¡C¤ÀªR®v«ç»ò¥i¯à¤ñ¥L­ÌÁÙÁA¸Ñ???

«ç»ò¥i¯à¹ï¤W¥«¾P°âªººÞ¹D©Î­q»ùµ¥¤è­±¤£ÁA¸Ñ¡C¤ÀªR®v«ç»ò¥i¯à¤ñ¥L­ÌÁÙÁA¸Ñ???

´£¥X¤F¤@¨Ç²ö¦Wªº½èºÃ??¦³®É­ÔÅ¥¥L­Ì¤ÀªRªºÀYÀY¬O¹D¡A¥i¬O±q²z½×¨Ì¾Ú¸ò¹w¦ô°²³]¨Ó¬Ý¡A³£«ÜÁ¡®z¡C­ü¡A¤Ï¥¿²{¦b¥Í§Þ¥«ªp¤£¨Î¡A¥´¸¨¤ôª¯¤H¤H³£·|¡C¦bPV¯e¯f»â°ì¸Ì¡A¥L­ÌÀ´±o®£©È³£¤£¤ñª©¤W»{¯uªº¦U¦ì¤j¤j¨Ó±o¦h¡C

¥ú¬O¹q¤l·~ªº¤ÀªR®v§Y¤À¦¨³\¦h¤£¦PÃþ«¬²£·~ªº¬ã¨sªÌ(¦pWafer¡BPCB¡B¤â«ù¸Ë¸m¡BÅX°ÊIC¡BÅÞ¿èIC¡BLCD¡BLEDµ¥µ¥)¡A¦³¤H¬O¥þ¯àªº¶Ü??§ó¦óªp½ÆÂø§ó°ªªº·sÃÄ»â°ì¡A©~µM¦P¤@­Ó¤ÀªR¤H­û¹ï§K¬ÌÀøªk¡BAIDS¸ò¦å²G¯e¯f³£À´¡B³£±Mºë¡A³£·|¤ÀªRªº¡C¯u·Q¸ò§Ú¨à¤lÁ¿¡A©Þ©Þ¹J¨ì¶W¤H¤F¡C

³Ì«á¡BÃÄÃҤ譱¡A¸òEMA¥Ó½Ð¤T´ÁÁ{§É®É´N¬O¤@½u¥ÎÃÄ¡AÀ³¸Ó¨S¤°»ò¦n½èºÃªº¡CAOP¤]¨M©w¤µ¦~¤G¤ë´£¥X¥Ó½Ð¡C¦pªG¤G¤ë¯uªº¦p´Á¥Ó½Ð¡Aªí¥Ü.....conti-PVµ²ªGÀ³¸Ó¤]¦p¹w´Á¡A©Î³\ªÑ»ù¤Ï§ðªº¾÷·|·|¨Ó¡C¤£¹L¡B¥´½ìªºÁ¿¡A¦pªG¯uªº¬O­ã¤G½u¥ÎÃÄ....¨ºJakafi¸òPegasy³oºØ¤G½uÃij£¤jÁȤF¡AP1101¤]¬O¤G½u¡A¤£¤]À³¸Ó¤jÁȶÜ??±zÁÙ¾á¤ß¤°»ò!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2017/1/17 ¤U¤È 10:41:39²Ä 1951 ½g¦^À³
¡uAOP ©ó2013/09 ¼W¥[¬°´Á1 ¦~ªº©µ¦ù©Ê¸ÕÅç¡A¤S§ï¬°3 ¦~¡A¥B

¸ÕÅ示®e¥Ñ·íªì»PHU ¤ñ¸û§ó§ï¬°¡¨HU ¥ÎÃĤ@¦~«á§ï¥ÎBAT(Best available

therapy)Àøªk¡¨¨Ó°µ¤ñ¸û¡A¹w´Á¨ì2017/04 ·|¦³§¹¾ã¯f¤H¥ÎÃÄ2 ¦~¤§¼Æ¾Ú¡C¡v

©Ò¥H©µ¦ù©Ê¸ÕÅç¬OPK BAT

¡uJakafi ¤§«e¦]臨§É¸ÕÅç

(»PHydroxyurea ¹ï·Ó)¥¼¹F¥D­nÀø®Ä«ü¼Ð¡A¦]¦ÓµLªk±À¶iPV ¤@½uªv療¥«³õ¡A¥Ø«e

¶È¬°¤G½u¥ÎÃÄ¡C«á¨ÓJakafi ¸ÕÅçÀø®ÄÀu©óBAT(Best available therapy)Àøªk¡A »PBAT ¤§¼Æ­È¤À§O¬°62.2%

»P18.7%¡AP<0.0001¡C¡v

¥H¤W¬O²Ä¤@ª÷ÃÒ¨é2016/12/06¤§­ÓªÑ³t³ø¤§³¡¤À¸ê®Æ¡Cwww.fcmi.com.tw/9_CMS/member2/member2_20161206_5576/%E8%97%A5%E8%8F%AF%E8%97%A5(6446)-%E5%8D%80%E9%96%93%E6%93%8D%E4%BD%9C.pdf

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSirius10142542  µoªí®É¶¡:2017/1/17 ¤U¤È 10:17:18²Ä 1950 ½g¦^À³
Ãĵإثe§Þ³N­±¤£¨Î¬O¨Æ¹ê(«e´X¤Ñ­è¯}©³)¡A¤£¹L²{¦b¶ZÂ÷¤W¦¸ªk»¡¤w¤@­Ó¦h¤ë¡ACONTI-PV¨S¦³¸Ñª¼ªº°ÝÃD¡A©Ò¥H¤½¥q«Ü²M·¡¥Ø«e¼Æ¾Úªº¶i®i¡A¬Ý¤½¥q³o¤@­Ó¦h¤ë¨Óªº°Ê§@¡A§Ú·Pı¤½¥qªº«H¤ß¬O¤ñ¤@­Ó¤ë«e§ó±j¤F¡A±q«e´X¤Ñ¸³¨Æ·|¨Ó¬Ý¡A¤£¦ý¬ü°ê¤l¤½¥q¶}©l°Ê¡A³s¤é¥»¤]¶}©l¡AÁÙªá¿ú½Ð·sªºÂå¾Çªø¡F¤W¶g­P¨çµ¹°]°T¡AÁÙ©ú¥Ü¨ä¥¦¤zÂZ¯À¥H«á¥i¯à«OÀI¤£·|µ¹¥I¡A§Ú­Ëı±o°ò¥»­±µLºÃ¡A¦ý¥«³õ®ðª^¹ê¦b¤ÓÁV¡A¤µ¤Ñ¨ì®Ñ©±Âø»x°Ï¡A¦n´X¥»«Ê­±³£¬O¥Í§Þ­t­±¼ÐÃD¡A¤@¯ë¤£¼ô°ò¥»­±ªº¤H´±¶R¶Ü?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2017/1/17 ¤U¤È 09:23:45²Ä 1949 ½g¦^À³
±µÄò¤W¤@½gªº¤À¨É¡A¦b¬Ý¤FP1101»PHUªº°Æ§@¥Î¤ñ¸û¼Æ¾Ú«á¡A­Ó¤H¤ß±o¬O¡K.. ³oÁû­°²Ó­MÀøªk(Cytoreduction)ªºHU¯uªº«Ü±j¡A¦ý¦ü¥G±j¨ì¦³ÂI±þ¹LÀY¤F!

* Anemia³h¦å (P1101: 6.3% vs. HU: 24.4%, p<0.01)

* Leukopenia¥Õ¦å²y¹L§C (P1101: 8.7% vs. HU: 21.3%, p<0.01)

* Thrombocytopenia¦å¤pªO¹L§C (P1101: 15.0% vs. HU: 28.3%, p<0.01)

¾ãÅé°Æ§@¥Î(AEs)

*Treatment-related AE (P1101: 59.6% vs. HU: 75.6%) ->Ãĵطs»D½Z¦³¤½¥¬

*Grade 3 AE (P1101: 16.5%, 29 events in 21 patients) vs. (HU: 20.5%, 45 events in 26 patients)

¦Ü©ó¦bHU¹ï·Ó²ÕÆ[¹î¨ìªº5¨Ò´c©Ê¸~½F¡Aªº½TºI¦Ü¥Ø«eªº¬ã¨s¨ÃµLªkÃÒ¹êªø´ÁªA¥ÎHU·|¾É­P´c©Ê¸~½F¡A¦bªA¥ÎHU¬°·í«e¥D­nªvÀøPVªº¤è¦¡¤U¡AÅý³\¦hÂå®v©Î¬ã¨s¤H­û»{¬°ªø´ÁªA¥ÎHU¥i¯à·|¾É­PAML¡A¥]¬ADr. John Mascarenhas¦b±µ¨üPatient Power±M³X®É¡A¤]´£¨ì¡¨HU¦³ºÃ¼{ªº¬O¥¦¦³¥i¯à¾É­P(induce)¥Õ¦å¯f°ò¦]¡¨¡C

­Ë¬O­ì¥»PV¯f¤H´N¦³ªø´Á¶iµ{(progression)¨ì«æ©Ê¥Õ¦å¯f(AML)ªº¾÷²v¡A°Ñ¦Ò¤åÄm ¡¨Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study (Blood 2005)¡¨¡A¦b1638¦W¨Ï¥Î§C¾¯¶qªü´µ¤ÇÆFªºPV¯f¤H¤¤¦³22¤H¶iµ{¨ìAML/MDS(¬ù1.34%)¡C¦]¦¹¡A©Î³\§Ú­Ì¹L¥h»{ª¾HU¾É­PAML¬O±N¦]ªGÃö«Y²V²c¤F¡CProud-PV¦bHU±Ú¸sÆ[¹î¨ìªº2¨ÒAML(2/127=1.57%)¡A¥¼¥²¬°ªA¥ÎHU¦Ó¾É­PAML¡A©ÎÀ³¬°P1101ªvÀø±Ú¸s¦]¬°¬I¥´¤zÂZ¯À¦Ó­°§C¤F¶iµ{¨ìAMLªº¾÷²v¡A³o¬O¦bProud-PV¥D­n/¦¸­n¸ÕÅç«ü¼Ð¥H¥~ªº·N¥~µo²{¡C·íµM¡A³o¼Ëªº±À½×Áٻݭn¶i¤@¨B°lÂܨâ­Ó±Ú¸sªº«áÄò®×¨Ò¡A¥H§@¬°ªí¹FP1101¦bÁ{§É¤Wªº®Ä¯q¡C

³Ì«á¡AEMA©MFDA¹ï©óÃÄÃÒªº¼f®Ö¡A³£·|¦Ò¼{¨ì®Ä¯q»P­·ÀIªº¥­¿Å(Benefit-Risk Balance)¡A¤£¬OÃÄ·U±j´N·U¦n¡C

EMA: The balance of benefits and risks occupies a central place in licensing

and approval decisions

(www.ateliersdegiens.org/wp-content/uploads/Regulatory-point-of-view-on-clinical-benefit-assessment-and-parallel-EMA-HTA-advice-Stiina-Aarum-Mode-de-compatibilit%C3%A9.pdf)

FDA: The company must show that the drug is safe and effective for its intended uses. ¡§Safe¡¨ does not mean that the drug has no side effects. Instead, it means the FDA has determined the benefits of using the drug for a particular use outweigh the potential risks.

(www.fda.gov/ForPatients/Other/OffLabel/ucm20041767.htm)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2017/1/17 ¤U¤È 08:04:38²Ä 1948 ½g¦^À³
ÁöµM§Úªø½u«D±`¬Ý¦n6446,¦ý¬O¥Ø«e«¬ºA¤£¨Î¬O¨Æ¹ê.§Ú­Ó¤H»{¬°³Ì§Ö¤]­n¦b5¤ë¤~·|ªíºA,©Î¬O©ú¦~²Ä¤@©u¤]¤£¬O¤£¥i¯à,²{¦b«ü¼Æ¦b°ªÀÉ,¸U¤@«ü¼Æ¤j­×¥¿¤j®a¤£¨£±o©ê±o¦í,¤p¶R¥i¤jÀ£ÁÙ­nµ¥µ¥

¥H¤W­Ó¤H¬Ýªk,§Æ±æ¤£¼vÅT¦U¦ì¾Þ§@

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gj310142799  µoªí®É¶¡:2017/1/17 ¤U¤È 07:06:46²Ä 1947 ½g¦^À³

Á{§É2´Á: ªø®Ä«¬¤zÂZ¯Àªºªº¤À¤l¤ÏÀ³¡]¬I¥´¤zÂZ¯À52©P«á¤À¤l¤ÏÀ³¬°33%¡F114©P«á¬°78%¡^

¦b¥»¬ã¨s­è¶}©l®É¡AJAK2 V617Fªºµ¥¦ì°ò¦]­t²üªº¤¤¦ì¼Æ¬°41%¡]½d³ò¡A2%-100%¡^, ¦ÜªvÀø²Ä18¶g«á, ¤¤¦ì¼Æ©úÅã­°§C¦Ü35%¡]½d³ò¡A0%-95%¡^¡]P=.479¡^, ªvÀø²Ä50¶g«á§ó­°¦Ü25¢H¡]½d³ò¡A0%-92%¡^¡]P <0.001¡^¡C¼Æ¾ÚÅã¥Üµ¥¦ì°ò¦]­t²üÀH®É¶¡ªº´î¤ÖÅãµÛ§e²{ª½½u©Êªº¤U­°,¨C­Ó¤ëµ¥¦ì°ò¦]­t²ü´î¤Ö1.2%¡]¦b95%«H¿à°Ï¶¡¤U[CI]¡A¥Ñ-1.7­°¬°-0.8; P < .001¡^¡C¥u¦³5¨Ò¡]10%¡^¯f±wJAK2µ¥¦ì°ò¦]­t²ü¼W¥[, ¦ý³o°ò·Ç¤p©ó10%¡C¦Ó¦³24¡]47%¡^¯f±w¡Aµ¥¦ì°ò¦]­t²üªº´î¤Ö> 20%¡C

¯f±w¤À¤l¤ÏÀ³²v(§¹¥þ¦³®Ä+³¡¤À¦³®Ä)©óªvÀø50¶g¥H¤Î114¶g«áªº²Ö¿n¼Æ¾Ú¤À§O¬°33%(12%§¹¥þ¦³®Ä, 21%³¡¤À¦³®Ä)¥H¤Î78% (21%§¹¥þ¦³®Ä, 57%³¡¤À¦³®Ä)¡C¦bJAK2 V617Fµ¥¦ì°ò¦]­t²ü¦Ü¤Ö20%ªº°ò·Ç¤U, 43¦W²Å¦X±ø¥óªº¯f±w¤¤¡F­ÓÅ骺³Ì¨Î¤À¤l¤ÏÀ³¼Æ¾Ú¬°¡G21%ªº±wªÌ§e²{§¹¥þ¦³®Ä¥H¤Î47%ªº¯f±w§e²{³¡¤À¦³®Ä¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRookie10143115  µoªí®É¶¡:2017/1/17 ¤U¤È 07:04:48²Ä 1946 ½g¦^À³
ÁÂÁ¤pªL¤j¡A¦n¹B¤j¡A°]°È¤jÄÀºÃ¡A¬Ý¨ÓÁÙ¬O­nµ¥Conti-PV¼Æ¾Ú¥X¨Ó¡A¤~¦³§ó©ú½TªºÃÒ¾Ú
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°]°È¦Û¥Ñ¤H10132540  µoªí®É¶¡:2017/1/17 ¤U¤È 06:51:24²Ä 1945 ½g¦^À³
JAK2 ¤U­°ÁͶեi¥H°Ñ¦ÒÁ{§É¤G´Áªº¸ê°T¡AÁöµM¨S¦³¹ï·Ó²Õ¡A¦ý³J¥Õ½èÃĪº¯S©Ê¤£·|®t¤Ó¦h¡A¥i¥H¬Ý¥X¤@­Ó¤è¦V¡A¤]¦]¬°Á{§É¤G´ÁªºJAK2 ¤U­°ÁͶռƾڸê°T, ¼w°êFDA «Øij±N²Ä¤GªvÀø«ü¼Ð¬ðÅÜ­×´_(functional cure)²¾¬°²Ä¤@ªvÀø«ü¼Ð¡C

¥Ø«e³Ì·sªº¼Æ¾Ú¸ê°T¦Ü¤Ö­nµ¥ conti-PV 24­Ó¤ëªº¼Æ¾Ú¡A¤~¯à¬Ý¥X»P HU ¬Û¸ûªºÁͶաC¤@­Ó­n¥´(¦Y)¼Æ¦~ªºÃÄ¡A³æ¬Ý²Ä¤@¦~µLªk¿s±o¥þ»ª¡A¦ý­Y P1101 JAK2 ¤U­°ÁͶլO½T©wªº¡A¥u­nª¾¹D¤GªÌªº¥æ¤eÂI´N¥i¥H¤F¡A³Ñ¤U³¡¥÷¥i¤W¥«(Phase 4)¦A°lÂܧY¥i¡C

´N³o¦¸Á{§É¼Ò«¬¨Ó¬Ý¡A12 ­Ó¤ëªº®É¶¡ÂI¡A HU »P P1101 ¤£¬Û¤W¤U¡AHU ¤À¤l¼Æ¾Ú¬Æ¦Ü¦n¤W¤@¨Ç¡C

¸Õ·Q¡A HU ªº¤À¤l¤ÏÀ³­Y³£¯à³o»òÀuªº¸Ü¡A¬°¦óµLªk¦¨¬°¤@½u¥ÎÃÄ¡H ¬°¦ó·|´X¥G³£·|´c¤Æ MF ¡H ¬°¦ó·|¦³¤Þµo AML ªº­·ÀI¡H­n¬O HU ³o»ò¦n¡AJAKAFI ¦b PV/MF ªvÀø»Ý¨D¬O«ç»ò«_¥X¨Óªº¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦n¹B10137114  µoªí®É¶¡:2017/1/17 ¤U¤È 05:47:12²Ä 1944 ½g¦^À³
Rookie ¤j

±zªº°ÝÃDªk»¡§ë¼v¤ù¦³¤@­¶¹Ïªí¡A¬Ý°_¨ÓJAK2¤U­°¤ñ¨Ò¡AHU¬O¤ñP1101­n¦n¤@ÂIÂI¡A

¤½¥qªº»¡ªk¬O¹ï¦¹¤]·P¨ì·N¥~¡A¦ý¬Û«H®É¶¡©Ôªø³o³¡¤À·|¤ñHU ¦n«Ü¦h¡C

³o³¡¤À§Úªº¥ß³õ¬O¡AÁÙ¨S½T©wªº¨Æ´N¬O¦³­·ÀI¡A½Ð¤j®a¦h¦hª`·N¸ê²£ªº¤À°t¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2017/1/17 ¤U¤È 05:45:06²Ä 1943 ½g¦^À³
½Ð°Ñ¦ÒClinical Care Options¦bASH Meeting«á±NProud-PV studyµoªí¤º®e§@ªº­«ÂI¾ã²z¡A°£¤F¤½¥q¤wµo§Gªº¸ê°T¥~¡A³o¥÷²³ø¦³¸û¦h°Æ§@¥Î²Ó¶µªº¤ñ¸û¼Æ¾Ú¡C

(¥i§K¶Oµù¥U¬°·|­û¡Aµn¤J«áÂI¿ïDownload²³øÀÉ)

www.clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202016/MDS%20and%20MPNs/475.aspx

¥t¥~¥i¥H·f°tHematology Timesªº¡§Novel interferon appears safer than HU in PV¡¨³o½g³ø¾É¤@°_¾\Ū¡A´N¥i¥H«Ü²M·¡Proud-PVªºropeginterferon alfa-2b©Mhydroxyureaµ²ªG¤ñ¸û¡C¦Ü©ó¦pªG­n¬Ý¨ì§ó¸Ô²Óªº²Î­p¹Ïªí¡A¥i¯à´N­nµ¥Blood Journal¤Wªºµoªí¤F¡C

www.hematologytimes.com/p_article.do?id=6690&sid=-1966098774

¡§Novel interferon appears safer than HU in PV¡¨

Jen Smith

Published: 12/12/16

SAN DIEGO¡XResults of the PROUD-PV trial suggest ropeginterferon alfa-2b is safer than hydroxyurea (HU) for patients with polycythemia vera (PV).

In this phase 3 trial, ropeginterferon alfa-2b demonstrated non-inferiority to HU with regard to complete hematologic response (CHR).

Ropeginterferon alfa-2b also had a significantly better overall safety profile.

Unlike the patients who received HU, none of the patients on ropeginterferon alfa-2b developed secondary malignancies.

Heinz Gisslinger, MD, of the Medical University of Vienna in Austria, presented these results at the 2016 ASH Annual Meeting (abstract 475). The PROUD-PV study was sponsored by AOP Orphan Pharmaceuticals AG.

Dr Gisslinger noted that interferons have been successful in treating PV since the 1980s, although toxicities contribute to discontinuation rates of approximately 25%. Still, interferons are the only known drugs with the potential for disease modification by specific targeting of the malignant clone.

Ropeginterferon alfa-2b is a long-acting, mono-pegylated proline interferon with improved pharmacokinetic properties that allow for administration once every 2 weeks.

The goal of PROUD-PV was to determine how this drug stacks up against HU in both treatment-naive and HU-pretreated patients with PV.

¡§Our results from the first and largest, prospective, controlled trial of an interferon in polycythemia vera confirm previously reported efficacy,¡¨ Dr Gisslinger said.

¡§The observed safety and tolerability profile of ropeginterferon appears to be superior compared to previously reported data of interferon treatment. The unique disease-modification capability of interferon and its potential to improve progression-free survival hold promise for long-term benefit for patients.¡¨

Patients and treatment

PROUD-PV enrolled 254 patients, and they were randomized to receive ropeginterferon alfa-2b (n=127) or HU (n=127). In both arms, 100% of patients were Caucasian, slightly more than half were female, and the median age was 60 (overall range, 21-85).

The median disease duration was 1.9 months in the ropeginterferon alfa-2b arm and 3.6 months in the HU arm. Thirty-seven percent (n=47) of patients in each arm had previously received HU.

The mean hematocrit was about 50% in both arms, the median spleen length was about 13 cm, about 90% of patients had a normal/slightly enlarged spleen, and the mean JAK2V617F burden was slightly more than 40%.

The median plateau dose was 450 µg in the ropeginterferon alfa-2b arm and 1250 mg in the HU arm.

A quarter (25.2%) of patients had dose reductions due to adverse events (AEs) in the ropeginterferon alfa-2b arm, as did 51.2% of patients in the HU arm. The 12-month discontinuation rate was 16.5% in the ropeginterferon alfa-2b arm and 12.6% in the HU arm.

Response

The study¡¦s primary objective was to demonstrate non-inferiority of ropeginterferon alfa-2b compared to HU. For this, the researchers used the 12-month CHR rate. CHR was defined as normalization of red blood cell, white blood cell, and platelet counts (without phlebotomy).

At 12 months, in the intent-to-treat population, the CHR rate was 43.1% in the ropeginterferon alfa-2b arm and 45.6% in the HU arm (P=0.0028). In the per-protocol population, the C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRookie10143115  µoªí®É¶¡:2017/1/17 ¤U¤È 04:25:02²Ä 1942 ½g¦^À³
80%ªºPV±wªÌ§¡¦³µo²{JAK2 °ò¦]¬ðÅÜ

Incyte ªºJakafi ´N¬O¤@ºØJAK2 ªº§í¨î¾¯(¦ý°±Ãīᤣ¦ý¦^´_¥B§ó¬°´c¤Æ¡^

©Ò¥H¦p¦óªv¡PV¡A°£¤F­n¬Ý¥D­n«ü¼Ð¬O§_¹F¼Ð¥~¡A¦p¦ó­°§CJAK2 °ò¦]Åܲ§¶q¤~¬OÃöÁä

¦b2016 ASH AOPµoªíªº¤å³¹¤¤¡A¶È¦³»¡©úJAK2 ¬ðÅÜ°ò¦]ªºµ¥¦ì°ò¦]­t¾á¤¤¶¡«ü¼Æ±q42.5%­°¨ì28.7%¡A¦ý¨S¬Ý¨ìP1101»PHUªº¤ñ¸û¡A¦pªGP1101¦b³o¤è­±ªº®ÄªGÀu©óHU¡A¬O§_¥i»¡©úÃÄ®ÄÀu©óHU¡H

¤£ª¾­þ¦ì¤j¤j¦³³o¤è­±ªº¼Æ¾Ú¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°]°È¦Û¥Ñ¤H10132540  µoªí®É¶¡:2017/1/17 ¤U¤È 04:15:56²Ä 1941 ½g¦^À³
Understanding Unapproved Use of Approved Drugs Off Label

www.fda.gov/ForPatients/Other/OffLabel/ucm20041767.htm

¾á¤ß³Q°OªÌ°äÄê¡H ´N¬Ý¬Ý US-FDA ªº©x¤è¤å¥ó¡A¤º¤å¤£ªø¤]¼gªº«Ü²M·¡¡A­^¤å¤]¤£²`¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³Á§JªL10142093  µoªí®É¶¡:2017/1/17 ¤U¤È 04:07:32²Ä 1940 ½g¦^À³
µLµß®ñ¤j¡A

Ãö©ó²Ä¤GÂI¥i¥H¥h¬ÝÃĵؤQ¤G¤ëªºªk¤H»¡©ú·|¡AªL°êÄÁ¡]²{¬°°õ¦æªø¡^¦³»¡©ú¡A

¦Û¤v¦bµy·L·Q¤@¤U´Nª¾¹D¤F¡C©Ò¿×´X½u¡A¬O¦bÁ{§É³]­pªº®É­Ô´N¨M©w¤F¡A¤£¬OµoÃÄÃÒªº®É­Ô¤~½T©w¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p´²¤á10028616  µoªí®É¶¡:2017/1/17 ¤U¤È 03:46:42²Ä 1939 ½g¦^À³
µLµß®ñ¤j¡A´£¨Ñ±z°Ñ¦Ò

1. °Ñ¦Ò¤½¥q¤§¤½¶}»¡©ú®ÑP11~12¤§»¡©ú¡A¡u¥»¤½¥q¶}µo¤¤·sÃÄP1101«Y·s¤@¥Nªø®Ä«¬¤zÂZ¯À¡AÂå¾Ç¬É¤w½T»{¤zÂZ¯À¤§Àø®Ä(¥«­±¤W¤w¸g¦³Pegasys¤ÎPeg-intronµ¥¤zÂZ¯À)¡A¦ý°Æ§@¥Î¤@ª½§xÂZµÛ¯f¤H¤ÎÂå¥Í¡A¤]¥i¯à¤]¬O°ò©ó³o¨Ç¦]¯À¡A¥Ø«eÀ³¥Î©óªvÀøPV¯e¯fªº¤zÂZ¯ÀÃĪ«(Pegasys)¶È¯à¥H¥é³æ¥~ªvÀø(off-label use)ªº¤è¦¡¶i¦æ¡A¦ý¦³¨Ç¦{©Î°ê®a¯f¤H´N¥²¶·¦Û¦æ­t¾á¶O¥Î¡A¥t¥~¥«­±¤W¤£¤[«e¤~®Ö­ãªº¤p¤À¤lÃĪ«Jakafi«h¶È¯à¥Î©ó²Ä¤G½u¥ÎÃÄ¡F¥ç§Y¥Ø«e¨ÃµL¥DºÞ¾÷Ãö¥¿¦¡®Ö­ã¥Î©óªvÀøPV¯e¯fªº²Ä¤@½uÃĪ«¡C¡v¡A¥t¡u²Ä¤T´ÁÁ{§É¸ÕÅç¥Ø¼Ð«Y¤ñ¸ûP1101»PHydroxyurea(HU/«Y¥Ø«eÀu¥ý¨Ï¥Îªº¤ÆÀø¤è¦¡)ÃĪ«ªvÀøPV¤§Àø®Ä»P¦w¥þ©Ê¡A¿z¿ï°Ñ»P¡K¡K..¡v

2. ²Ä¤GÂI§Ú²q­nµ¥ÃÄÃҥӽФU¨Ó¤~ª¾¹D¡A§Ú¤]¤£²M·¡¡C

3. ²Ä¤TÂI¡A°Ñ¦Ò¤½¥q¦V°]°T(520´Á)ªº¼á²M¤º®e²Ä¤GÂI¡A¡u¤zÂZ¯À¤w³QÂå¥Í¥Î¨ÓªvÀøPV¯f¤Hªø¹F¤T¤Q¦~¤§¤[¡A¤w³Q»{©w¬O¦³Àø®Äªº¡A¦ý¨ü­­©ó¨äÃø¥H§JªAªº°Æ§@¥Î¡A¨´¤µ¨S¦³¥ô¦ó¤@ºØ¥«­±¤Wªº¤zÂZ¯À¬O¸gFDA©ÎEMA®Ö­ãªvÀøPVªº¥ÎÃÄ¡C¤SP1101¦pªG³QFDA©ÎEMA®Ö­ã¨Ï¥ÎªvÀøªº¤zÂZ¯ÀÃÄ«~¤W¥«¡A¨º»ò²{¦b§{¶¡©Ò¦³off-labelªº¤zÂZ¯À±N¤£¦A·|¦³«OÀI¤½¥qµ¹¥I¡A¦P®É¤]¤£·|¦³Âå¥ÍÄ@·N¶}¥ßoff-labeÃĪ«¡C³o¤¤¶¡ªº®t²§«Ü¤j¡A¥B´N¼vÅT¼h­±Äõ»¡¡A¹ïÃĵØÃĥثeÁ{§É¤¤ªºP1101À³¬O¨ü´fªÌ¤§¤@¤~¹ï¡C¡v

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2017/1/17 ¤U¤È 03:18:09²Ä 1938 ½g¦^À³
§Ú»{¬°HU¬O²Ì¸}¥Û,¦pªG¯à®³¶}´N«Ü¦n,©Ò¥H§Ú·Qª¾¹D¥H¤Uªº±¡ªp,¤£ª¾¹D¬O§_¦³¤H¯à«Ü½T©wªº§iª¾,ÁÂÁÂ!(«Ü½T©w¤£¬O·Q·íµMº¸³o¼Ë®@)

1.HU¦b¬ü°ê¹ïpv¯e¯f¬O¤£¬Ooff-label use?

2.¬O¤£¬Oµ¹ÃÄÃҮɷ|©ú½T¬O¤@½u¥Î­n©Î¤G½u¤T½u?

3.­Yp1101¯à¦¨¬°¤@½uÃÄ,¨º»ò¬ü°êÂå®v¦³¨S¦³³W©w(©Î¤£¦¨¤å³W©w)´N¤£¯à¶}off-label¤F?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G275810143547  µoªí®É¶¡:2017/1/17 ¤U¤È 02:43:13²Ä 1937 ½g¦^À³
¦¿¤j¤á¤j

°]°È¦Û¥Ñ¤j

ÁÂÁ¤£§[½ç±Ð¡AÀò¯q¨}¦h¡AÃø±oªº¬O°w¹ï´£°ÝÁ`¯à¨¥¤§¦³ª«¡A¬Ý¨Ó«Dªxªx¤§½ú.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/1/17 ¤U¤È 02:38:35²Ä 1936 ½g¦^À³
³Á§JªL¤j,½Ð¤Å¤¤­p,¦³¨Ç¤H´N¬O­n²V²cµøÅ¥,Åý¯u¥¿¦³¤º洆ªº¤HÂ÷¶}¦¹½×¾Â,µM«á¦A´²¼½¤£¹ê¨¥½×,³o¬O¤­¤òÄÒªº§@­·,¦A»¡¤@¦¸,½Ð¤Å¤¤­p
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10000004  µoªí®É¶¡:2017/1/17 ¤U¤È 02:33:15²Ä 1935 ½g¦^À³
A¬O¤p²Õªø, ÆgÁnªºB/C¬O·s¶i²Õ­û...
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦¿¤j¤á10140161  µoªí®É¶¡:2017/1/17 ¤U¤È 02:24:54²Ä 1934 ½g¦^À³
­ì¨Ó¦p¦¹¡AÁÂÁ¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³Á§JªL10142093  µoªí®É¶¡:2017/1/17 ¤U¤È 02:22:02²Ä 1933 ½g¦^À³
¦A¦¸ÄY­«Äµ§i¤Å°w¹ï­Ó¤H¡A

¤£­n¥H¬°´£´X­Ó¤£°µ¥\½Òªº°ÝÃD´N¥i¥HµL­­¤Wºõ«ü³d²Û°d§O¤H¡A

§Ú­Ó¤H¬O§¹¥þ¨S¦³­n¦^Âгo¨Ç°ÝÃDªº·N«ä¡A¦Û§Ú¿±µÈ¹L«×¤F§a¡A

­Y¦A¦³¦¹ºØ´c¦H¦æ³w¡A´N¥u¦n·í¦¨¬O¨S¦³±Ð¾iªººÆª¯¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°]°È¦Û¥Ñ¤H10132540  µoªí®É¶¡:2017/1/17 ¤U¤È 02:07:50²Ä 1932 ½g¦^À³
Ãe¨©¤ó¯gªvÀø¥ÎÃÄ Myozyme ¡A¾ã­Ó¤W¥«(¥Í²£)¹Lµ{¬O¼Æ®a¤À¤u¡A³Ì«áÂà¤â±ÂÅv Genzyme¡C

¤¤¾ó¦³ 15% ¤À¼í¡A­Ó¤Hı±oºâ°ª¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G275810143547  µoªí®É¶¡:2017/1/17 ¤U¤È 02:05:23²Ä 1931 ½g¦^À³
¦¿¤j¤á¤j

±zªGµM¬O²`Âä£ÅSªº°ª¤â¡A¨Æ²z¸g¼h¼hªº±´¯Á¡A

¯ßµ¸¤wµM¤À©ú²M´·¡A¹ê¦b´Ü¨Ø±z¤£¦ý¯à¥ß°¨´x´¤¡A

¥ç¯à«D±`²z©Ê¦a«ü³¯°ÝÃDªºÃöÁä®Ö¤ßÂI.¨ØªA~~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10000004  µoªí®É¶¡:2017/1/17 ¤U¤È 01:53:27²Ä 1930 ½g¦^À³
¤­¤òÄÒ¥X¨S...
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦¿¤j¤á10140161  µoªí®É¶¡:2017/1/17 ¤U¤È 01:50:47²Ä 1929 ½g¦^À³
¤¤¾ó¤l¤½¥qªºÃe¨©¤ó¯gªvÀø¥ÎÃĤ£­n»¡¤@½u¡A²{¦b¤]¥u¦³¥¦¥i¥HªvÀø¡A±ÂÅv¥u©â15%¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¹L«È10137290  µoªí®É¶¡:2017/1/17 ¤U¤È 01:41:05²Ä 1928 ½g¦^À³
¬ü°ê°ß¤@³q¹LFDA¨ú±oPV¤@½u¥ÎÃĪº©t¨àÃÄ....Âå¥Í¤£·|¶}off-label....¥Boff-label¨S¦³«OÀI¤½¥q·|µ¹¥I

·Q¤£¥X¦æ¾P·|«Ü§xÃø¶Ü???

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦¿¤j¤á10140161  µoªí®É¶¡:2017/1/17 ¤U¤È 12:16:20²Ä 1927 ½g¦^À³
¦³Å²©ó¤§«e¤¤¸Îñ¬ù«áªº«áÄò®ÄÀ³¡A¨ä¥L¤½¥q¹ïñ¬ù±ÂÅv®ø®§µo¥¬·|ÁקK­«ÁÐÂÐÂá¡A°ÝÃD¬O¦b·í¦a³]¦æ¾P³q¸ô½Í¦ó®e©ö¡A°£«D¤T´ÁÃÒ©úÃįuªº¬OµL¼Ä¤â¡A¦b°ê¤º¶Ò­Ó¤W¦Ê»õ¸êª÷¨ì¬ü°ê¥´¦æ¾P¾Ô¡A§_«h¥¼¨Ó°âÅv¾P°â¾÷²v¤ñ¸û¤j¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G275810143547  µoªí®É¶¡:2017/1/17 ¤W¤È 11:57:48²Ä 1926 ½g¦^À³
¦B«B¤j¡B¦¿¤j¤á¤j¡B°]°È¦Û¥Ñ¤j¡BRussell¤j

¦A¦¸·P®¦¦b¦¹¥­¥x¡A´£¨Ñ³Ì±M·~¡A¦P®É²`«×¼s«×­Ý¨ã

ªº¸ÑªR¡AÁÂÁ½ç±ÐÅo!!

¤]Åý§Ú¨£ÃÑ»â±Ð¨ì¦U¦ì¦b¯u¹ê¥@¬É¸Ì¯à¦s¬¡¤U¨Óªº

Ävª§¹ê¤O!!

¦¿¤j¤á¤j

§A©Ò¨¥¬Æ¬O¡A±ý«e©¹¬ü°ê¥Ó½ÐIPO½Í¦ó®e©ö¡A¶O¥Î·¥°ª¡A

§Úªº¤@¦ì¥¼¤W¥«¤½¥q¦ÑÁóªB¤Í¡A´N´¿½ÐÃҨ餽¥qÀ°¨ä¥J²Ó

µû¦ô¹L¡A±©¦Ò¶q¬ÛÃö¦¨¥»¹ê¦bÀ~¤H¡A¤@¯ë¥ø·~­Y¤£¨ã¶¯«p

ªº°]¤O«ÜÃø­t¾á±o°_¡A³Ì²×¥u¦n¥´°h°ó¹ª¡A¿ï¾Ü©ñ±ó­u¬ü

°ê¤W¥«ªº´Ý©À!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³Á§JªL10142093  µoªí®É¶¡:2017/1/17 ¤W¤È 11:55:36²Ä 1925 ½g¦^À³
2578¤j¡A

¥H¤U¤~¬O¦^À³§Aªº°ÝÃD¡A

¤t´¶¤W¥ô°ªÃÄ»ùªº°ÝÃD¡A

À³¸Ó¥Î©t¨àÃĪº¨¤«×¨Ó¬Ý¡A¤§«e¤w¦³³\¦h¤j¤j¸ÑÄÀ¹L¡A

½Ð°µÂI¥\½Ò¦hª¦¤å¡A¦n¶Ü¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦¿¤j¤á10140161  µoªí®É¶¡:2017/1/17 ¤W¤È 11:26:12²Ä 1924 ½g¦^À³
¦b¬ü°ê¤W¥«ªº¦¨¥»«D±`°ª¡A°£«D¬O·sÃĤ½¥q¡A¥u¬O¾P°âªº¸Ü¥¼¨Ó¦¨¬°§N­á¤ô»åªÑ¤£¨£±o¦³§Q¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³Á§JªL10142093  µoªí®É¶¡:2017/1/17 ¤W¤È 11:23:09²Ä 1923 ½g¦^À³
2578¤j¡A

¦Ñ¹ê»¡§ÚÃi±o¬Ý§A¦b¼g¤°»ò¡A

¦³³W©w¤@©w­n¦^µª§Aªº°ÝÃD¶Ü¡A

±µ¦b§A«á­±ªºµo¨¥¤]¤£ªí¥Ü¦b¦^µª§A¡A

§A³o­ÓÅÞ¿è§Úı±o¤~¯«¡A

½Ð¤Å¦Û§Ú¿±µÈ¡A¥H¬°¨C­Ó¤Hµo¨¥³£­n»¡ªA§A¡A

¤]½Ð¤£­n¹³­Óxx¤@¼Ë¶Ã«r¤H¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦B«B10138946  µoªí®É¶¡:2017/1/17 ¤W¤È 11:14:49²Ä 1922 ½g¦^À³
1.¬ü°ê¤l¤½¥q¬O¿W¥ßªºªk¤H...¤À¤½¥q¤£¬O

2.¤l¤½¥q´N¬O¬ü°ê¤½¥q...¤À¤½¥q¤£¬O

3.ªk¤H½èºÃÃĵئb¬üµL¿W¥ß¾P°â¯à¤O..©Ò¥H100%¤l¤½¥q¨Ã¤£¬O§Q¦h..³Ì¦n¬O»P°ê»Ú¤j¼t¦X¸ê¦¨¥ß¤l¤½¥q¥h¦æ¾P....³o¤ñ¤À¼íµ¹¹ï¤è§ó¦n..¹³¤¤¸Î¤À¼í³»¦h¤]¬O5¦¨...¦pªG

©M¤j¼t¦X¸ê¦¨¥ß¤l¤½¥q...°£»{¦CÀò§Q»P¤À¼í¬Û·í¤§¥~...³Ì­«­nªº¬O¤l¤½¥q¥i¦b¬ü¤W¥«(¤À¤½¥q¤£¦æ)..¤W¥«°£¥i¨É¨ü¸ê¥»§Q±o¥~...

§ó¥iÂǭɬü°êªÑ¥«°ª¥»¯q¤ñªº¯S©Ê¨Ó¹F¨ì©Ô¥x¥À¤½¥qªÑ»ùªº®ÄªG...¤@Á|¼Æ±o.....³o¦¸¤½¥q¦³¥Î¤ß...

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦¿¤j¤á10140161  µoªí®É¶¡:2017/1/17 ¤W¤È 08:58:35²Ä 1921 ½g¦^À³
¦b¬ü¤éªº¤l¤½¥q³æ¿W¤W¥«©ÎÄw¸ê¤£¤Ómake sense¡A¦]¬°¬ü¤é¤l¤½¥q¥u¬O­t³d¥Ó½ÐÃÄÃҩξP°â¡A³Ì²×±M§QÁÙ¬O¦bÃĵءA100%¨Ó¦ÛÃö«Y¤H¥æ©ö¤W¥«¾÷²v¤]«Ü§C¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G275810143547  µoªí®É¶¡:2017/1/17 ¤W¤È 08:17:35²Ä 1920 ½g¦^À³
³Á§JªL¤j

§A©l²×°õµÛ©ó¡A

¥u·Q±j½Õ¤d¸U¤£­n¥~¦æ»â¾É¤º¦æ¡A¤£¬O»¡¤£¯à°Q½×¡A¦Ó¬O¦Û¥H¬°°Q½×¥X¤°»òµ²ªG¡A

§Aı±oÃĵةΤW¥«Âd¥ô¦ó¤@®a¤½¥q¨ä¥ô¦ó¨Mµ¦¦³¥i¯à¥ÑªÑªF¨Ó§@©w¹Ü¶Ü?

§ó¹N½×¬O§A¤f¤¤©Ò¿×ªº¶m¥Á¡A¹ê¦b­ê©Ò«ä!¦Ó§AªºÅÞ¿è¡A¦A«×¥O¤H¿e¥Øµ²¦Þ!

ÁöµM¡Aª¾±x§A«D±`¤£±M·~¡A¦ý§A¹ð¹ðºòÀH¦b§Ú´£°Ý¤§«á¡A

(¦Ó§Ú¤w«D±`¦h¦¸©ú½T«ü¥X§Æ±æ±o¨ì³Ì±M·~ªº¨£¸Ñ)¡A

¥ß°¨µo¥X¤í¯Ê°w¹ï°Ý´£¥X½×­zªº¯à¤O¡A

³o¨Ã¤£¬O·Q³z¹L¤j®a³Ì±M·~ªº¨£¸Ñ¥æ´«·N¨£¡A¨ì¤¬¬Û¾Ç²ß¦¨ªø¶D¨Dªº§Ú¡A

©Ò·Q­nªº¨ãÅé¦^À³¡A§_«h§AªºÀH¿³¤À¨É¡A

»P©Ò¿×ªº¤£´¿²`¤J±´°Q°µ¨¬¥\½Òªº°]¸g°OªÌ¤S¦³¦ó²§¡A

³Ì¸ÛÀµªº©¾§i¡A·q¬ß§A§O¹³´CÅé°OªÌ¯ë¡A§Q¥Î¤½¾¹¡A

°µ¥X»~¾É¤@¯ë§ë¸ê¤H§@¥X¨Mµ¦ªºªÅªx¨¥½×!

¥R¨ä¶q¡A®Ú¥»´N¬O«H¤f¶}ªe¡AÅý¤H³Ú¯º¬Ò«D½}¤F.

§Ú³oµf¦^À³¡A·q¬ß§A¤´¨ã¦³²`«äªº«äºû¯à¤O¡A¨¥ºÉ©ó¦¹~~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³Á§JªL10142093  µoªí®É¶¡:2017/1/17 ¤W¤È 12:23:49²Ä 1919 ½g¦^À³
2578¤j¡A

§Ú¨S·Q¨ì³o¼Ë¦^¤Þ°_§A³o»ò¤jªº¤Ï¼u¡A

­Y¦³¤£·qÁÙ¬O½Ð§A¦h¥]²[¡A

¨ä¹ê§Ú¨Ã¨S¦³¦^µª§Aªº°ÝÃD¡A¦]¬°§Ú¤£Ä±±o«Ü­«­n¡A

§Ú¥u¬Oµo¨¥¦Ó¤w¡A

¥u·Q±j½Õ¤d¸U¤£­n¥~¦æ»â¾É¤º¦æ¡A¤£¬O»¡¤£¯à°Q½×¡A¦Ó¬O¦Û¥H¬°°Q½×¥X¤°»òµ²ªG¡A

¨Ò¦p¡A±ÂÅv»P¦Û¦æ¾P°âªºª§Ä³¡A¤l¤½¥q¬O§_­n¤Þ¶i¥~°ê¥ø·~¡A­n¤£­n¹ê¬I®wÂêѵ¥µ¥¡A

°£«D§Aªº¸ê¾ú¤ñ¤½¥qªº»â¾É¤H¤h¸ê²`¡A¤£µM§ÚÁÙ¬O¹çÄ@Åý¤½¥q¨M©w¦Ó¤£¬O¤@¸s¶m¥Á¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G275810143547  µoªí®É¶¡:2017/1/17 ¤W¤È 12:13:22²Ä 1918 ½g¦^À³
³Á§JªL¤j¡A

§A©Ò¨¥:¦]¦¹µ´¹ï¤£­n¥~¦æ¥h«ü¾É¤º¦æ¡AÁÙ¬O¥æµ¹¤½¥q¨Ó³B²z¡C

¤W­z¨¥½×¡A±q¦ó¦Ó¨Ó?

¥O¤H¶O¸Ñ¡A

ªÑªF¸Ì¦³½Ö¥h¹ï¤½¥q¤U«ü¾É´Ñ?¤£ª¾§A¨º¨Óªº¯«ÅÞ¿è!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G275810143547  µoªí®É¶¡:2017/1/16 ¤U¤È 11:48:26²Ä 1917 ½g¦^À³
°]°È¦Û¥Ñ¤j

ÁÂÁ¡A´£¨Ñ¨£¸Ñ¡A¤]ÂI¥X­«ÂI¡A¤l¤½¥q¨ì°ê¥~IPOÄw¸ê¤£©ö³o¨Æ¹ê!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°]°È¦Û¥Ñ¤H10132540  µoªí®É¶¡:2017/1/16 ¤U¤È 11:38:39²Ä 1916 ½g¦^À³
¬ü°ê¤½¥qªº©t¨àÃĤW¥«¡A¬ü°ê¬F©²¦³µ|°È¤WªºÀu´f¡A¥[¤W¦b¬ü°ê«áÄò¤´¦³ET µ¥Á{§É­n¶i¦æ¡A³o¨Ç¦]¯ÀÀ³¸Ó¬OµØÃĵئ¨¥ß100% ¤l¤½¥qªº¥Øªº¡A­Y¥u¬O¦¨¥ß¤À¤½¥qªº¸Ü¡A¬OµLªk¨É¨ü³o¨ÇÀu´fªº¡C

¦Ü©ó¤l¤½¥q¤£±Æ°£­n IPO ¶Ò¸ê¡AµØÃĵتº¤jªÑªF¬O¬F¦æ°|°êµo°òª÷¡A¤l¤½¥q­n¦b°ê¥~ IPO ®£©È¤£¬O³o»ò®e©ö¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G275810143547  µoªí®É¶¡:2017/1/16 ¤U¤È 11:38:08²Ä 1915 ½g¦^À³
³Á§JªL¤j¡A

®¤§Úª½¨¥¡A±æ½Ð®ü²[¡A¦³Ãö§A­Ó¤H¥ô¦ó¨£¸Ñ¨¥½×¡A¥»¤H¤©¥H´L­«¡A

¦ý¦pµLªk¥Î±M·~ªº¤ÀªR¨Ó»¡ªA§Ú¡A¥u¬O®ö¶O¤j®aÄ_¶Qªº®É¶¡!!

¯uªºÅ¥¿°¤½¥q·|¥HªÑªFªº§Q¯q¬°Àu¥ý¡A³oºØªÅ¸Ü!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³Á§JªL10142093  µoªí®É¶¡:2017/1/16 ¤U¤È 11:27:44²Ä 1914 ½g¦^À³
¤l¤½¥q³o­Ó°ÝÃD§Ú·Q¤½¥q¤ñ§Ú­Ì§ó¦³¸gÅç¡A§Ú·Q¤½¥q¤@©w·|¥H¤½¥q³Ì¤j§Q¯q¥h¦Ò¼{¡Aµ´«D§Ú­ÌªÑªF¦Û¤v·Q¹³³o»ò²³æ¡C

­Y¤½¥q¤@ª½¦³¦b§G§½¤]«Ü¦³§â´¤¡A¤£±Æ°£¤l¤½¥q¥ÑÃĵثùªÑ¦Ê¤À¤§¦Ê¡A³o¬O¹ï¤½¥qÀò§Q³Ì¦³§Qªº±¡ªp¡C

§Ú­Ó¤H§¹¥þ¬Û«H¤½¥q³o¸s¹Î¶¤¡A¦]¦¹µ´¹ï¤£­n¥~¦æ¥h«ü¾É¤º¦æ¡AÁÙ¬O¥æµ¹¤½¥q¨Ó³B²z¡C

¶¶«K´£¤@¤U¤¤¸Îªº¨Ò¤l¡A­Ó¤H»{¬°¤¤¸ÎªºÃ±¬ù«d®z¤F¤¤¸ÎÀò§Qªº·Q¹³ªÅ¶¡¡A³Ì¦nªº±¡ªpÀ³¬O¤¤¸Îª½±µ´«ªÑÁʨÖTH.TO

¤£»Ý¤À¬ù¤@¥bªºÀò§Qµ¹¦æ¾P¤½¥q¡A³o¬O¤¤¸Î±ÂÅvªº¤@¤j±Ñµ§¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G275810143547  µoªí®É¶¡:2017/1/16 ¤U¤È 10:37:34²Ä 1913 ½g¦^À³
Russell¤j

ÁÂÁ½ç±Ð!!

¥ç§Y¡A¬O§_³]¥ß¤l¤½¥q¡A«h¥À¤½¥q¹ê»ÚÀò¯q¡A±N»·§C©ó¥À¤½¥q

¦Û¦æ³]¥ß®ü¥~¤À¤½¥qª½±µ¦æ¾P°ê»Ú¨Ó±o§C¡C

¤£ª¾¦p¦¹¸ÑŪ¥¿½T§_?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/1/16 ¤U¤È 10:23:34²Ä 1912 ½g¦^À³
2758¤j

§A°Ýªº°ÝÃD¤£Ãø...¦ýÃøªº¬Oµ|²v(¦U°êµ|²v¤£¦P)¸ò«ùªÑ¤ñ²v¡C

¦b¤£¦Ò¼{¥À¤l¤½¥q¶¡¬Û¤¬¥æ©ö©Î¥æ¤e«ùªÑ±¡ªpªº¸Ü....¦pªG¬O....

100%«ù¦³¤§¤l¤½¥q¡Bµ|²v¬O20%¡B²b§Q10»õ¡A«h10*(1-20%)¥À¤½¥q¥i»{¦C8»õ

80%«ù¦³¤§¤l¤½¥q¡Bµ|²v¬O20%¡B²b§Q10»õ¡A«h10*(1-20%)*80%¥À¤½¥q¥i»{¦C6.4»õ

¥H¦¹Ãþ±À.....

¥u¬O³o­Ó·s»D¥H§Ú¨Ó¬Ý¦³´X­Ó¼h­±ªº°ÝÃD

²Ä¤@­Ó¬OªÑªF¦¨¥÷

«e¤@°}¤l¤½¥qªk»¡·|·s»D¦³¶Ç¥X°ê¥~¤j¼t¨Ó´M¨D¦X§@¡A¨º©Ò¿×ªº¦X§@¬O§_¥]¬A¦X¸ê¦¨¥ß¤½¥q

²Ä¤G­Ó¬OÁöµM®³¨ìÃÄÃÒÀ³¸Ó«ü¤é¥i«Ý¡A¦ý¥Ø«eÃÄÃÒ©|¥¼¥¿¦¡®³¨ì¡AÃĤ]©|¥¼¶}©l¾P°â¡A¥H³Ì§Ö¤µ¦~²Ä¥|©u¨Ó»¡¡A¤½¥qÁö¤w»{¯u¶}©l§G§½¡A¦ý°Q½×³o­Óµy¶û¤Ó¦­¡CÀ³¸Óµ¥®ø®§©ú½T¤@ÂI¦A»¡§a!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G275810143547  µoªí®É¶¡:2017/1/16 ¤U¤È 09:57:10²Ä 1911 ½g¦^À³
Àµ¤Á§Æ±æ¹ï¤½¥qªk©Î°ê»ÚÃÒ¨é·~°È¾Ç¦³±Mºëªº±q·~¤H­û

¡A¤£§[µ¹¤©³Ì¤¤ªÖ¥B¨ãÅ骺±M·~¤ÀªR¡A

©Î³\¡A¦pªG¥H¥~¸êªk¤Hªº¨¤«×¤Î¥ß³õ¡A¦p¦ó²`¤J¸ÑŪ?

«ã§Úª½¨¥¡A§Ú¤£·Q¥u¤@¬N¦a¬~¸£:¬Y®a¥~°ê¤½¥qÀò§Q¦h¤Ö¡A

©Ò¥H¡A±À½×Ãĵتº¿ú´º¥ç¯àµL¥i±ÏÃĦa¥Rº¡´Á«Ý.¡C

¥i§_¡A¤@°_±´°Q§Úªº´£°Ý¡A

¬O§_­ì¥ý¦ôºâ¨C¦ì¯f±w¦¬¶O8¸U¬ü¤¸¡A

«h¦³Ãö³o³¡¥÷ªº¬Õ·~§Q¯q¡A¥À¤½¥q»P¤l¤½¥q¤§¶¡­n¦p¦ó

­pºâÂà´«¡C

¦Ó¤t´¶¤W¥ô­º­n¥ô°È¡A§Y¬OÅý°ªÃÄ»ù­«·s½Õ¾ã¡AÁÙ¯à°÷

­q©w¦¹»ù®æ?

³Ì«á¡A§Ú¦ó¹Á¨S¦³«ä¦Ò¨ì¡A¥xÆW¸ê¥»¥«³õ¤zÂZªº³¡¥÷¦]¯À

¡A¦ý§Ú¬ã§P¯u¥¿¥Øªº¡A¬O»P¬ü¤éµ¥°ê¦@¦P¦X²Õ¤l¤½¥q¸gÀç

¹Î¶¤¡AÃe¤j§Q¯q¤]¤~¯à¥ýÅý¥´«e¾Wªº¬ü¤é¦æ¾P¹Î¶¤¥ý¤À¨É

¬ãµo¦¨ªG¡A§_«h¡A½ÖªÖ½æ©R¦æ¾P?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³Á§JªL10142093  µoªí®É¶¡:2017/1/16 ¤U¤È 03:29:22²Ä 1910 ½g¦^À³
¦pªG¬O¤@Áû·sÃÄ¡A¥i¯à¤£¬O0´N¬O1¡A

¥i¬Op1101¥¦¬O¤@­Ó§ï¨}«¬ªº¤zÂZ¯À¡A

¥i¥H½Ð±M·~ªº¥h¬d¬d¥¼§ï¨}ªº¤zÂZ¯À¤@¦~¾P°âÃB¡A

­Y°Æ§@¥Î¤jªº¤zÂZ¯À³£¥²»Ý¨Ï¥Î¤F¡A

°Æ§@¥Î¤pªº¤zÂZ¯ÀÁÙ­nÃhºÃ¶Ü¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦B«B10138946  µoªí®É¶¡:2017/1/16 ¤U¤È 02:16:50²Ä 1909 ½g¦^À³
À³¸Ó¬O¹ï»OÆWªº¸ê¥»¥«³õ·P¨ì¥¢±æ..³Q¤@¸s¤£¾ÇµL³Nªº¤ÀªR®vÄY­«¼vÅT¥«³õ»ù­È...

©Ò¥H¦V¥~´M¨D®üÁï¤ÑªÅ¥i¥H®¡·N¾Cµ¾ªº¤Ñ¦a..³Ì­«­nªº¬O..

¤é¥»¦å²G±M®aªº­I®Ñ¤w¥´Áy°]°T¨º§å¤Hªº¼P¶©°^¤ÀªR¨¥½×..ÃĬO¦³®Ä¦Ó¥B¦³»ù­Èªº...½Ð¦w¤ß«ù¦³

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³Á§JªL10142093  µoªí®É¶¡:2017/1/16 ¤U¤È 01:46:08²Ä 1908 ½g¦^À³
¥¼¨Ó¤l¤½¥q¤£±Æ°£¦b¬ü¤é¥Ó½Ð¤W¥«Âd¡A­Ó¤H»{¬°¸ò°ê»Úµ²­yµ´¹ï¬O¶W¯Å¤j§Q¦h¡A

Incyte ªº¥«­È¤wöt¯}¤C¤d»õ¥x¹ô¡A­Ó¤Hµû¦ôÃĵتº«e´ºµ´¹ï¶W¹LIncyte¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G275810143547  µoªí®É¶¡:2017/1/16 ¤U¤È 12:07:36²Ä 1907 ½g¦^À³
¾Ú³ø¸ü

Ãĵتí¥Ü¡A¦¹¦¸¦b¬ü¡B¤é³]¥ß¤l¤½¥q¡A¥]¬A¬ì¾Ç»P¦æ¾P¹Î¶¤±N¦P¨B«Ø¥ß¡A

¥¼¨Ó¤l¤½¥q¤£±Æ°£¦b¬ü¡B¤é¥Ó½Ð¤W¥«Âd¡A¶Ò¶°°ê»Ú¸êª÷¡C

¬O§_·N¨ýµÛÃĵؤw´Â¨«¶°¹Î±±ªÑ¤Æ¸ô½u¸gÀç?

¦Ó±N¨Ó¤l¤½¥qªº¬Õ¦¬¦Ûµ²¤À°t«á¡A¤~·|Ѻª`¨ì¥À¤½¥q¶Ü?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GBESREMi10143176  µoªí®É¶¡:2017/1/16 ¤W¤È 11:39:38²Ä 1906 ½g¦^À³
ÁÂÁ Sirius ¤À¨É ¥H¤Î ¤p¥¿¥¿ ¹ï©óÃĵظê°T¾ã²z, ´Á«Ý2017¦~²æõ¦Ó¥X¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p´²¤á10028616  µoªí®É¶¡:2017/1/16 ¤W¤È 08:29:21²Ä 1905 ½g¦^À³
Ãĵضi­x¬ü¤é ±Ò°Ê¥þ²y¦æ¾P

udn.com/news/story/7485/2232120

ÃĵØÂåÃĤ½§i¡A¸Ó¤½¥q±N«e¶i¤é¥»¡B¬ü°ê³]¥ß¤l¤½¥q¡A±Ò°Ê¥þ²y²£«~¦æ¾P¥¬§½¡CÃĵتí¥Ü¡A¦¹¦¸¦b¬ü¡B¤é³]¥ß¤l¤½¥q¡A¥]¬A¬ì¾Ç»P¦æ¾P¹Î¶¤±N¦P¨B«Ø¥ß¡A¥¼¨Ó¤l¤½¥q¤£±Æ°£¦b¬ü¡B¤é¥Ó½Ð¤W¥«Âd¡A¶Ò¶°°ê»Ú¸êª÷¡C

Á{§É¤è­±¡AÃĵؤ饻¥«³õ±N»P¦å²G¯e¯f»â°ìÅv«Â¤pªQ«h¤Ò±Ð±Â¦X§@¡A¦b¤é¥»¾ú¥v³Ì±y¤[ªº¶¶¤Ñ°óÂå°|¶i¦æ¾ô±µ¸ÕÅç¡]Bridge Study¡^¡A¥¼¨Ó¥¿¦¡¤W¥«¾P°â«á¡A¹w¦ôÀ禬ÃB«×¤W¬Ý4»õ¬ü¤¸¡]¬ù·s¥x¹ô130»õ¤¸¡^¡C

ÃĵغX¤Uªº·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀP1101¡]PEG proline interferon alfa-2b¡^ªñ´Á¤w¸g¦b¼Ú¬w§¹¦¨Á{§É¤T´Á¸Ñª¼¡A¨äµ²ªG¦w¥þ©Ê¡BÀø®Ä§¡Àu©ó¹ï·Ó²Õ¥ÎÃÄHU¡A¹F¨ìÁ{§É¸ÕÅç¥Ø¼Ð¡Aªñ´Á±N¥Ó½Ð¼Ú·ùÃÄÃÒ¡A·m§ð²Ä¤@½uªº¬õ¦å²y¼W¥Í¯g¥ÎÃÄ¡C

ÃĵؤU¤@¨B±N¶i­x¬ü°ê¡B¤é¥»¡C¬ü°ê¤è­±¤wÀò¬ü°ê­¹Ãĸp¡]FDA¡^®Ö¥i¶i¤J¤T´Á¸ÕÅç¡A¥i±æ¥H¼Ú¬w¼Æ¾Úª½±µ¥Ó½ÐÃÄÃÒ¡A¤é¥»«h¶È»Ý°µ¾ô±µ¸ÕÅç¡A¸ÕÅ禬®×³W¼Ò¶È¼Æ¤Q¤H¡AÄÝ©ó³Ì¤p«¬ªºÁ{§É¸ÕÅç¡C

Ãĵذõ¦æªøªL°êÄÁªí¥Ü¡A¤é¥»¥«³õ±N¦P®É°µ¨â¶µ¾AÀ³¯g¡A°£¤F¬õ¦å²y¼W¥Í¯g¡]PV¡^ÁÙ¦³¦å¤pªO¼W¥Í¯g¡]ET¡^¡A¥Ñ©ó³o¨âºØ¯e¯f¦PÄݨu¨£ªº¦å²G¯e¯f¡A­P¯f¾÷¨î¬Û¦P¡A³£¥i¥ÎP1101ªvÀø¡C

°£¤FPV»PET¨â¬Û¾AÀ³¯g¥~¡A¾Ú±x¡A¤é¥»¤pªQ«h¤Ò±Ð±Â·¥¬°¬Ý­«ÃĵتºP1101¡A§Æ±æ±N¤§ÂX¤j¨ì¨ä¥L¦å²G¯e¯fªºªvÀø¡A¦b¤é¥»ªº¥«³õ¤]¥i±æ¶i¤@¨BÂX¤j¡C

¾Ú±x¡A¦¹¦¸Ãĵئb¤é¥»¦X§@ªº¡u¶¶¤Ñ°ó¤j¾ÇÂå¾Ç³¡ªþÄݶ¶¤Ñ°óÂå°|¡v³Ì¦­¦¨¥ß©ó¹õ©²®É¥N1838¦~¡A¬O¤é¥»­º®aÂå°|¡A¦³±Nªñ180¦~ªº¾ú¥v¡A¦Ó¦¹¦¸PV¡BET¨â¶µ¾AÀ³¯gªºÁ{§É¥D«ù¤H¤pªQ«h¤Ò¡A«h¬O¸Ó°|ªº¦å²G¬ì¥D¥ô±Ð±Â¡A¬O¤é¥»¦å²G¯e¯f»â°ìªº­º®u¡C

¶¶¤Ñ°óÂå°|¦ì©ó¤é¥»ªF¨Ê³£¡A®Ú¾Ú·~¬É«ü¥X¡A¸Ó°|ÁöµM¬O¨p¤HÂå°|¡A¦ý¦Û¦¨¥ß¥H¨Ó´N¬O¡u¤é¥»¬Ó«Ç±s¥ÎÂå°|¡v¡A¦uÅ@¤é¥»¬Ó±Úªº°·±d¡A¸¹ºÙ¬O¡u¤é¥»°ê®a¦uÅ@ªÌªº¦uÅ@ªÌ¡v¡A¦b¤é¥»ªñ¥NÂå¾Ç¥v¤W¥e¦³¤@®u¤§¦a¡A¦]¦¹¯à¦b¸Ó°|¥ô¾ªºÂå®v¦bÂå¬É¡B¾Ç¬É³£¦³¤@©wªºÁn±æ¡C

Ãĵؤº³¡«ü¥X¡A¤é¥»¶¶¤Ñ°óÂå°|»P¤é¥»¬Ó«ÇÃö«Yºò±K¡A¤]¾Ö¦³¬Ó«Ç®a±Ú¦¨­ûªº§ë¸ê¡A¥¼¨ÓÃĵØP1101¦b¤é¥»¤W¥««á¡A¤]¤£±Æ°£¤Þ¶i¤é¥»°êµo°òª÷ªº§ë¸ê¡C

·s¤zÂZ¯À Àò¤éÅv«ÂªÖ©w

udn.com/news/story/7485/2232121

2017-01-16 05:00¸gÀÙ¤é³ø °OªÌ¶À¤å©_¡þ¥x¥_³ø¾É

Ãĵضi­x¤é¥»¡AºX¤U²£«~·s¤@¥Nªø®Ä¤zÂZ¯ÀP1101¡A¨ü¤é¥»¦å²G¯e¯f»â°ìÅv«Â¤pªQ«h¤Ò±Ð±ÂªÖ©w»P­«µø¡A°£¤F²£«~Ävª§¤O¥~¡AÃöÁä±À¤â¬O¤é¥»²±©M¹Ñ¦b¥x¥Nªí¤H¡]¥@¸Ü¤H¡^ĬÄRµØªº²o½u¡A¤~ÅýÂù¤è¦X§@±o¥H¶¶§Q¶i¦æ¡C

²±©M¹Ñ¬O¤é¥»¸gÀ礧¯«¡þ¨Ê²¡¶°¹Î³Ð¿ì¤H½_²±©M¤Ò©Òµo°_¡A¸¹¥l¥ø·~®aªº¦Û¥D©Ê¾Ç²ß·|¡A¦Ó½_²±©M¤Ò¬O¤é¥»­º©}¤@«üªº¥ø·~®a¡A¨ü¨ì¤é¥»¬F°Ó»â°ìªº·q­«»P«H¥ô¡C

¾Ú±x¡A¤pªQ«h¤Ò±Ð±Â¶i¦~Àò±x¼Ú¬w¦³¤@ºØªø®Ä¤zÂZ¯À¡A¹ï¦¹²£«~¿n·¥Ãöª`¡A¥h¦~¡AÃĵئb²±©M¹Ñµ¥¯S®íºÞ¹D¤U¡AÁܽФpªQ±Ð±Â¨Ó¥x«ô³X¡A¤èª¾³o­Ó¤zÂZ¯À¥¿¬OÃĵرÂÅvµ¹¼Ú¬wÃļtAOPªºP1101¡AÅý¥L¤j¬°ÅåÆA¡C

¤pªQ«h¤Ò±Ð±Â¦b¤F¸ÑP1101«á¡A¿n·¥·Q­n§â¸Ó²£«~¤Þ¤J¤é¥»¥«³õ¡AªvÀø¤é¥»°ê¥Á¦å²G»â°ìªº¯e¯f¡A¦Ó³o¤]¬OÂù¤è¦X§@ªº°_©l¾÷½t¡C

·~¬É«ü¥X¡A¤é¥»¶¶¤Ñ°óÂå°|¬O¤é¥»³Ì¯S®íªºÂå°|¡A¬O¤é¥»¬Ó±Úªº±s¥ÎÂåÀø°|©Ò¡A¤@¯ëÃļt­YµL¯S®íÃö«Y¡AÃø¥H±µÄ²¨ì°|¤ºªºÂå¥Í¡A§ó¹N½×¦X§@¡C

¦¹¦¸ÃĵرµÄ²¨ì¤pªQ«h¤Ò±Ð±Â¡A°£¤F²±©M¹ÑªºÃö«Y¥~¡AÅ¥»¡ÁÙÅå°Ê¤é¥»Á`²z¤j¦Ú¦w­¿®Ê¤T¯S§OÃö¤ß¦¹¨Æ¡A¤~¯àÅý³o­Ó¡u¤é¥»¬Ó«ÇÂå°|¡vÄ@·NÂIÀY¦X§@¡C

ª¾±x¤º±¡¤H¤h«ü¥X¡A¤é¥»¬Ó«Ç¬O«D±`«O¦uªº³æ¦ì¡A¤@¯ë¤HÃø¥H¿s¨ä°ó¶ø¡A°£«D¦³¡u·¥¬°«H¥ô¡vªºÃö«YºÞ¹D¡A§_«h°ê¥~¤H¤h·Q­n¬¢½Í¦X§@¬O¤£¥i¯àªº¨Æ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/1/15 ¤U¤È 07:36:42²Ä 1904 ½g¦^À³
®£Äß VS ³g°ý¡H

ºîÆ[ÃĵØ2016¦~ªí²{¤£¦p¹w´Á¡AªÅ¤è¦]¯À¯ÉÂZ¡AªÑ»ù¥ç¶^¯}ªÑªF²{ª÷¼W¸ê»ù150¤¸¡A¦Ó2017¦~¾ã¦~ªÑ»ù¨«¶Õ¡A±N·|¦p¦ó¡A¬O¾÷·|©Î¬O©R¹B¡A¬Û«H¨C­Ó¤H¤ß¤¤¦Û¦³¤@§â¤Ø¡A¦U¦Û¸ÑŪ¥¼¨Ó¨«¶Õ·|¦p¦ó¡H

¤@¡B§QªÅ¦]¯À¡G

(¤@)ÃĵؤT´ÁªvÀø®ÄªG¹ï·ÓHU¶È«D¦H©Ê¡G°]°T³ø¾É½èºÃÃĵؤT´ÁÀø©Ê»PHU¶È«D¦H©Ê¡A¨ÃµLÀu¶V©Ê¡C¦P®É¡A°ê¥~¾ÇªÌ¥ç¦h©Ò½èºÃ¡A¦p¥¼À»±ÑHU©Î²Ä¤@¦^¦X®À±Ñ¡B§Æ±æ¬Ýªº¬OÀu¶V©Êµ¥µ¥¡C

(¤G)HUÃÄ»ù§C·G¡G(60 capsules of hydroxyurea 500mg About$30¦Ü$60)¡C

(¤T)HU¨Ã¥¼­PÀù¡G°]°T³ø¾ÉHU¨Ã¥¼­PÀù¡A¦]PV¥»¨­¥¼ªvÀø¡A§Y¦³¥i¯à­PÀù¡C¦]¦¹¡A¹ï©óPV±wªÌ­PÀù¡A¤£¯àª½±µ±À½×¨Ï¥ÎHU¤§µ²ªG¡C°ê¥~¥ç¦³´£¤ÎHU¨Ã¥¼­PÀù(hematologist mentioned that HU ¡§rarely¡¨ causes a shift to AML)¡C

(¥|)ÃĵØC¨xÃÄ®£µLÄvª§¤O¡G¤p¤À¤lÃIJ³¦h¡B®ÄªG¦n¡A¥BÃÄ»ù¤w¤U­°¡AÃĵØP1101¦bÃĮĤλù®æ¤wµLÀu¶Õ¡C

(¤­)ù¤ó¨ÃµL°±²£PEGASYS¡G(¡§Roche has no plans to stop PEGASYS production in the near future.)

¤G¡B§Q¦h¦]¯À¡G

(¤@)ÃĵØ18­Ó¤ëªvÀø©ÊªG¤wÀu©óHU¡G

ÁöµM°ê¥~¾ÇªÌ¦h©Ò½èºÃ¡A¦ý¬O¥ç´Á«Ý®É¶¡ÃÒ©úÃĵØÀu¶VªºªvÀø®ÄªG¡A¬O¥O¤H­È±o¹ª»Rªº¬ã¨s(Although ropeginterferon didn¡¦t beat HU, it is well documented that interferons take time to show prominent activity, so the study is encouraging.)¡C¨Æ¹ê¤W¡AÃĵػPHU¤§ªvÀø®ÄªG¬Û¤ñ®ÄªG¬Û¦P¤§¼Æ¾Ú¶È¤@¦~®É¶¡¡C¦ý¦b18­Ó¤ë¼Æ¾Ú¤w§e²{¶Àª÷¥æ¤e¡C¦ÓPROUD-PV¥[CONTI-PVªº¾ã­Ó24­Ó¤ëÁ{§É¦b2017¦~4¤ëªì§¹¥þµ²§ô¡B5¤ë§¹¦¨©Ò¦³¼Æ¾Úªº¾ã²z¡AAOP©ó6¤ë«e°e¥æEMP¡C­Y©¡®É¤½¥¬ÃĵØ2¦~¼Æ¾ÚªvÀø®ÄªG¤j³ÓHU®É¡A©Ò¦³½èºÃªºÁn­µ¦Û¥i®ø°£¡A¹ï¨ú±oÃÄÃÒÀ³§U¯q¬Æ¤j¡C¥t¥~¡A°ê¤º¾ÇªÌ¤j¦P¤j¾Ç¥Íª«¤uµ{¨t±Ð±Â´å¦N¶§«ü¥X¡AÃĵسo¦¸¸Ñª¼³Ì¤jªº¬ð¯}¦b©óP1101ªº°Æ§@¥Î»·¸ûHU§C¡A¤ñ¸ûµL­PÀù­·ÀI¡C¡B¡B¡B¤£¬O¦]¬°«D¦H©Ê³o­Ó¦r²´¡A§Y·sÃÄÀø®Ä»PÂÂÃĤ@¼Ë¡A´N§_»{·sÃÄ»ù­È¡CÂå¾Çµo®i¨º»ò¤[¤F¡A­°§C°Æ§@¥Î¤Ï¦Ó¬O¥Ø«e·sÃĬãµoªº¬ð¯}­«ÂI©Ò¦b¡C(°Ñ·Ó1047¤µ©P¥Z¡Bp80)

(¤G)Ãĵةw»ù¦³Ävª§¤O¡G

ªk»¡·|°õ¦æªø»¡Ãĵةw»ù¬ù¤@¦~8¸U¬ü¤¸¡A¹ï·ÓHUÃÄ»ù§C·G¬O§_®£µLÄvª§¤O¡H©¡®É¡A­Y¤G¦~¼Æ¾Ú¥XÄl¤j³ÓHU¡A¶¶§Q¨ú±o¤@½u¥ÎÃÄÃÄÃÒ¡A¥BHUÃĮĬr©Ê±j¡AÁöµL©úÅã¬ã¨sÃÒ¾ÚÃÒ©ú­PÀù¡A¦ýÃĵؤ½¥¬¤T´Á¼Æ¾Ú¡AÅã¥Ü¨Ï¥ÎHU¯f±w¦³5¦W­PÀù¡A¨Ï¥ÎHU³B©ó¥i¯à¦³­PÀù¤§ºÃ¼{¤´Ä~Äò¦s¦b¡C¥[¤W¼Ú¬üÂåÀø«OÀI¨î«×¡AÂå®v¤§²Ä¤@¿ï¾ÜÀ³¬OÃĵءAÃĵؾP°â¦Û¥i´Á«Ý¡Cªp¥B¡A¬ü°ê²Ä2©u§Y±N±Ò°ÊRESCUE Trial¡A¥ÑÃĵØP1101¨ú¥NPEGASYS¡APEGASYSªº»ù®æ¥ç¤£´´(1 kit (4 syringes) of Pegasys 180mcg/0.5ml usually once per week. About $4000)¡A¹ï©óÃĵØP1101¤é«á±µ¦¬PEGASYSªº¯f±w¡A¾P°â¥ç¤j¦³À°§U¡C¥t¥~¡A¤G½u¥ÎÃÄJakafi¨C¦~­q»ù13¸U¬ü¤¸¡A¦ô­p2017¦~¾P°â10»õ¬üª÷(­Ó¤H¤£ª¾PV»PMF¦U¦û¦h¤Ö¡A¬dµL¸ê®Æ)¡C¦ÓÃĵحY¨ú±o¤@½u¥ÎÃĸê®æ¡A¨Ì¤½¶}»¡©ú®Ñ¦ô­p¸û2½u¥ÎÃįf±w¦³¤T­¿¤§¦h¡C­Y§ó¼ÖÆ[´Á«Ý¡AÃĵؤ½¥q¦Û¤v¤½¥¬·s»DPV¨C¦~¼ç¦b°Ó¾÷¥i¹F¬üª÷100»õ¤¸¡C

(¤T)ù¤ó¥Í²£PEGASYS¤é«á¾P°â±N¦¨°ÝÃD¡G

ÃĵئbC¨x¤@«¬ÃĮĤñPEGASYS¦n¡A°Æ§@¥Î§C(ÃĵؤG´Á§¹¦¨¡A©|µL­pµe¤T´Á´Áµ{)¡B¦bC¨x¤G«¬ÃĮĻPPEGASYS¤@¼Ë¡A¦ý°Æ§@¥Î§C(ÃĵؤT´Á¦¬®×¤¤)¡CB¨x¤è­±ÃĮĻPPEGASYS¬Û¤ñ¤£±o¦Óª¾(­Ó¤H¬dµL¸ê®Æ)¡C¦bPV¤è­±¡AÃĵؤG¬P´Á¥ÎÃĤ@¦¸(ropeginterferon is administered every two weeks instead of every week as is Pegasys.)¡A¥B°Æ§@¥Î§C¡A¥B¬ü°ê²Ä2©u§Y±N±Ò°Ê°ÊRESCUE Trial¡A¥ÑÃĵØP1101¨ú¥NPEGASYS¡C¥H¤WÅã¥Ü¡A§Y¨Ïù¤ó¨ÃµL°±²£PEGASYS¡A¦b­±¹ïÃĵرj¯PÄvª§¡A¤é«áù¤ó©Ò¥Í²£PEGASYS¡A¾P°â±N¥X²{°ÝÃD¡C

(¥|)RESCUE Trial§Y±N¶}©l¡G

1¡BÃĵؤ½¥q©x¤èºô¯¸´£¨Ñªº¼v¤ù¡AJohn Mascarenhas¥ç´£¤ÎRESCUE Trial¡A§Æ±æ©ó2017¦~²Ä2©u¶}©l¡C

2¡B¬ü°ê²Ä2©u§Y±N±Ò°Ê°ÊRESCUE Trial¡A¥ÑÃĵØP1101¨ú¥NPEGASYS(So this looks like a potentially viable agent in MPNs and the MPD-RC is planning a trial called RESCUE which would allow patient that were receiving Pegasys on the MPD-RC 111 and 112 trials to transition onto ropeginterferon. This investigator initiated multi-center trial will hopefully open 2nd Q of 2017)¡C

3¡BPharmaEssentia-US°õ¦æ§Y±N±Ò°ÊªºRESCUE Trial(´À´«Pegasys)¡C

(¤­)ÃĵبxÃĤ´¦³¤@©wÄvª§¤O¡G

ÃĵØC¨x2«¬¤w¦b¤T´Á¶i¦æ¤¤¡AÁöµM²{¦bC¨x¤p¤l¤ÀÃIJ³¦h¡A¦ý§Y¨Ïªv·U¡A¤´¥i¯à´_µo­PÀù(Alarm over Cancer Recurrence after DAA Treatment¡B¼Ú·ù¾P°âDAAªº¤½¥q¤w³Q­n¨D°õ¦æ¨xµw¤Æ/¨xÀù´_µoªº¬ã¨s)¡CÅã¥ÜÃĵؤzÂZ¯À¦³¤@©w¥«³õ¡C§Y¨ÏµLªk³æ¿W¨Ï¥Î¤zÂZ¯ÀªvÀø¡A¤´¥i·f°t¨ä¥L¤p¤À¤lÃĪvÀø¡AÁÙ¬O¦³¤@©w§Q°ò¡C¥t¥~Jean-Pierre Sommadossiªº¤p¤l¤ÀÃÄDAA»PÃĵØP1101¦X§@¡A¤£ª¾¶i®i¦p¦ó¡A­Y¦¨¥\¹ïÃĵئӨ¥¡A¤S¬O¤@¶µ§Q¦h¡C¦ÓB¨x·s»D¤è­±¡A¤w¦³³ø¾É¨Ï¥Î¤zÂZ¯ÀªvÀø¤@¦~¦¨¥\ªº®×¨Ò¡A¦ÓÃĵاY±N©ó2017¦~²Ä2©u©Î²Ä3©u±Ò°ÊB¨x²Ä¤T´Á¹êÅç¡C

(¤»)Ãĵإþ²y

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G275810143547  µoªí®É¶¡:2017/1/15 ¤U¤È 06:53:08²Ä 1903 ½g¦^À³
¬°¦ó¤S¨£¬O´CÅé¦Û¦æÁr´úªº¤½§iÁn©ú?

¤£¥u¦³¯E¹©¡BÃĵءB´¼Àºµ¥¡A

ºK¿ý¦ÛÃÒ¥æ©Ò­«¤j°T®§¤½§i

¨Ò¦p

¤µ©P¥Z1047´Á ¥Í§ÞÂåÀø·sÁÍ¶Õ ²Ä80­¶~81­¶

6.³ø¾É¤º®e:¦Ü©ó¤w¸g®³¨ì¼Ú¬üÃÄÃÒªº´¼Àº¯ØŦÀù·sÃÄ¡K¡K±ÂÅvª÷¤À¼í(¬ù10%)¡A

¡K¡K¦ô­p´¼Àº¤µ¦~EPS¬D¾Ô¤Q¤­¤¸¡A¦ý¯ØŦÀùÃĪ«¥Ø«e¤w¦³¤T¦Ü¥|ºØµ¥±Ô­z¡C

8.¦]À³±¹¬I:°w¹ï´CÅé³ø¾É¡A¥»¤½¥q»¡©ú¦p¤U:

(1) ONIVYDE¨Ö¥Î5-FU/LVÀøªk¨Ï¥Î©ó¯Ø¸¢Àù¯f¤H¦b±µ¨ü¹L¼Ð·ÇÃĪ«

gemcitabine¬°°ò¦¤§Àøªk¥¢±Ñ«áªºªvÀø¡A¹ï©ó¾ãÅé¦s¬¡´Á¡]overall survival¡^

¦³Á{§É¤W¤Î²Î­p¾Ç¤WªºÅãµÛ®ÄªG¡C¥»¶µÀøªk¦P®É¬O²Ä¤@­Ó¤]¬O¥Ø«e°ß¤@³Q¬ü°êFDA

©M¼Ú·ùEMA®Ö­ã¨Ï¥Î©ó´¿±µ¨ü¹Lgemcitabine¤§Âಾ©Ê¯Ø¸¢Àù¯f±wªºªvÀø¤èªk¡A

¦b2015¦~9¤ë¤§ESMO¡]European Society of Medical Oncology¡^ªvÀø«ü¤Þ¤¤¡A

³Q»{¬°¬OÂಾ©Ê¯Ø¸¢Àù¯f±w¦b±µ¨ü¹LgemcitabineªvÀø«áªº³Ì¨Î¿ï¥ÎÀøªk¡A

¨Ã©ó2016¦~3¤ëÀò±o¬ü°ê°ê®aÀù¯g¸ê°Tºô

¡]NCCN, National Comprehensive Cancer Network¡^¦C¤J

2016¦~³Ì·sª©¤¤¹ï©ó¯Ø¸¢Àù²Ä¤G½uªvÀø«ü¤Þªº²Ä¤@¯Å¡]Category 1¡^ªvÀø«Øij¡C

(2)¤W­z´CÅé³ø¾É°]°È·~°È¬ÛÃö¸ê°T¡A«YÄÝ´CÅé¦Û¦æÁr´ú¡A¥¼¨Ó°]°È·~°Èµ¥¬ÛÃö

°T®§½Ð¨Ì¥»¤½¥q¤½§i¸ê°T¬°·Ç¡C

¨C·í´CÅ馳Ãö©ó¦U®a¥Í§Þ·sÃij̷sÁ{§É¶i«×³ø¾É©Î¬ÛÃöµo®i«e´º¶i¦æ¹w´ú®É¡A

¦ý¬O§ë¸ê¤H¦]¬Û«H´CÅ骺«H¤f³ø¾É§ë¤J¸êª÷¡A­Pª÷¿ú·l¥¢ºG­«¡A¸Ó¥Ñ½Ö­t³d?

¦Ó¦U¥Í§Þ¤½¥q´N¥u¯à³Q°Êªºµo¥X¤½§iÁn©ú¦Ó¤w¶Ü?

°]¸g°OªÌ¥¼¸g¨DÃÒ¥i¥H¥ô·Nµo§G¤£¹êªº°T®§¨Ó»~¾É§ë¸ê¤j²³?

½Ð°Ý¥DºÞ¾÷ÃöµL­p¥i¬I¶Ü?µLªk¥iºÞ¶Ü?§ë¸ê¤j²³ªºÅv¯q½Ö¨Ó§âÃö¤Î«O»Ù.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSirius10142542  µoªí®É¶¡:2017/1/15 ¤U¤È 03:28:30²Ä 1902 ½g¦^À³
³o¤@´Áªº°]°TÂø»x(520´Á)¦³¤@½g¡¨ÃĵØÂåÃĨӨç·Óµn¡¨¡A¨ä¤¤¬Y¨Ç¤å¦r¡A¨Ã¥¼¥X²{¦b¤½¥q¥h¦~12/30ªº¤½§i¤W¡A§Ú²³æºK­nµ¹¤j®a°Ñ¦Ò¡G

¤zÂZ¯À¤w³QÂå¥Í¥Î¨ÓªvÀøPV¯f¤H¹F¤T¤Q¦~¤§¤[¡AÁö¨ãÀø®Ä¦ý¨ü­­©ó¨äÃø¥H§JªAªº°Æ§@¥Î¡A¨´¤µ¨S¦³¥ô¦ó¤@ºØ¥«­±¤Wªº¤zÂZ¯À¬O¸gFDA©ÎEMA®Ö­ãªvÀøPVªº¥ÎÃÄ¡C¤SP1101¦pªG³QFDA©ÎEMA®Ö­ã¨Ï¥ÎªvÀøªº¤zÂZ¯ÀÃÄ«~¤W¥«¡A¨º»ò²{¦b§{¶¡©Ò¦³off-labelªº¤zÂZ¯À¥i¯à¡u¨S¦³«OÀI¤½¥qµ¹¥I¡v¡A¹ïÃĵØÃĥثeÁ{§É¤¤ªºP1101À³¦³¨ü´f¡C

¤zÂZ¯À¨ãªvÀøÀù¯gªº®ÄªG¦­¤w¬Òª¾¡A¥Ø«eFDA®Ö­ãªºµu®Ä«¬¤zÂZ¯À¡A¤w´¶¹M¥Î©óªvÀø¥]¬A¤ò²Ó­M¥Õ¦å¯f¡B´c©Ê¶Â¦â¯À¸~½F¡BÂoªw©Ê²O¤Ú½F¡B¥Í´Þ¾¹¬Ð¡B»PAIDS¬ÛÃöªº¥dªi¦è¦×½F¡BºC©ÊB«¬¨xª¢¡BºC©ÊC«¬¨xª¢µ¥¡AÅã¥Ü¤zÂZ¯À¦b¦å²G»P¼ç¥ñ«¬¸~½F¯e¯f¡A¥i¥H¹F¨ìªvÀø®ÄªG¡C¦]¦¹PROUD-PVªºµ²ªGÀ³¬O»¡¹ïPV¯f±w¨ã¦³ªº¼ç¦bÀù¯g¯à¦³¹w¨¾¤§®ÄªG¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/1/15 ¤U¤È 01:01:16²Ä 1901 ½g¦^À³
ªÑ¥«§ë¸ê¬O¤@ªùªÀ·|¬ì¾Ç...¨S¦³¼Ð·Çµª®×

¤@¼Ëªº¨«¶Õ....¨C­Ó¤H¸Ñªk¤£¦P

¤p§Ì³£¤©¥H´L­«

¨ä¹ê¦Û¤T´Á¼Æ¾Ú¤½¥¬¥H¨Ó...Ãĵتº¨«¶Õ¨Ã¨S¦³¹w´Áªº¼ö±¡

´N¦p¦P¤µ¶g¥Z¤ÀªRªº¤@¼Ë¡A¤½¥¬«e³\¦h½ä½L·|´é¤J

¦ÓP1101¥\®Ä¤ÎÀò§Q©Ê¥«³õ½èºÃÁn­µ¤£Â_

¥B¾A³{ªñ´Á¤º¥Í§ÞªÑ´CÅé¤j¸v§å§P...¥Í§Þ¨«¶^

³\¦h¤¤µu½u§ë¸êªB¤Í¤U¨®

180¶Rªº...

¶^¨ì160½æ¤£½æ??¶^¨ì150½æ¤£½æ??

¨C­Ó¤HÀ£¤Oªº©Ó¨ü«×¡B¸êª÷¦¨¥»¡B°±·lÂI...³£¤£¦P

·í»ù®æ§e²{«D¹w´Á¨«¶Õ¡A¦³¤H¤W¨®¡B¦³¤H¤U¨®.....

¥[¤W¦³¤@°¦¬Ý¤£¨£ªº¤â¸ò´CÅé§U§ð.....

¬Ý¨Ó­n­«·s®¶§@¡A­nµ¥¨ìAOP¥¿¦¡´£¥XÃÄÃҥӽСA¤~¯à¥´¯}§ë¸ê¤H¹ïÃÄÃҥӽЪº½èºÃ¡A²¦³ºHUÁöµM°Æ§@¥Î¤j¡A¦ý²Ä¤@¦~ªí²{¥X¥G·N¥~ªº¦n¤]¬O¨Æ¹ê¡C©Ò©¯¨Ì¦U¤èµû¦ô¨Ó¬Ý¡A¨ú±oÃÄÃÒ³o¤è­±¨ÃµL¤H½èºÃ¡AÀ³¬O«ü¤é¥i«Ý¡C

¦Ó¤W¥««áªºÀò§Q¬O§_¯à¦p¹w´Á¤]¬O¥t¥~¤@­Ó°ÝÃD!!

¤£¹L¡B³o¤@ÂI¤p§Ì§Ú­Ë¬O¼ÖÆ[¥H¹ï...

«Ü¦h¤H½èºÃÃÄ»ù°¾°ª..

¦ý¡B¤@¤è­±¬°¤F¹ªÀyÃļt§ë¤J¨Ã¯à¦^¦¬¦¨¥»¡A©t¨àÃįS©Ê¬O±j¨î«OÀI¤½¥q¶R³æ¥B»ù®æ¥iij¡C¤G½uÃÄJakafi¸òPegasy³£¯à¦³«G²´ªí²{¡A¥h½èºÃP1101¡A§Ú¬Oı±o¦³ÂI²o±j¡C

¥t¤@¤è­±¡A³\¦h¤ÀªRªÌ©¿²¤¤F¼Ú¬ü©Ò±o±`¬O¥xÆW¤H§¡©Ò±oªº2~3­¿¡A¥H¹ê½èÁʶR¤O¨Ó¬ÝP1101³oºØ±Ï©RªºÃÄ­q»ù¨Ã«D¤Ñ»ù¡C

¤p§Ì§Ú¤ñ¸û»{¦PLKK¤jÆ[ÂI¡A¥Í§Þ¬Oªø½u§ë¸ê¡C©Èªº¬O¤T´Áµ²ªG¤£¦p¹w´Á¡A¬JµMµ²ªG¤j­P»P¤@¡B¤G¬Û·í¡A¤Ï¦Ó¾á¤ß¥¼¨Óµo®i¡A¦n¹³¦³ÂI©Ç¡C

¦Ü©óªÑ»ù¡A¤p§Ì·Qªk¬O¦A§Ô§Ô¡AÁÙ¬O¨º¥y¸Ü....ªÑ»ùÁ`·|¨«¨ì¥¦¸Ó¨ìªº¦a¤è¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gyo10138368  µoªí®É¶¡:2017/1/15 ¤W¤È 10:31:23²Ä 1900 ½g¦^À³
¨º½Ð±Ð¤@¤U«ç»ò­Ó¶^ªk¤~¬O­Ë³f©O??
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/1/15 ¤W¤È 10:20:33²Ä 1899 ½g¦^À³
´N¬OÀ£§C¶i³f,±z¥u­n§âªÑ²¼¦n¦nªº©ñ¦n,µM«á¹L¥­±`ªº¥Í¬¡,´N¦³¤@­Ó°×§a¨à¤lÀ°±zÁÈ¿ú
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¦ÌªG10143740  µoªí®É¶¡:2017/1/15 ¤W¤È 12:15:41²Ä 1898 ½g¦^À³
¤j¤j¤£¹³­Ë³f¡A¬°¦óªÑ»ù¡K¡K¡K¡K

¥i¥HÁ¿²M·¡¡A»¡©ú¥Õ¬°¦óªÑ»ù¶^¶^¤£¥ð¶Ü¡K¡K

§Ú¤w¦³¦~¬ö¤F¡A¤ßŦ¥i¨ü¤£¤F¡K¡K¡K¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/1/14 ¤U¤È 11:58:08²Ä 1897 ½g¦^À³
sorry...»~·|§Aªº·N«ä¤F

¤£¹L....

¦ü¥G§A¸ò¤½¥q¥Ç¤F¦P¼Ëªº¤ò¯f...

¨S¦³»¡²M·¡....¦Ü¤Ö¬Ýªº¤H®»¤£¨ì­«ÂI

¤£¹L...§Ú¬Ýªº­«ÂI¬O....

¤@¨Ó¤½¥q¹ï¨úÃÄÃÒ¦³¬Û·í«H¤ß

¤G¨Ó¤½¥q¬°¤F§Ö³t¶i¤J¥«³õ¡A¤wµÛ¤â¥ý¦æ§G§½

¦Ü©óªÑ»ù......¦³°­

³oºØ¶^ªk......¯uªº¦³°­

¤£¹³¦b­Ë³f...­Ë¹³.....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSirius10142542  µoªí®É¶¡:2017/1/14 ¤U¤È 11:22:31²Ä 1896 ½g¦^À³
Russell¤j

§A»¡ªº§Ú·íµMª¾¹D¡A©Ò¥H¥²¶·­n¦¨¥ß¤@®a¤l¤½¥q(¬ü°Ó)¡A¤~¯à§â©Ò¦³ªº¶O¥Î¤ä¥XÄé¶i¥h¨É¨üµ|­tÀu´f¡A¤À¤½¥q´N¤£¦æ¡A³o¬O¥Ó½ÐÃÄÃÒªº²Ä¤@¨B¡C

¨ä¹ê¨M©w¦¨¥ß¤@®a¤l¤½¥q¡A´Nºâ­n¤½§i¡A¤]¤£¥²»¡©ú¨º»ò¦h¡A¤½¥qÀ³¸Ó¤]¬O·QÂdzo­Ó¤½§i¡AÂç²M¥«³õ¤W¤@¨Ç¿ù»~ªº»{ª¾¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/1/14 ¤U¤È 10:14:25²Ä 1895 ½g¦^À³
Sirius¤j

§A¥i¯à¤£ÁA¸Ñ¤À¤½¥q»P¤l¤½¥qªº®t§O

¦b¬ü°ê¦¨¥ßªº¤l¤½¥q¬O¨Ì偱¬ü°êªº¤½¥qªk¦¨¥ßªº¤½¥q¡A¬O¬ü°ê¤½¥q¡A¥u¬O¤jªÑªF¬OÃĵإç©Î¥ÑÃĵإþ¸ê¦¨¥ß¡C

¤l¤½¥q¬O¿W¥ßªºªk¤H¡A¤À¤½¥q´N¤£¬O¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦B«B10138946  µoªí®É¶¡:2017/1/14 ¤U¤È 09:59:44²Ä 1894 ½g¦^À³
¹w¦ô­È¬O·|ÀH®É¶¡¤ÎÀò§Q¦Ó§ïÅܪº...5¦~«eªk¤H¹ï¤j¥ß¥úªº¹w¦ô­È¤]¥u¦³500¤¸...

²{¦b¤j¥ß¥ú³£4000¤¸¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/1/14 ¤U¤È 06:08:12²Ä 1893 ½g¦^À³
¸Ó©P¥Z¹ïÃĵتº¹w¦ô­È¥u¦³¤G¦Ê¦h¹ï¤T¦Ê¦h,·|¤£·|¤Ó¤Ö
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSirius10142542  µoªí®É¶¡:2017/1/14 ¤U¤È 05:08:10²Ä 1892 ½g¦^À³
¸ÑÄÀ¤@¤U¬°¦ó­n³]¥ß¬ü°ê¡¨¤l¤½¥q¡¨¡A­«ÂI¤£¬O­n°µRESCUE Trial¡A¦Ó¬O¬ü°êµ¹¤©©t¨àÃij\¦hµ|­tÀu´f¡A¥]§t¨úÃÒ«eªº¬ãµo¬ÛÃö¶O¥Î¡B¥Ó½ÐÃÄÃÒ¶O¥Îµ¥¡A¤£¹L³o¨ÇÀu´fµ¹ªº¬O¡¨¬ü°ê¤½¥q¡¨¡A¥~°ê¤½¥q¬O¨S¦³ªº¡A©Ò¥H³o­Ó¬ü°ê¤l¤½¥qªº³]¥ß¡A¥NªíP1101¦b¬ü°êªº¨úÃÒµ{§Ç±N­n¶}©l¡A¤]¬O¤½¥q¹ïÃĮīH¤ßªº®i²{¡A¤j®a­n¬ÝÀ´­I«áªº·N¸q¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSirius10142542  µoªí®É¶¡:2017/1/14 ¤U¤È 04:32:57²Ä 1891 ½g¦^À³
¤µ©P¥Z³o½g¤å³¹¡A¦³¨â­Ó©úÅ㪺¿ù»~¡A´CÅé°OªÌ¦Û¤vÀ³¸Ó¤]¤£À´¡C

²Ä¤@¡A¤å³¹«e«á¨â¦¸´£¨ì¯E¹©¦b¬ü°ê¥u¬O¡¨Á{§É¤@´Á¡¨¡A³s¤@´Á¤G´Á³£·d¿ù¡A·íµM¦bºâ²{ª÷§é²{ªkªº®É­Ô¡A²z½×»ù®æ·|®t«Ü¤j¡C

²Ä¤G¡A¦b¬Ý¤d±i¥H¤W«ùªÑ¤ñ­«ÅܤƮɡA­n¤p¤ß¨â­Ó¤zÂZ¦]¯À¡A¤@­Ó¬O³o¬q´Á¶¡¦³µL¿ì²z¼W¸ê¡A¦pªG¦³(¹³ÃĵØ)¡A³o­Ó¤ñ­«´N·|ÅÜ¡A¤£ªí¥Ü¦ÑªÑªF¦³½æªÑ²¼¡C¤G¬O¦pªG¦³¤j¶q­É¨é½æ¥XªºªÑ²¼¡A³o­Ó¤ñ­«¤]·|¨ü¼vÅT¡CÁ|¯E¹©ªº¨Ò¤l¡A¯E¹©ªº­É¨é½æ¥X±i¼Æ¤w¹F12467±i¡A¦ûªÑ¥»ªº¤ñ¨Ò¬O7.27%¡A·íµM¤]¦³¤@¨Ç¤p¤á¦³­É¥X¡A¤£¹L¥H§Ú¬ã¨s¤Q¤jªÑªF¤Î¨é°Ó¶i¥Xªº¤ß±o§i¶D§Ú¡A³\¦h«D¤½¥q¬£ªº¤d±i¤j¤á¡A³z¹L§â¨é­É¥X¡AÅý¦Û¤v²æÂ÷¤Q¤jªÑªF¦W³æ¡A°£¤F¦hÁÈÂI§Q®§¡A¥t¥~¤]¥i¥H¤£¨º»ò©Û·n¡C

©Ò¥H¤j®aÁÙ¬O­n¦Û¤v¦h¥Î¥\¡A´CÅ骺°OªÌ»P±M®a¡A¤]¬O¿ù»~¦Ê¥Xªº¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2017/1/14 ¤W¤È 10:33:16²Ä 1890 ½g¦^À³
¦U¦ì§ë¸ê¤H¦­¦w¡A³o´Áªº¤µ¶g¥Z¦³¸Ô²Ó«ÈÆ[¦a»¡©ú:¯E¹©/¤¤¸Î/ÃĵØ/¨ä¥L¼Æ¤ä¥Í§Þ·sÃÄÂå§÷¡A¥Í§ÞÂåÀø·sÁͶաA

¡u¥Í§ÞªÑ­I«áªº³g°ý¹CÀ¸¡v¡A§ë¸ê¤H¤@©w­n¥hÁʶR¡A¹ï±z§ë¸ê¥Í§ÞªÑ¦³¤@©wªºÀ°§U¡K¡K¡K¡K¡K¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬ù¿«10143522  µoªí®É¶¡:2017/1/13 ¤U¤È 11:46:36²Ä 1889 ½g¦^À³
§Ç¸¹ 3 µo¨¥¤é´Á 106/01/13 µo¨¥®É¶¡ 22:36:48

µo¨¥¤H ¶À¥¿¨¦ µo¨¥¤H¾ºÙ Á`¸g²z µo¨¥¤H¹q¸Ü 02-26557688

¥D¦® ¤½§i¥»¤½¥q¸³¨Æ·|¨Mij³q¹L¥x¤¤¤À¤½¥q¸g²z¤H²§°Ê

²Å¦X±ø´Ú ¡@²Ä 51 ´Ú ¨Æ¹êµo¥Í¤é 106/01/13

»¡©ú 1.¨Æ¹êµo¥Í¤é:106/01/13

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.¶Ç¼½´CÅé¦WºÙ:¤£¾A¥Î

6.³ø¾É¤º®e:¤£¾A¥Î

7.µo¥Í½t¥Ñ:

¥»¤½¥q¸³¨Æ·|³q¹L©e¥ô÷á­l´ÉÀç¹Bªø¾á¥ô¥x¤¤¤À¤½¥q¤§¸g²z¤H(­ì¾¶À¥¿¨¦

Á`¸g²z­Ý¥ô)¡A¥H¸¨¹ê¥x¤¤¼t¤§²ÎÄwºÊºÞ¡A¥]¬A°ê¥~¬d¼t¤§ªk³W¿í´`µ¥¬ÛÃö

¨Æ©y¡C÷áÀç¹Bªøªð¥xªA°È«e¡A¥ô¾©ó´f¤ó¡B½÷·çµ¥¤jÃļt¹F¤G¤Q¾l¦~¡A»â¾É

¶}µo¹Î¶¤´£°ª°Ó·~²£«~ªº¥Í²£²v¡A±q¹êÅç«Ç³W¼Ò¨ì¤j³W¼Ò¤u¼t¥Í²£¡A¤Î¼¶¼g

¬dÅçµn°O¤å¥ó¥Ó½Ð°ê»ÚÃÄÃÒµ¥¡C

8.¦]À³±¹¬I:¦Û106/01/13¶}©l¥Í®Ä¡C

9.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬ù¿«10143522  µoªí®É¶¡:2017/1/13 ¤U¤È 11:41:48²Ä 1888 ½g¦^À³
§Ç¸¹ 4 µo¨¥¤é´Á 106/01/13 µo¨¥®É¶¡ 22:37:33

µo¨¥¤H ¶À¥¿¨¦ µo¨¥¤H¾ºÙ Á`¸g²z µo¨¥¤H¹q¸Ü 02-26557688

¥D¦® ¤½§i¥»¤½¥q¸³¨Æ·|¨Mij³q¹L·s¥ôÂå¾Çªø

²Å¦X±ø´Ú ¡@²Ä 8 ´Ú ¨Æ¹êµo¥Í¤é 106/01/13

»¡©ú 1.¤H­ûÅܰʧO¡]½Ð¿é¤Jµo¨¥¤H¡B¥N²zµo¨¥¤H¡B­«­nÀç¹B¥DºÞ¤§¦WºÙ¡B°]°È¥DºÞ¡B·|­p¥D

ºÞ¡B¬ãµo¥DºÞ¡B¤º³¡½]®Ö¥DºÞ©Î¶D³^¤Î«D³^¥N²z¤H¡^:Âå¾Çªø

2.µo¥ÍÅܰʤé´Á:106/01/13

3.ÂÂ¥ôªÌ©m¦W¡B¯Å¾¤Î²¾ú:µL

4.·s¥ôªÌ©m¦W¡B¯Å¾¤Î²¾ú:¯³¤p±jÂå¾Ç³Õ¤h¡A¥ô¥»¤½¥qÂå¾Çªø¡A¯³³Õ¤h«Y¬ü°ê

«¢¦ò¤j¾ÇÂå¾Ç°|¥Í¤Æ¤Î¤À¤lÃIJz¾Ç³Õ¤h¡B¤sªF¤j¾ÇÂå¾Ç°|Âå¾Ç¨t²¦·~¡C´¿¥ô

©ó¬ü°ê¦yºÝ¥Í§Þ¤½¥qBiogen¡B¸ó°ê¤jÃļt«ô¦Õ¡B½÷·ç¡B¦bBostonªºImmunoGen

Inc¥H¤Î¦b¤é¥»ªF¨ÊªºSymBio»sÃĤ½¥qµ¥ª¾¦W°ê»Ú¥Í§ÞÂåÃIJ£·~¡A¾á¥ô¹L¸ê²`

¬ì¾Ç®a¡AÁ{§É°Æ³¡ªø¡AÁ{§ÉÁ`ºÊ¡A­º®u¬ì¾Ç°õ¦æ©x©M°õ¦æ¸³¨Æµ¥Â¾¡A¦b¥[¤JÃÄ

µØ¤§«e¡A¾á¥ô¤¤°êÂåÀø¶°¹Î­º®uÂå¾Ç©x¡C

5.²§°Ê±¡§Î¡]½Ð¿é¤J¡uÃ㾡v¡B¡u¾°È½Õ¾ã¡v¡B¡u¸ê»º¡v¡B¡u°h¥ð¡v¡B¡u¦º¤`¡v¡B¡u·s

¥ô¡v©Î¡u¸Ñ¥ô¡v¡^:·s¥ô

6.²§°Ê­ì¦]:·s¥ô

7.¥Í®Ä¤é´Á:106/01/13

8.·s¥ôªÌÁpµ¸¹q¸Ü:(02)2655-7688

9.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬ù¿«10143522  µoªí®É¶¡:2017/1/13 ¤U¤È 11:37:05²Ä 1887 ½g¦^À³
§Ç¸¹ 1 µo¨¥¤é´Á 106/01/13 µo¨¥®É¶¡ 22:35:16

µo¨¥¤H ¶À¥¿¨¦ µo¨¥¤H¾ºÙ Á`¸g²z µo¨¥¤H¹q¸Ü 02-26557688

¥D¦® ¤½§i¥»¤½¥q¸³¨Æ·|¨Mij³q¹L³]¥ß¤é¥»¤l¤½¥q

²Å¦X±ø´Ú ¡@²Ä 51 ´Ú ¨Æ¹êµo¥Í¤é 106/01/13

»¡©ú 1.¨Æ¹êµo¥Í¤é:106/01/13

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.¶Ç¼½´CÅé¦WºÙ:¤£¾A¥Î

6.³ø¾É¤º®e:¤£¾A¥Î

7.µo¥Í½t¥Ñ:

¥»¤½¥q°ò©ó»{ª¾¤é¥»¥«³õ´X¥e¥þ²y·sÃÄ¥«³õªñ20%¡A¯S§O¬O¦b¨u¨£ÃĪº°Ó¾÷

Ãe¤j¡A¿n·¥±À°Ê¤é¥»·~°È¡A±N¥H¤é¥»¤l¤½¥q(PharmaEssentia-Japan)¤§¦W¸q

¦V¡uÂåÃÄ«~ÂåÀø¾÷¾¹Á`©M¾÷ºc(PMDA)¡v´£¥X¥ý´Á¿Ô¸ß¡A¥HÁYµu¤é¥»Á{§É¸ÕÅç

´Áµ{¤Î¦³®Ä­°§C¸ÕÅçºÞ±±¡A¤]·|¿n·¥°õ¦æPV(»Î±µ©ÊÁ{§É)¤ÎETªº²Ä¤T´ÁÁ{§É¡A

¦P®É´£¨Ñ«Ø¥ß¦b¤é¥»MPN»â°ì²Ä¤@ªº¤½¥q§Î¶H¤Îª¾¦W«×¡B°õ¦æÃöÁä¤W¥««e¬¡°Ê

¡B°õ¦æ»ù®æ¤Î¥«³õº¯³z­pµe¡A½T«OÃÄ«~¦w¥þºÊ±±²Å¦Xªk³W¤Î«Ø³]ÃÄ«~¨ÑÀ³Ãì¡C

°ò©ó¥H¤Wªº»{ª¾¤Î¦Ò¶q¡A¸³¨Æ·|¨Mij³q¹L³]¥ß100%«ùªÑ¤é¥»¤l¤½¥q¡C

8.¦]À³±¹¬I:µL

9.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤Óºò±i10135421  µoªí®É¶¡:2017/1/13 ¤U¤È 11:21:30²Ä 1886 ½g¦^À³

$$ §Y±N±Ò°ÊªºRESCUE Trial(´À´«Pegasys)

¤½§i¥»¤½¥q¸³¨Æ·|¨Mij³q¹L³]¥ß¬ü°ê¤l¤½¥q

²Å¦X±ø´Ú ²Ä 51 ´Ú ¨Æ¹êµo¥Í¤é 106/01/13

»¡©ú

1.¨Æ¹êµo¥Í¤é:106/01/13

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.¶Ç¼½´CÅé¦WºÙ:¤£¾A¥Î

6.³ø¾É¤º®e:¤£¾A¥Î

7.µo¥Í½t¥Ñ:

¥»¤½¥q°£¤w¦b¼Ú¬w±ÂÅvAOP¨u¨£ÃĤ½¥q¨ó§U§¹¦¨§¹¾ãªº²Ä¤@´Á¨ì²Ä¤T´ÁÁ{§É¡A

²{¥¿¶i¦æ¨ú±o¾P°â³\¥iÃÒ(MAA)¤Î§G§½¦æ¾P¥~¡A¥»¤½¥q¬°±À°Ê¬ü°ê·~°È¡A±N¥H

¬ü°ê¤l¤½¥q(PharmaEssentia-US)¤§¦W¸q¦VFDA´£¥X¥ý´Á¿Ô¸ßBLAªº¥Ó½Ð¡A¨Ã°õ

¦æ§Y±N±Ò°ÊªºRESCUE Trial(´À´«Pegasys)¡A¤]·|¨ó§U°õ¦æETªº²Ä¤T´ÁÁ{§É¹ê

Åç¡A¦P®É´£¨Ñ«Ø¥ß¦b¬ü°êMPN»â°ì²Ä¤@ªº¤½¥q§Î¶H¤Îª¾¦W«×¡A½T«OÃÄ«~¦w¥þºÊ

±±²Å¦Xªk³W¤Î«Ø³]ÃÄ«~¨ÑÀ³Ãì¡A°õ¦æÃöÁä¤W¥««e¬¡°Ê¡B°õ¦æ»ù®æ¤Î¥«³õº¯³z­p

µe¡C°ò©ó¥H¤Wªº»{ª¾¤Î¦Ò¶q¡A¸³¨Æ·|¨Mij³q¹L³]¥ß100%«ùªÑ¬ü°ê¤l¤½¥q¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/1/13 ¤U¤È 11:11:55²Ä 1885 ½g¦^À³
Anderson¤j

§A¤@Á¿´N¯}¥\¤F...¥D¤O¤£©Ô¤F

«¢....

³o´N¬O§Ú»¡ªº

¹w´ú¨«¶Õ¬O¨S¦³·N¸qªº

¤ï»x¸òéw¤H·Qªº³£¤£¤@¼Ë....

¤£¥Î......

ªÑ»ù¦ÛµM·|¨«¨ì¥¦¸Ó¥hªº¦a¤è

¦ý......¤£¬O§Ú­Ì¨M©wªº

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/1/13 ¤W¤È 10:30:18²Ä 1884 ½g¦^À³
¤µ¤Ñ¯d±ø¤U¼v½u¡A©ú¤Ñ´N¯àÄ~ÄòÄF¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2017/1/13 ¤W¤È 10:00:16²Ä 1883 ½g¦^À³
¬Q¤Ñ§ë«H©M¦ÛÀç°Ó¬Ý¨ì¯E£|¶^,¦pÅå¤}¤§³¾,·Q»¡¥ý±þ¥ýĹ,µ²ªG§À½L³Q©Ô¤W¥h,¦pªG¤µ¤Ñ¤S¦A¤@¦¸¤£«H¨¸´N·|³Q¬~¥ú¤F¡C¡u¥~°ê¤ë«G¤ñ¸û¶ê¡vªº¤ÀªR®v»¡¤F¤@¨Ç¦ü¬O¦Ó«Dªº¨¥½×¨Ó°g´b¸s²³,³y¦¨ªÑ»ù¤@§C°g,¬Ý¨Ó¥²¶·µ¥EPS¶]¥X¨Ó¤~¯à»¡ªA¸s²³¤F¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªÑªF10143235  µoªí®É¶¡:2017/1/13 ¤W¤È 09:50:30²Ä 1882 ½g¦^À³
³o¨â¤Ñ§ë«H©M¦ÛÀç¦b°±·l¡A¯ÂºéÄw½X°ÝÃD¡A´N¬Ý·~¤º¼µ¤£¼µ±o¦íÅo¡I
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/1/13 ¤W¤È 08:25:49²Ä 1881 ½g¦^À³
¤£¦H©ó¤£¬OEMA­ãªº¶Ü¡H

³£²Å¦X­n¨D¤]¹LÃö¤F

¤£¬O¶Ü¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G275810143547  µoªí®É¶¡:2017/1/13 ¤W¤È 07:57:27²Ä 1880 ½g¦^À³
§ë¸ê¦æ¬°¦p¤@·N©t¦æ¡A¤Ñ¯u¨ì¤£ªÖ­±¹ï²{¹ê¡A¤£Ä@¦Ò¶q¨ì­·ÀI¼h­±ªºµû¦ô(¥]¬A®É¶¡¦¨¥»)¡A¥u·|µ¹¦Û¤w±a¨Ó§óºG­«ªº·l¥¢¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°¶¤j¤j10136951  µoªí®É¶¡:2017/1/13 ¤W¤È 07:23:44²Ä 1879 ½g¦^À³
§A¥á§Ú¾ß

³Ìªñ¬y¦æ¤@ºØ¹CÀ¸¡Aª±ªk¦³¨âºØ¡A

1,¦pªG¤j®a¦b150ªº®É­Ô,¥L¬G·N¥á´X±i¦b140,µ²ªG,¤j®a¤@®£·W,§Ôµh©ß¥X¡A¥L§t¯º¦¬³Î.

2 ¥t¥~¤@ºØ¡A»¡¬Y¬Y¤j©@­n©ß°â¡A¦³¤°»òÃa¨Æµo¥Í¤F¡A©ó¬O®£·Wªº½æÀ£¡A¤S¨Ó¤F¡A¥L¤S§t¯º¦¬³Î.

°¨¸ô¥i¥HÅ¥¨ì«Ü¦h®ø®§!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°¶¤j¤j10136951  µoªí®É¶¡:2017/1/13 ¤W¤È 01:11:27²Ä 1878 ½g¦^À³
¤U­Ó¤ë¥Ó½ÐÃÄÃÒ

AOP±N©ó¤U­Ó¤ë(2)¤ë´£¥XÃÄÃҥӽСC

http://www.aoporphan.com/en.html

­ì¥ý§Ú­Ì»{¬°ÃĵسoÀuµ¥¥ÍÀ³¸Ó¦Ò85¤À¡A«ç»ò¥u¦³¤C¤Q¤À?

ÁöµM¶W¹L¥Ó½ÐÃÄÃÒªº60¤À¡AÁÙ¬O¥i®³¨ì²¦·~ÃҮѡAÁ`¬O¦³¤@¨Ç¿ò¾Ñ¡A¦]¬°¤£¬O¥«ªø¼ú¡C

¤£¹L¨SÃö«Y¦Ñ®vµ¹¤©¥[¦Ò¾÷·|¡A

§Ú­Ì¬Ý¨ì¦Ò¨÷¤W¤wµª¹ï20ÃD¤¤¤§18ÃD¡A18­Ó¤ë¤w¸g©Ô¶}¶ZÂ÷¡A

ÁͶլO¶V¨Ó¶V©úÅã¡C

³oµ¥«Ýªº®É¨è¡A·í§O¤H·QÅý§Ú­Ì®£Ä߮ɡA§Ú­Ì«o¦Û¤v§ó®£Äß?

¤U­Ó¤ë°¨¤W´N¨ì¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G´¶³q§ë¸ê¤H10141467  µoªí®É¶¡:2017/1/13 ¤W¤È 12:08:24²Ä 1877 ½g¦^À³
ªø´Á«ù¦³,¥u©È500¤¸¨Sµ¥¨ì ,µ¥¨ì¤F50¤¸
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G275810143547  µoªí®É¶¡:2017/1/12 ¤U¤È 10:06:13²Ä 1876 ½g¦^À³
¤f³U«Ü²`ªº«Ü²`ªº¡A¤@©w­n°íªø´Á«ù¦³¦Ü500¤~¯à¥X²æ¤º.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/1/12 ¤U¤È 09:14:55²Ä 1875 ½g¦^À³
¬Ý¤F¦U¦ìÄw½X¸ò§Þ³N¤j®vªº¤ÀªR...

¤p§Ì¥\¤O¤£¨¬.....¹ê¦b¦½ÃC

¤£¹L.....³o­Óª©­±....

¦n¹³¬O¡X¡Xªø´Á«ù¦³¼Ð»ù500¤¸¥H¤W

¬°¤F¤è«K¦U¦ì¤j®v½×­z...

¤p§Ì¤æÁx....°_¤F­Ó¡X¡XÃĵتºÄw½X»P§Þ³N¤ÀªR

½Ð²¾¾r¦Ü¸Óª©

¦n¦nÀ°§Ú­Ì¤ÀªR¤@¤U¥¼¨Ó¨«¶Õ

¦h¤Ö»ù¦ì¶R¶i/½æ¥X

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G275810143547  µoªí®É¶¡:2017/1/12 ¤U¤È 08:52:30²Ä 1874 ½g¦^À³
³s¤é¨ÓªÑ»ùÀWÀW³Ð·s§C¡A¤ß±¡Ãø§K§C¸¨¡A§¹¥þ²z¸Ñ¤]«Ü¦P±¡.°O¦í¡A¦Ü¤Ö¡A¤@©w­nªø©ê¦Ü2020³á~~
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gucss10142657  µoªí®É¶¡:2017/1/12 ¤U¤È 08:27:12²Ä 1873 ½g¦^À³
¤µ¤Ñ§Ú¤S¸É¤F£¸±i143¤¸¡A¤@¼Ë°ò¥»­±¤£ÅÜ¡Aªø´Á«ù¦³¨ì2020¡A¥[ªo¡A¦U¦ì
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLKK10141678  µoªí®É¶¡:2017/1/12 ¤U¤È 07:07:13²Ä 1872 ½g¦^À³
¥»¨Ó´N¬Oªø´Á§ë¸ê,¤£¹L«Ü©_©Ç,¤§«e¤£¬O¤@¤j°ï¤H»¡ªø´Á§ë¸ê,«ç»ò¤@¶^´N¤f®ð¤£¤@¼Ë¤F,
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G275810143547  µoªí®É¶¡:2017/1/12 ¤U¤È 06:31:25²Ä 1871 ½g¦^À³
«ùªÑªÌ¸Ó¦³ªø´Á«ù¦³ªº¤ß²z·Ç³Æ.­YµL¦¹¥´ºâ¡A«Øij´«ªÑ¾Þ§@!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/1/12 ¤U¤È 05:30:23²Ä 1870 ½g¦^À³
¾¤©ú«eªº¶Â·t¡H

°]°T³ø¾ÉÃĵجO¸Ñ¯íÁÙ¬O¸Ñª¼¡H¸Ñª¼¹LÃö«oµL¼y¯¬¦æ±¡¤@¤å¡A½èºÃÃĵØÃĮĨå¼Àu©óHUµ¥°ÝÃD¡A¦ü¥GªÑ»ù¥ç¨ü¤F¼vÅT¡Aª½¦Ü¤µ¤é¡A¤w¶^¯}ªÑªF²{ª÷¼W¸ê»ù150¤¸¡C¨Æ¹ê¤W¡A¥~°ê¾ÇªÌ¡A¥ç¦³©Ò½èºÃÁn­µ¡A¦pÃĵبå¼À»±ÑHU(ropeginterferon didn¡¦t beat HU¡BJohn Crispino¡A©Î¬O¶È¬O³æ¯Â°l¨DÃÒ©ú«D¦H©Ê(It¡¦s simply trying to demonstrate non-inferiority.Zhenya Senyak)¡C©Î¬OÃĵؾD¨ü®À±Ñ(P-1101 might have suffered a setback in this first round confrontation¡BMPN Magize)µ¥Án­µ¡C¸Û¦p¾ÇªÌBrady Steinªí¥Ü¡A´N­Ó¤H¦Ó¨¥§Æ±æ¬Ý¨ìªº¬OÀu¶V©Ê(Personally, I was hoping for superiority)¡C¦]¦¹¡A«ùÄò©ÊÁ{§É¹êÅç¡v¡]CONTINUATION-PV¡^µ²ªG¬Û·í­«­n¡A¥u¯àÀR«ÝPROUD-PV¥[CONTI-PVªº¾ã­Ó24­Ó¤ëÁ{§É¦b2017¦~4¤ëªì§¹¥þµ²§ô¡B5¤ë§¹¦¨©Ò¦³¼Æ¾Úªº¾ã²z¡AAOP©ó6¤ë«e°e¥æEMP¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
²Ä¤@­¶¤W¤Q­¶¤W¤@­¶373839404142434445¤U¤@­¶³Ì«á¤@­¶

         

¡@

§Ú¡@¡@­n¡@¡@¦^¡@¡@À³¡@¡@¥»¡@¡@¸Ü¡@¡@ÃD

·| ¡@­û¡G

  

§@ ªÌ ¡G

 

¬ÛÃöªÑ²¼¤½¥q¦WºÙ ¡G

ÃĵØÂåÃÄ

¤º¡@ ®e¡G

¡@
½Ð¥ýµn¤J ­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹ ¡@
¡@

°Q½×°Ï¬ÛÃö³W©w¡G
    1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«Øij¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
    2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    4.¬°ÁקK®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C


¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178   ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѠ ¬ÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ  ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß  ¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!